date generated: 2024-02-26
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Here is the first few lines of the input profile.
x | |
---|---|
5_8S_rRNA | -1.1769575 |
7SK | 0.3057012 |
A1BG | -0.3509761 |
A1BG.AS1 | -1.0241247 |
A2M | 0.9618886 |
A2M.AS1 | 2.2323813 |
Here are some metrics about the input data profile:
Profile metrics | |
---|---|
num_genesets | 2612 |
num_genes_in_profile | 17294 |
duplicated_genes_present | 0 |
num_profile_genes_in_sets | 8504 |
num_profile_genes_not_in_sets | 8790 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Here are some metrics about the gene sets used:
GMT file of genesets: ReactomePathways_2023-09-01.gmtGene sets metrics | |
---|---|
num_genesets | 2612 |
num_genesets_excluded | 1129 |
num_genesets_included | 1483 |
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Significance is calculated by -log10(p-value). Top N sets shown irrespective of FDR.
Top N= 50 gene sets
## Warning in kable_styling(., "hover", full_width = FALSE): Please specify format
## in kable. kableExtra can customize either HTML or LaTeX outputs. See
## https://haozhu233.github.io/kableExtra/ for details.
set | setSize | pANOVA | s.dist | p.adjustANOVA |
---|---|---|---|---|
SARS-CoV-1 modulates host translation machinery | 36 | 5.31e-15 | 0.753 | 2.92e-13 |
Peptide chain elongation | 87 | 3.14e-32 | 0.732 | 1.16e-29 |
Eukaryotic Translation Elongation | 92 | 3.56e-33 | 0.723 | 2.70e-30 |
Classical antibody-mediated complement activation | 13 | 7.28e-06 | -0.718 | 2.08e-04 |
Viral mRNA Translation | 87 | 5.89e-31 | 0.717 | 1.46e-28 |
Selenocysteine synthesis | 91 | 1.02e-30 | 0.698 | 2.15e-28 |
Formation of a pool of free 40S subunits | 99 | 3.64e-33 | 0.697 | 2.70e-30 |
Eukaryotic Translation Termination | 91 | 1.00e-28 | 0.674 | 1.48e-26 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 93 | 1.44e-28 | 0.664 | 1.94e-26 |
L13a-mediated translational silencing of Ceruloplasmin expression | 109 | 2.87e-32 | 0.655 | 1.16e-29 |
Formation of the ternary complex, and subsequently, the 43S complex | 51 | 1.17e-15 | 0.648 | 6.66e-14 |
Response of EIF2AK4 (GCN2) to amino acid deficiency | 99 | 1.61e-28 | 0.644 | 1.99e-26 |
GTP hydrolysis and joining of the 60S ribosomal subunit | 110 | 2.01e-31 | 0.643 | 5.95e-29 |
FCGR activation | 20 | 7.34e-07 | -0.639 | 2.59e-05 |
Creation of C4 and C2 activators | 16 | 1.28e-05 | -0.630 | 3.29e-04 |
Cap-dependent Translation Initiation | 117 | 1.78e-29 | 0.603 | 2.93e-27 |
Eukaryotic Translation Initiation | 117 | 1.78e-29 | 0.603 | 2.93e-27 |
SARS-CoV-2 modulates host translation machinery | 49 | 3.70e-13 | 0.600 | 1.66e-11 |
Expression and translocation of olfactory receptors | 22 | 1.34e-06 | 0.595 | 4.52e-05 |
Translation initiation complex formation | 58 | 7.83e-15 | 0.590 | 4.15e-13 |
Mucopolysaccharidoses | 11 | 8.14e-04 | -0.583 | 1.37e-02 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 59 | 2.49e-14 | 0.573 | 1.27e-12 |
Ribosomal scanning and start codon recognition | 58 | 4.77e-14 | 0.572 | 2.36e-12 |
Selenoamino acid metabolism | 113 | 1.10e-25 | 0.570 | 1.25e-23 |
Initial triggering of complement | 24 | 1.44e-06 | -0.568 | 4.73e-05 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 113 | 3.45e-24 | 0.552 | 3.19e-22 |
Nonsense-Mediated Decay (NMD) | 113 | 3.45e-24 | 0.552 | 3.19e-22 |
SRP-dependent cotranslational protein targeting to membrane | 110 | 5.44e-23 | 0.545 | 4.74e-21 |
Scavenging of heme from plasma | 14 | 6.59e-04 | -0.526 | 1.14e-02 |
Gluconeogenesis | 28 | 1.69e-06 | -0.523 | 5.33e-05 |
Olfactory Signaling Pathway | 26 | 5.38e-06 | 0.515 | 1.57e-04 |
Trafficking and processing of endosomal TLR | 12 | 2.05e-03 | -0.514 | 2.44e-02 |
Role of LAT2/NTAL/LAB on calcium mobilization | 20 | 9.59e-05 | -0.504 | 2.09e-03 |
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 19 | 1.60e-04 | -0.500 | 3.21e-03 |
SARS-CoV-2 modulates autophagy | 11 | 5.40e-03 | -0.484 | 5.48e-02 |
Transcriptional regulation of pluripotent stem cells | 16 | 8.97e-04 | 0.480 | 1.43e-02 |
Scavenging by Class A Receptors | 16 | 9.54e-04 | -0.477 | 1.49e-02 |
WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 13 | 3.45e-03 | -0.468 | 3.94e-02 |
ABC transporters in lipid homeostasis | 12 | 5.06e-03 | -0.467 | 5.29e-02 |
Interleukin-2 signaling | 11 | 8.73e-03 | -0.457 | 7.99e-02 |
The role of Nef in HIV-1 replication and disease pathogenesis | 26 | 6.19e-05 | -0.454 | 1.43e-03 |
Influenza Viral RNA Transcription and Replication | 134 | 1.51e-19 | 0.452 | 1.12e-17 |
TRAF3-dependent IRF activation pathway | 13 | 5.40e-03 | -0.446 | 5.48e-02 |
Packaging Of Telomere Ends | 13 | 6.56e-03 | 0.435 | 6.40e-02 |
Retrograde neurotrophin signalling | 14 | 5.61e-03 | -0.427 | 5.63e-02 |
Binding and Uptake of Ligands by Scavenger Receptors | 39 | 4.39e-06 | -0.425 | 1.30e-04 |
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 12 | 1.09e-02 | 0.425 | 9.17e-02 |
Synthesis of PIPs at the Golgi membrane | 15 | 5.48e-03 | -0.414 | 5.52e-02 |
Other semaphorin interactions | 19 | 1.87e-03 | -0.412 | 2.29e-02 |
Role of phospholipids in phagocytosis | 32 | 6.82e-05 | -0.407 | 1.53e-03 |
set | setSize | pANOVA | s.dist | p.adjustANOVA |
---|---|---|---|---|
SARS-CoV-1 modulates host translation machinery | 36 | 5.31e-15 | 0.753000 | 2.92e-13 |
Peptide chain elongation | 87 | 3.14e-32 | 0.732000 | 1.16e-29 |
Eukaryotic Translation Elongation | 92 | 3.56e-33 | 0.723000 | 2.70e-30 |
Classical antibody-mediated complement activation | 13 | 7.28e-06 | -0.718000 | 2.08e-04 |
Viral mRNA Translation | 87 | 5.89e-31 | 0.717000 | 1.46e-28 |
Selenocysteine synthesis | 91 | 1.02e-30 | 0.698000 | 2.15e-28 |
Formation of a pool of free 40S subunits | 99 | 3.64e-33 | 0.697000 | 2.70e-30 |
Eukaryotic Translation Termination | 91 | 1.00e-28 | 0.674000 | 1.48e-26 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 93 | 1.44e-28 | 0.664000 | 1.94e-26 |
L13a-mediated translational silencing of Ceruloplasmin expression | 109 | 2.87e-32 | 0.655000 | 1.16e-29 |
Formation of the ternary complex, and subsequently, the 43S complex | 51 | 1.17e-15 | 0.648000 | 6.66e-14 |
Response of EIF2AK4 (GCN2) to amino acid deficiency | 99 | 1.61e-28 | 0.644000 | 1.99e-26 |
GTP hydrolysis and joining of the 60S ribosomal subunit | 110 | 2.01e-31 | 0.643000 | 5.95e-29 |
FCGR activation | 20 | 7.34e-07 | -0.639000 | 2.59e-05 |
Creation of C4 and C2 activators | 16 | 1.28e-05 | -0.630000 | 3.29e-04 |
Cap-dependent Translation Initiation | 117 | 1.78e-29 | 0.603000 | 2.93e-27 |
Eukaryotic Translation Initiation | 117 | 1.78e-29 | 0.603000 | 2.93e-27 |
SARS-CoV-2 modulates host translation machinery | 49 | 3.70e-13 | 0.600000 | 1.66e-11 |
Expression and translocation of olfactory receptors | 22 | 1.34e-06 | 0.595000 | 4.52e-05 |
Translation initiation complex formation | 58 | 7.83e-15 | 0.590000 | 4.15e-13 |
Mucopolysaccharidoses | 11 | 8.14e-04 | -0.583000 | 1.37e-02 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 59 | 2.49e-14 | 0.573000 | 1.27e-12 |
Ribosomal scanning and start codon recognition | 58 | 4.77e-14 | 0.572000 | 2.36e-12 |
Selenoamino acid metabolism | 113 | 1.10e-25 | 0.570000 | 1.25e-23 |
Initial triggering of complement | 24 | 1.44e-06 | -0.568000 | 4.73e-05 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 113 | 3.45e-24 | 0.552000 | 3.19e-22 |
Nonsense-Mediated Decay (NMD) | 113 | 3.45e-24 | 0.552000 | 3.19e-22 |
SRP-dependent cotranslational protein targeting to membrane | 110 | 5.44e-23 | 0.545000 | 4.74e-21 |
Scavenging of heme from plasma | 14 | 6.59e-04 | -0.526000 | 1.14e-02 |
Gluconeogenesis | 28 | 1.69e-06 | -0.523000 | 5.33e-05 |
Olfactory Signaling Pathway | 26 | 5.38e-06 | 0.515000 | 1.57e-04 |
Trafficking and processing of endosomal TLR | 12 | 2.05e-03 | -0.514000 | 2.44e-02 |
Role of LAT2/NTAL/LAB on calcium mobilization | 20 | 9.59e-05 | -0.504000 | 2.09e-03 |
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 19 | 1.60e-04 | -0.500000 | 3.21e-03 |
SARS-CoV-2 modulates autophagy | 11 | 5.40e-03 | -0.484000 | 5.48e-02 |
Transcriptional regulation of pluripotent stem cells | 16 | 8.97e-04 | 0.480000 | 1.43e-02 |
Scavenging by Class A Receptors | 16 | 9.54e-04 | -0.477000 | 1.49e-02 |
WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 13 | 3.45e-03 | -0.468000 | 3.94e-02 |
ABC transporters in lipid homeostasis | 12 | 5.06e-03 | -0.467000 | 5.29e-02 |
Interleukin-2 signaling | 11 | 8.73e-03 | -0.457000 | 7.99e-02 |
The role of Nef in HIV-1 replication and disease pathogenesis | 26 | 6.19e-05 | -0.454000 | 1.43e-03 |
Influenza Viral RNA Transcription and Replication | 134 | 1.51e-19 | 0.452000 | 1.12e-17 |
TRAF3-dependent IRF activation pathway | 13 | 5.40e-03 | -0.446000 | 5.48e-02 |
Packaging Of Telomere Ends | 13 | 6.56e-03 | 0.435000 | 6.40e-02 |
Retrograde neurotrophin signalling | 14 | 5.61e-03 | -0.427000 | 5.63e-02 |
Binding and Uptake of Ligands by Scavenger Receptors | 39 | 4.39e-06 | -0.425000 | 1.30e-04 |
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 12 | 1.09e-02 | 0.425000 | 9.17e-02 |
Synthesis of PIPs at the Golgi membrane | 15 | 5.48e-03 | -0.414000 | 5.52e-02 |
Other semaphorin interactions | 19 | 1.87e-03 | -0.412000 | 2.29e-02 |
Role of phospholipids in phagocytosis | 32 | 6.82e-05 | -0.407000 | 1.53e-03 |
TNFs bind their physiological receptors | 21 | 1.37e-03 | -0.404000 | 1.87e-02 |
XBP1(S) activates chaperone genes | 47 | 1.82e-06 | -0.402000 | 5.61e-05 |
Diseases associated with N-glycosylation of proteins | 20 | 1.88e-03 | -0.401000 | 2.29e-02 |
Regulation of expression of SLITs and ROBOs | 162 | 2.08e-18 | 0.398000 | 1.40e-16 |
Regulation of KIT signaling | 16 | 5.82e-03 | -0.398000 | 5.80e-02 |
Influenza Infection | 153 | 2.32e-17 | 0.397000 | 1.50e-15 |
IRE1alpha activates chaperones | 49 | 1.54e-06 | -0.397000 | 4.97e-05 |
Major pathway of rRNA processing in the nucleolus and cytosol | 179 | 8.19e-20 | 0.395000 | 6.40e-18 |
Free fatty acids regulate insulin secretion | 10 | 3.09e-02 | -0.394000 | 2.00e-01 |
rRNA processing in the nucleus and cytosol | 189 | 4.34e-20 | 0.387000 | 3.58e-18 |
Transferrin endocytosis and recycling | 28 | 4.33e-04 | -0.384000 | 7.92e-03 |
FOXO-mediated transcription of cell cycle genes | 15 | 1.01e-02 | 0.384000 | 8.75e-02 |
Maturation of nucleoprotein 9683610 | 11 | 2.76e-02 | -0.384000 | 1.89e-01 |
Insulin receptor recycling | 26 | 8.00e-04 | -0.380000 | 1.36e-02 |
Interleukin receptor SHC signaling | 22 | 2.06e-03 | -0.380000 | 2.44e-02 |
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 18 | 5.30e-03 | -0.380000 | 5.46e-02 |
Downregulation of ERBB2:ERBB3 signaling | 13 | 1.80e-02 | 0.379000 | 1.41e-01 |
Assembly of the ORC complex at the origin of replication | 16 | 9.10e-03 | 0.377000 | 8.13e-02 |
Plasma lipoprotein assembly | 11 | 3.06e-02 | -0.377000 | 2.00e-01 |
RHO GTPases activate PKNs | 38 | 6.37e-05 | 0.375000 | 1.45e-03 |
Hyaluronan metabolism | 16 | 9.68e-03 | -0.374000 | 8.45e-02 |
TRAF6 mediated IRF7 activation | 15 | 1.23e-02 | -0.373000 | 9.99e-02 |
RNA Polymerase I Promoter Opening | 10 | 4.18e-02 | 0.372000 | 2.40e-01 |
Phosphorylation of CD3 and TCR zeta chains | 13 | 2.10e-02 | -0.370000 | 1.53e-01 |
Interleukin-2 family signaling | 36 | 1.27e-04 | -0.369000 | 2.61e-03 |
rRNA processing | 199 | 2.81e-19 | 0.369000 | 1.99e-17 |
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 10 | 4.42e-02 | -0.368000 | 2.51e-01 |
Erythrocytes take up carbon dioxide and release oxygen | 10 | 4.54e-02 | 0.365000 | 2.54e-01 |
O2/CO2 exchange in erythrocytes | 10 | 4.54e-02 | 0.365000 | 2.54e-01 |
Prefoldin mediated transfer of substrate to CCT/TriC | 25 | 1.57e-03 | 0.365000 | 2.01e-02 |
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 49 | 1.00e-05 | 0.365000 | 2.75e-04 |
Formation of annular gap junctions | 11 | 3.78e-02 | -0.362000 | 2.25e-01 |
Synthesis of PE | 12 | 3.08e-02 | -0.360000 | 2.00e-01 |
PD-1 signaling | 14 | 1.98e-02 | -0.360000 | 1.49e-01 |
Lysosome Vesicle Biogenesis | 33 | 3.52e-04 | -0.359000 | 6.60e-03 |
Synthesis of bile acids and bile salts via 24-hydroxycholesterol | 10 | 4.97e-02 | 0.358000 | 2.62e-01 |
Regulation of Complement cascade | 38 | 1.73e-04 | -0.352000 | 3.42e-03 |
Cellular response to starvation | 149 | 1.63e-13 | 0.350000 | 7.79e-12 |
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 11 | 4.46e-02 | -0.350000 | 2.51e-01 |
alpha-linolenic acid (ALA) metabolism | 11 | 4.46e-02 | -0.350000 | 2.51e-01 |
Glucose metabolism | 83 | 4.33e-08 | -0.348000 | 1.69e-06 |
CD28 dependent Vav1 pathway | 11 | 4.63e-02 | -0.347000 | 2.57e-01 |
FGFR2 ligand binding and activation | 10 | 5.82e-02 | 0.346000 | 2.92e-01 |
PI-3K cascade:FGFR4 | 11 | 4.71e-02 | 0.346000 | 2.57e-01 |
Formation of tubulin folding intermediates by CCT/TriC | 21 | 6.10e-03 | 0.346000 | 6.03e-02 |
Plasma lipoprotein remodeling | 19 | 9.11e-03 | -0.346000 | 8.13e-02 |
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 28 | 1.58e-03 | 0.345000 | 2.01e-02 |
Complement cascade | 43 | 1.02e-04 | -0.342000 | 2.13e-03 |
FCGR3A-mediated IL10 synthesis | 44 | 8.51e-05 | -0.342000 | 1.88e-03 |
Protein methylation | 15 | 2.21e-02 | 0.341000 | 1.59e-01 |
ROS and RNS production in phagocytes | 31 | 1.03e-03 | -0.341000 | 1.55e-02 |
Striated Muscle Contraction | 32 | 8.88e-04 | -0.340000 | 1.43e-02 |
cGMP effects | 13 | 3.48e-02 | 0.338000 | 2.14e-01 |
Cellular hexose transport | 14 | 2.87e-02 | -0.338000 | 1.92e-01 |
WNT5A-dependent internalization of FZD4 | 14 | 3.07e-02 | -0.334000 | 2.00e-01 |
SHC1 events in EGFR signaling | 13 | 3.77e-02 | -0.333000 | 2.25e-01 |
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 102 | 6.82e-09 | -0.332000 | 2.81e-07 |
LDL clearance | 17 | 1.90e-02 | -0.329000 | 1.44e-01 |
Translocation of ZAP-70 to Immunological synapse | 10 | 7.24e-02 | -0.328000 | 3.35e-01 |
Defects in cobalamin (B12) metabolism | 12 | 4.92e-02 | 0.328000 | 2.61e-01 |
Cholesterol biosynthesis | 26 | 4.29e-03 | 0.324000 | 4.64e-02 |
Regulation of IFNA/IFNB signaling | 12 | 5.28e-02 | -0.323000 | 2.72e-01 |
GPVI-mediated activation cascade | 32 | 1.59e-03 | -0.323000 | 2.01e-02 |
Interleukin-15 signaling | 14 | 3.71e-02 | -0.322000 | 2.25e-01 |
Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 23 | 8.19e-03 | -0.319000 | 7.64e-02 |
Maturation of nucleoprotein 9694631 | 15 | 3.32e-02 | -0.318000 | 2.08e-01 |
Glycosphingolipid metabolism | 36 | 9.88e-04 | -0.317000 | 1.53e-02 |
Gap junction degradation | 12 | 5.73e-02 | -0.317000 | 2.88e-01 |
Aggrephagy | 34 | 1.40e-03 | 0.317000 | 1.87e-02 |
Pexophagy | 11 | 7.01e-02 | 0.315000 | 3.33e-01 |
RHO GTPases activate CIT | 19 | 1.89e-02 | 0.311000 | 1.44e-01 |
Other interleukin signaling | 21 | 1.37e-02 | -0.311000 | 1.11e-01 |
TNFR1-induced proapoptotic signaling | 25 | 7.38e-03 | -0.310000 | 7.10e-02 |
Cleavage of the damaged purine | 16 | 3.24e-02 | 0.309000 | 2.04e-01 |
Depurination | 16 | 3.24e-02 | 0.309000 | 2.04e-01 |
Recognition and association of DNA glycosylase with site containing an affected purine | 16 | 3.24e-02 | 0.309000 | 2.04e-01 |
Glycolysis | 66 | 1.45e-05 | -0.309000 | 3.63e-04 |
Maturation of spike protein 9694548 | 37 | 1.21e-03 | -0.307000 | 1.75e-02 |
GAB1 signalosome | 16 | 3.41e-02 | -0.306000 | 2.13e-01 |
DNA methylation | 11 | 8.03e-02 | 0.305000 | 3.54e-01 |
Caspase activation via extrinsic apoptotic signalling pathway | 23 | 1.22e-02 | -0.302000 | 9.99e-02 |
Signaling by ROBO receptors | 203 | 1.80e-13 | 0.300000 | 8.34e-12 |
NR1H2 and NR1H3-mediated signaling | 39 | 1.22e-03 | -0.299000 | 1.75e-02 |
RHO GTPases Activate ROCKs | 19 | 2.41e-02 | 0.299000 | 1.71e-01 |
TP53 Regulates Transcription of Caspase Activators and Caspases | 11 | 8.76e-02 | -0.297000 | 3.76e-01 |
LGI-ADAM interactions | 10 | 1.04e-01 | -0.297000 | 4.08e-01 |
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 17 | 3.45e-02 | -0.296000 | 2.14e-01 |
HSF1 activation | 25 | 1.10e-02 | 0.294000 | 9.19e-02 |
Interleukin-10 signaling | 36 | 2.32e-03 | -0.293000 | 2.73e-02 |
Folding of actin by CCT/TriC | 10 | 1.10e-01 | 0.292000 | 4.22e-01 |
Assembly of active LPL and LIPC lipase complexes | 12 | 8.18e-02 | -0.290000 | 3.60e-01 |
E3 ubiquitin ligases ubiquitinate target proteins | 44 | 1.02e-03 | 0.286000 | 1.55e-02 |
DAP12 interactions | 35 | 3.40e-03 | -0.286000 | 3.90e-02 |
Translation | 291 | 5.21e-17 | 0.286000 | 3.09e-15 |
CD22 mediated BCR regulation | 11 | 1.01e-01 | -0.286000 | 4.04e-01 |
Attenuation phase | 22 | 2.03e-02 | 0.286000 | 1.50e-01 |
Interferon gamma signaling | 74 | 2.17e-05 | -0.286000 | 5.26e-04 |
Diseases associated with the TLR signaling cascade | 27 | 1.03e-02 | -0.285000 | 8.83e-02 |
Diseases of Immune System | 27 | 1.03e-02 | -0.285000 | 8.83e-02 |
Keratan sulfate degradation | 13 | 7.80e-02 | -0.282000 | 3.49e-01 |
Aspirin ADME | 14 | 6.76e-02 | -0.282000 | 3.27e-01 |
Trafficking of GluR2-containing AMPA receptors | 15 | 5.91e-02 | -0.282000 | 2.95e-01 |
Gastrin-CREB signalling pathway via PKC and MAPK | 16 | 5.15e-02 | -0.281000 | 2.68e-01 |
GRB2 events in EGFR signaling | 12 | 9.25e-02 | -0.281000 | 3.91e-01 |
Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 7.24e-02 | -0.277000 | 3.35e-01 |
Sema4D induced cell migration and growth-cone collapse | 20 | 3.19e-02 | 0.277000 | 2.04e-01 |
Hyaluronan uptake and degradation | 11 | 1.14e-01 | -0.275000 | 4.30e-01 |
Collagen degradation | 56 | 3.80e-04 | -0.275000 | 7.04e-03 |
Signaling by BMP | 24 | 2.10e-02 | 0.272000 | 1.53e-01 |
Late SARS-CoV-2 Infection Events | 66 | 1.55e-04 | -0.269000 | 3.15e-03 |
Activation of the AP-1 family of transcription factors | 10 | 1.41e-01 | 0.269000 | 4.82e-01 |
Disorders of Developmental Biology | 12 | 1.09e-01 | -0.267000 | 4.19e-01 |
Disorders of Nervous System Development | 12 | 1.09e-01 | -0.267000 | 4.19e-01 |
Loss of function of MECP2 in Rett syndrome | 12 | 1.09e-01 | -0.267000 | 4.19e-01 |
Pervasive developmental disorders | 12 | 1.09e-01 | -0.267000 | 4.19e-01 |
Costimulation by the CD28 family | 56 | 5.49e-04 | -0.267000 | 9.92e-03 |
Activation of AMPK downstream of NMDARs | 21 | 3.44e-02 | 0.267000 | 2.14e-01 |
Cytosolic iron-sulfur cluster assembly | 13 | 9.71e-02 | -0.266000 | 4.03e-01 |
Insulin processing | 21 | 3.63e-02 | -0.264000 | 2.22e-01 |
PI-3K cascade:FGFR3 | 12 | 1.14e-01 | 0.263000 | 4.30e-01 |
Biosynthesis of specialized proresolving mediators (SPMs) | 13 | 1.01e-01 | -0.263000 | 4.04e-01 |
Inhibition of DNA recombination at telomere | 27 | 1.83e-02 | 0.262000 | 1.42e-01 |
Inflammasomes | 21 | 3.74e-02 | -0.262000 | 2.25e-01 |
Interferon alpha/beta signaling | 57 | 6.49e-04 | -0.261000 | 1.13e-02 |
CD28 dependent PI3K/Akt signaling | 21 | 3.94e-02 | -0.260000 | 2.33e-01 |
Intra-Golgi traffic | 41 | 4.23e-03 | -0.258000 | 4.62e-02 |
Germ layer formation at gastrulation | 10 | 1.58e-01 | 0.258000 | 5.10e-01 |
Dectin-2 family | 14 | 9.48e-02 | -0.258000 | 3.98e-01 |
Sema4D in semaphorin signaling | 24 | 2.89e-02 | 0.258000 | 1.93e-01 |
CD28 co-stimulation | 32 | 1.17e-02 | -0.257000 | 9.65e-02 |
SARS-CoV-1-host interactions | 95 | 1.48e-05 | 0.257000 | 3.65e-04 |
Pregnenolone biosynthesis | 10 | 1.59e-01 | -0.257000 | 5.10e-01 |
Translation of Structural Proteins 9694635 | 57 | 8.48e-04 | -0.256000 | 1.41e-02 |
RUNX3 regulates p14-ARF | 10 | 1.64e-01 | -0.254000 | 5.18e-01 |
Cardiogenesis | 19 | 5.58e-02 | 0.254000 | 2.81e-01 |
Cleavage of the damaged pyrimidine | 21 | 4.71e-02 | 0.250000 | 2.57e-01 |
Depyrimidination | 21 | 4.71e-02 | 0.250000 | 2.57e-01 |
Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 21 | 4.71e-02 | 0.250000 | 2.57e-01 |
Plasma lipoprotein assembly, remodeling, and clearance | 55 | 1.44e-03 | -0.248000 | 1.91e-02 |
HS-GAG degradation | 22 | 4.39e-02 | -0.248000 | 2.51e-01 |
Glycogen synthesis | 13 | 1.22e-01 | 0.247000 | 4.49e-01 |
Signaling by CSF1 (M-CSF) in myeloid cells | 31 | 1.76e-02 | -0.246000 | 1.38e-01 |
Processing and activation of SUMO | 10 | 1.78e-01 | 0.246000 | 5.39e-01 |
SUMOylation of immune response proteins | 11 | 1.60e-01 | -0.245000 | 5.10e-01 |
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | 13 | 1.29e-01 | 0.243000 | 4.59e-01 |
Cobalamin (Cbl, vitamin B12) transport and metabolism | 15 | 1.06e-01 | 0.241000 | 4.14e-01 |
PI-3K cascade:FGFR2 | 14 | 1.19e-01 | 0.241000 | 4.41e-01 |
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 32 | 1.86e-02 | -0.240000 | 1.43e-01 |
Cohesin Loading onto Chromatin | 10 | 1.88e-01 | 0.240000 | 5.41e-01 |
Paracetamol ADME | 19 | 6.98e-02 | -0.240000 | 3.33e-01 |
Constitutive Signaling by NOTCH1 HD Domain Mutants | 15 | 1.09e-01 | 0.239000 | 4.19e-01 |
Signaling by NOTCH1 HD Domain Mutants in Cancer | 15 | 1.09e-01 | 0.239000 | 4.19e-01 |
RHOBTB1 GTPase cycle | 23 | 4.74e-02 | 0.239000 | 2.58e-01 |
Early Phase of HIV Life Cycle | 14 | 1.25e-01 | -0.237000 | 4.50e-01 |
Blood group systems biosynthesis | 14 | 1.25e-01 | 0.237000 | 4.50e-01 |
FCERI mediated Ca+2 mobilization | 35 | 1.55e-02 | -0.236000 | 1.24e-01 |
DCC mediated attractive signaling | 13 | 1.41e-01 | 0.236000 | 4.82e-01 |
Fcgamma receptor (FCGR) dependent phagocytosis | 92 | 9.99e-05 | -0.235000 | 2.13e-03 |
Signalling to RAS | 20 | 7.05e-02 | -0.234000 | 3.33e-01 |
VLDLR internalisation and degradation | 15 | 1.18e-01 | -0.233000 | 4.41e-01 |
Amino acids regulate mTORC1 | 50 | 4.35e-03 | -0.233000 | 4.67e-02 |
EPHA-mediated growth cone collapse | 24 | 4.87e-02 | 0.232000 | 2.61e-01 |
Integrin signaling | 24 | 4.88e-02 | -0.232000 | 2.61e-01 |
Interleukin-35 Signalling | 10 | 2.06e-01 | -0.231000 | 5.67e-01 |
DAP12 signaling | 27 | 3.82e-02 | -0.230000 | 2.27e-01 |
Azathioprine ADME | 19 | 8.25e-02 | -0.230000 | 3.62e-01 |
Interleukin-3, Interleukin-5 and GM-CSF signaling | 43 | 9.21e-03 | -0.230000 | 8.13e-02 |
PECAM1 interactions | 12 | 1.69e-01 | -0.229000 | 5.24e-01 |
Nitric oxide stimulates guanylate cyclase | 17 | 1.02e-01 | 0.229000 | 4.04e-01 |
Regulation of actin dynamics for phagocytic cup formation | 68 | 1.12e-03 | -0.229000 | 1.64e-02 |
Regulation of FZD by ubiquitination | 16 | 1.14e-01 | 0.228000 | 4.30e-01 |
Chaperone Mediated Autophagy | 20 | 7.81e-02 | 0.228000 | 3.49e-01 |
FCGR3A-mediated phagocytosis | 66 | 1.40e-03 | -0.227000 | 1.87e-02 |
Leishmania phagocytosis | 66 | 1.40e-03 | -0.227000 | 1.87e-02 |
Parasite infection | 66 | 1.40e-03 | -0.227000 | 1.87e-02 |
Crosslinking of collagen fibrils | 15 | 1.28e-01 | -0.227000 | 4.55e-01 |
Signaling by Activin | 13 | 1.58e-01 | 0.226000 | 5.10e-01 |
PI-3K cascade:FGFR1 | 13 | 1.59e-01 | 0.226000 | 5.10e-01 |
EPH-ephrin mediated repulsion of cells | 46 | 8.19e-03 | -0.225000 | 7.64e-02 |
Apoptotic cleavage of cellular proteins | 35 | 2.18e-02 | 0.224000 | 1.58e-01 |
Citric acid cycle (TCA cycle) | 22 | 6.95e-02 | -0.224000 | 3.32e-01 |
MyD88 deficiency (TLR2/4) | 14 | 1.48e-01 | -0.223000 | 4.90e-01 |
G-protein beta:gamma signalling | 28 | 4.14e-02 | -0.223000 | 2.39e-01 |
trans-Golgi Network Vesicle Budding | 70 | 1.30e-03 | -0.222000 | 1.85e-02 |
Erythropoietin activates RAS | 13 | 1.66e-01 | -0.222000 | 5.19e-01 |
Generation of second messenger molecules | 24 | 6.00e-02 | -0.222000 | 2.98e-01 |
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 35 | 2.32e-02 | -0.222000 | 1.66e-01 |
Condensation of Prometaphase Chromosomes | 11 | 2.03e-01 | -0.222000 | 5.62e-01 |
FRS-mediated FGFR4 signaling | 13 | 1.67e-01 | 0.221000 | 5.20e-01 |
Repression of WNT target genes | 14 | 1.52e-01 | 0.221000 | 4.96e-01 |
Polo-like kinase mediated events | 14 | 1.52e-01 | -0.221000 | 4.96e-01 |
Amino acid transport across the plasma membrane | 21 | 8.01e-02 | -0.221000 | 3.54e-01 |
Base-Excision Repair, AP Site Formation | 23 | 6.72e-02 | 0.220000 | 3.26e-01 |
Intraflagellar transport | 49 | 8.06e-03 | 0.219000 | 7.61e-02 |
RAS processing | 22 | 7.58e-02 | 0.219000 | 3.44e-01 |
NGF-stimulated transcription | 35 | 2.53e-02 | 0.218000 | 1.78e-01 |
Downregulation of TGF-beta receptor signaling | 26 | 5.46e-02 | 0.218000 | 2.78e-01 |
TRP channels | 20 | 9.29e-02 | -0.217000 | 3.91e-01 |
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 15 | 1.46e-01 | -0.217000 | 4.88e-01 |
Regulation of CDH11 gene transcription | 10 | 2.38e-01 | -0.215000 | 6.05e-01 |
NOTCH2 intracellular domain regulates transcription | 11 | 2.17e-01 | -0.215000 | 5.81e-01 |
Translesion Synthesis by POLH | 18 | 1.16e-01 | 0.214000 | 4.34e-01 |
Synthesis of bile acids and bile salts via 27-hydroxycholesterol | 10 | 2.41e-01 | 0.214000 | 6.08e-01 |
Biosynthesis of DHA-derived SPMs | 11 | 2.19e-01 | -0.214000 | 5.85e-01 |
RHOBTB2 GTPase cycle | 23 | 7.61e-02 | 0.214000 | 3.44e-01 |
Zinc transporters | 10 | 2.42e-01 | -0.213000 | 6.09e-01 |
Processing of Intronless Pre-mRNAs | 20 | 9.90e-02 | -0.213000 | 4.04e-01 |
FCERI mediated MAPK activation | 36 | 2.72e-02 | -0.213000 | 1.88e-01 |
Collagen biosynthesis and modifying enzymes | 61 | 4.23e-03 | -0.212000 | 4.62e-02 |
Cell surface interactions at the vascular wall | 114 | 1.02e-04 | -0.211000 | 2.13e-03 |
Pre-NOTCH Processing in Golgi | 18 | 1.23e-01 | -0.210000 | 4.49e-01 |
Interaction between L1 and Ankyrins | 26 | 6.44e-02 | 0.210000 | 3.14e-01 |
Anti-inflammatory response favouring Leishmania parasite infection | 76 | 1.60e-03 | -0.209000 | 2.01e-02 |
Leishmania parasite growth and survival | 76 | 1.60e-03 | -0.209000 | 2.01e-02 |
Translation of Structural Proteins 9683701 | 29 | 5.10e-02 | -0.209000 | 2.67e-01 |
Apoptotic execution phase | 43 | 1.76e-02 | 0.209000 | 1.38e-01 |
PINK1-PRKN Mediated Mitophagy | 21 | 9.83e-02 | 0.208000 | 4.04e-01 |
SLBP independent Processing of Histone Pre-mRNAs | 10 | 2.54e-01 | 0.208000 | 6.19e-01 |
IRAK1 recruits IKK complex | 14 | 1.77e-01 | 0.208000 | 5.39e-01 |
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | 14 | 1.77e-01 | 0.208000 | 5.39e-01 |
Regulation of TP53 Activity through Association with Co-factors | 11 | 2.34e-01 | -0.207000 | 6.03e-01 |
Signaling by FGFR3 in disease | 16 | 1.52e-01 | 0.207000 | 4.96e-01 |
Apoptotic factor-mediated response | 20 | 1.11e-01 | -0.206000 | 4.22e-01 |
Establishment of Sister Chromatid Cohesion | 11 | 2.38e-01 | 0.205000 | 6.05e-01 |
Mitochondrial translation termination | 88 | 8.97e-04 | 0.205000 | 1.43e-02 |
IRAK4 deficiency (TLR2/4) | 15 | 1.70e-01 | -0.205000 | 5.26e-01 |
SUMOylation of DNA replication proteins | 46 | 1.69e-02 | -0.204000 | 1.34e-01 |
Mitochondrial translation initiation | 88 | 1.06e-03 | 0.202000 | 1.59e-02 |
Mitochondrial translation elongation | 88 | 1.09e-03 | 0.202000 | 1.61e-02 |
PLC beta mediated events | 45 | 1.97e-02 | -0.201000 | 1.49e-01 |
HSF1-dependent transactivation | 32 | 4.93e-02 | 0.201000 | 2.61e-01 |
Interferon Signaling | 166 | 8.45e-06 | -0.200000 | 2.36e-04 |
Regulation of pyruvate dehydrogenase (PDH) complex | 15 | 1.80e-01 | -0.200000 | 5.41e-01 |
RHOBTB GTPase Cycle | 35 | 4.11e-02 | 0.199000 | 2.38e-01 |
Assembly of collagen fibrils and other multimeric structures | 55 | 1.05e-02 | -0.199000 | 8.99e-02 |
Regulation of NPAS4 gene expression | 12 | 2.32e-01 | 0.199000 | 6.00e-01 |
Signaling by Hippo | 20 | 1.24e-01 | 0.199000 | 4.49e-01 |
TNFR1-induced NF-kappa-B signaling pathway | 33 | 4.84e-02 | -0.199000 | 2.61e-01 |
rRNA modification in the nucleus and cytosol | 59 | 8.50e-03 | 0.198000 | 7.83e-02 |
Inactivation, recovery and regulation of the phototransduction cascade | 20 | 1.26e-01 | 0.198000 | 4.50e-01 |
Nuclear Pore Complex (NPC) Disassembly | 36 | 4.02e-02 | -0.198000 | 2.35e-01 |
Post-chaperonin tubulin folding pathway | 18 | 1.47e-01 | 0.197000 | 4.90e-01 |
Degradation of cysteine and homocysteine | 12 | 2.36e-01 | -0.197000 | 6.03e-01 |
P2Y receptors | 11 | 2.57e-01 | 0.197000 | 6.22e-01 |
Ca-dependent events | 33 | 5.03e-02 | -0.197000 | 2.64e-01 |
SARS-CoV-2 activates/modulates innate and adaptive immune responses | 102 | 6.04e-04 | -0.197000 | 1.07e-02 |
The phototransduction cascade | 21 | 1.19e-01 | 0.196000 | 4.41e-01 |
Metabolism of carbohydrates | 259 | 5.77e-08 | -0.196000 | 2.19e-06 |
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 56 | 1.16e-02 | -0.195000 | 9.62e-02 |
Unfolded Protein Response (UPR) | 91 | 1.36e-03 | -0.194000 | 1.87e-02 |
Vitamin D (calciferol) metabolism | 10 | 2.87e-01 | -0.194000 | 6.47e-01 |
Activation of Matrix Metalloproteinases | 24 | 1.01e-01 | -0.193000 | 4.04e-01 |
Collagen formation | 82 | 2.52e-03 | -0.193000 | 2.94e-02 |
mitochondrial fatty acid beta-oxidation of saturated fatty acids | 10 | 2.92e-01 | 0.193000 | 6.49e-01 |
Regulation of TLR by endogenous ligand | 16 | 1.83e-01 | -0.192000 | 5.41e-01 |
Heparan sulfate/heparin (HS-GAG) metabolism | 45 | 2.61e-02 | -0.192000 | 1.83e-01 |
Mitochondrial translation | 94 | 1.33e-03 | 0.192000 | 1.87e-02 |
Selective autophagy | 71 | 5.27e-03 | 0.192000 | 5.46e-02 |
Cell recruitment (pro-inflammatory response) | 25 | 1.02e-01 | -0.189000 | 4.04e-01 |
Purinergic signaling in leishmaniasis infection | 25 | 1.02e-01 | -0.189000 | 4.04e-01 |
Regulation of PTEN mRNA translation | 11 | 2.78e-01 | 0.189000 | 6.43e-01 |
COPII-mediated vesicle transport | 65 | 8.42e-03 | -0.189000 | 7.80e-02 |
Elevation of cytosolic Ca2+ levels | 13 | 2.41e-01 | -0.188000 | 6.08e-01 |
Biotin transport and metabolism | 11 | 2.81e-01 | -0.188000 | 6.44e-01 |
Formation of the beta-catenin:TCF transactivating complex | 37 | 4.93e-02 | 0.187000 | 2.61e-01 |
Deposition of new CENPA-containing nucleosomes at the centromere | 31 | 7.26e-02 | 0.186000 | 3.35e-01 |
Nucleosome assembly | 31 | 7.26e-02 | 0.186000 | 3.35e-01 |
Membrane binding and targetting of GAG proteins | 14 | 2.29e-01 | 0.186000 | 5.97e-01 |
Synthesis And Processing Of GAG, GAGPOL Polyproteins | 14 | 2.29e-01 | 0.186000 | 5.97e-01 |
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 11 | 2.87e-01 | -0.185000 | 6.47e-01 |
Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 11 | 2.88e-01 | -0.185000 | 6.47e-01 |
Post-translational protein phosphorylation | 79 | 4.50e-03 | -0.185000 | 4.76e-02 |
Sensory perception of taste | 16 | 2.00e-01 | -0.185000 | 5.59e-01 |
Telomere C-strand synthesis initiation | 13 | 2.52e-01 | 0.184000 | 6.19e-01 |
Caspase activation via Death Receptors in the presence of ligand | 15 | 2.19e-01 | -0.183000 | 5.85e-01 |
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 2.93e-01 | 0.183000 | 6.49e-01 |
Translesion synthesis by POLI | 17 | 1.93e-01 | 0.182000 | 5.44e-01 |
EGR2 and SOX10-mediated initiation of Schwann cell myelination | 24 | 1.22e-01 | 0.182000 | 4.49e-01 |
SUMOylation of ubiquitinylation proteins | 39 | 4.95e-02 | -0.182000 | 2.61e-01 |
Plasma lipoprotein clearance | 32 | 7.60e-02 | -0.181000 | 3.44e-01 |
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 13 | 2.59e-01 | 0.181000 | 6.24e-01 |
Metal ion SLC transporters | 18 | 1.85e-01 | -0.181000 | 5.41e-01 |
p38MAPK events | 13 | 2.60e-01 | -0.181000 | 6.24e-01 |
Degradation of the extracellular matrix | 114 | 8.87e-04 | -0.180000 | 1.43e-02 |
G1/S-Specific Transcription | 27 | 1.06e-01 | -0.180000 | 4.12e-01 |
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 12 | 2.81e-01 | -0.180000 | 6.44e-01 |
PRC2 methylates histones and DNA | 20 | 1.64e-01 | 0.180000 | 5.18e-01 |
MECP2 regulates neuronal receptors and channels | 16 | 2.14e-01 | 0.179000 | 5.76e-01 |
Carboxyterminal post-translational modifications of tubulin | 31 | 8.43e-02 | 0.179000 | 3.67e-01 |
Antigen processing-Cross presentation | 92 | 3.01e-03 | -0.179000 | 3.49e-02 |
Diseases of carbohydrate metabolism | 29 | 9.70e-02 | -0.178000 | 4.03e-01 |
Metabolism of steroid hormones | 21 | 1.59e-01 | -0.177000 | 5.10e-01 |
Smooth Muscle Contraction | 38 | 5.93e-02 | 0.177000 | 2.95e-01 |
SIRT1 negatively regulates rRNA expression | 15 | 2.37e-01 | 0.176000 | 6.05e-01 |
RHO GTPases Activate NADPH Oxidases | 21 | 1.65e-01 | -0.175000 | 5.19e-01 |
RNA Polymerase I Promoter Escape | 38 | 6.25e-02 | 0.175000 | 3.06e-01 |
Ephrin signaling | 19 | 1.88e-01 | -0.175000 | 5.41e-01 |
ZBP1(DAI) mediated induction of type I IFNs | 20 | 1.77e-01 | -0.175000 | 5.39e-01 |
Signaling by PDGFRA extracellular domain mutants | 12 | 2.95e-01 | -0.175000 | 6.49e-01 |
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 2.95e-01 | -0.175000 | 6.49e-01 |
MET activates RAS signaling | 11 | 3.17e-01 | -0.174000 | 6.73e-01 |
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 19 | 1.89e-01 | 0.174000 | 5.41e-01 |
Downstream signaling of activated FGFR4 | 18 | 2.03e-01 | 0.173000 | 5.62e-01 |
Glycosaminoglycan metabolism | 110 | 1.69e-03 | -0.173000 | 2.09e-02 |
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 14 | 2.62e-01 | -0.173000 | 6.26e-01 |
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 16 | 2.31e-01 | -0.173000 | 5.99e-01 |
Metalloprotease DUBs | 19 | 1.94e-01 | 0.172000 | 5.44e-01 |
TNF signaling | 57 | 2.47e-02 | -0.172000 | 1.75e-01 |
Sema3A PAK dependent Axon repulsion | 16 | 2.34e-01 | -0.172000 | 6.03e-01 |
SHC1 events in ERBB4 signaling | 12 | 3.04e-01 | -0.171000 | 6.59e-01 |
RNA Polymerase III Transcription Termination | 23 | 1.59e-01 | 0.170000 | 5.10e-01 |
Retrograde transport at the Trans-Golgi-Network | 49 | 4.03e-02 | -0.169000 | 2.35e-01 |
Response of EIF2AK1 (HRI) to heme deficiency | 15 | 2.56e-01 | 0.169000 | 6.22e-01 |
RHO GTPases activate PAKs | 21 | 1.80e-01 | 0.169000 | 5.41e-01 |
Leishmania infection | 157 | 2.65e-04 | -0.169000 | 5.11e-03 |
Parasitic Infection Pathways | 157 | 2.65e-04 | -0.169000 | 5.11e-03 |
Mitochondrial Fatty Acid Beta-Oxidation | 34 | 8.87e-02 | 0.169000 | 3.78e-01 |
CaM pathway | 31 | 1.04e-01 | -0.169000 | 4.08e-01 |
Calmodulin induced events | 31 | 1.04e-01 | -0.169000 | 4.08e-01 |
RIP-mediated NFkB activation via ZBP1 | 17 | 2.30e-01 | -0.168000 | 5.97e-01 |
Laminin interactions | 28 | 1.24e-01 | 0.168000 | 4.49e-01 |
Signaling by NTRK3 (TRKC) | 17 | 2.30e-01 | -0.168000 | 5.97e-01 |
Receptor Mediated Mitophagy | 11 | 3.36e-01 | -0.168000 | 6.87e-01 |
Advanced glycosylation endproduct receptor signaling | 12 | 3.15e-01 | -0.168000 | 6.68e-01 |
Signaling by SCF-KIT | 42 | 6.15e-02 | -0.167000 | 3.03e-01 |
Meiotic synapsis | 33 | 9.74e-02 | 0.167000 | 4.03e-01 |
Josephin domain DUBs | 10 | 3.61e-01 | 0.167000 | 7.00e-01 |
Innate Immune System | 899 | 3.95e-17 | -0.166000 | 2.44e-15 |
Transport of Ribonucleoproteins into the Host Nucleus | 32 | 1.04e-01 | -0.166000 | 4.08e-01 |
Attachment and Entry 9694614 | 16 | 2.51e-01 | -0.166000 | 6.19e-01 |
Mitochondrial iron-sulfur cluster biogenesis | 13 | 3.02e-01 | 0.166000 | 6.55e-01 |
BBSome-mediated cargo-targeting to cilium | 21 | 1.90e-01 | 0.165000 | 5.41e-01 |
Regulation of TNFR1 signaling | 48 | 4.78e-02 | -0.165000 | 2.59e-01 |
Translesion synthesis by REV1 | 16 | 2.54e-01 | 0.165000 | 6.19e-01 |
Budding and maturation of HIV virion | 27 | 1.38e-01 | 0.165000 | 4.78e-01 |
Glutamate binding, activation of AMPA receptors and synaptic plasticity | 26 | 1.46e-01 | -0.165000 | 4.88e-01 |
Trafficking of AMPA receptors | 26 | 1.46e-01 | -0.165000 | 4.88e-01 |
Golgi Associated Vesicle Biogenesis | 55 | 3.48e-02 | -0.165000 | 2.14e-01 |
Assembly and cell surface presentation of NMDA receptors | 36 | 8.90e-02 | 0.164000 | 3.78e-01 |
GRB2 events in ERBB2 signaling | 14 | 2.89e-01 | -0.164000 | 6.47e-01 |
Negative regulators of DDX58/IFIH1 signaling | 34 | 9.89e-02 | -0.164000 | 4.04e-01 |
FGFR2 mutant receptor activation | 24 | 1.66e-01 | 0.163000 | 5.19e-01 |
Cargo recognition for clathrin-mediated endocytosis | 94 | 6.34e-03 | -0.163000 | 6.23e-02 |
Signaling by KIT in disease | 20 | 2.08e-01 | -0.163000 | 5.68e-01 |
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 20 | 2.08e-01 | -0.163000 | 5.68e-01 |
Transport of bile salts and organic acids, metal ions and amine compounds | 47 | 5.41e-02 | -0.162000 | 2.76e-01 |
The NLRP3 inflammasome | 16 | 2.61e-01 | -0.162000 | 6.26e-01 |
Cargo concentration in the ER | 30 | 1.24e-01 | -0.162000 | 4.49e-01 |
Triglyceride metabolism | 25 | 1.62e-01 | -0.161000 | 5.14e-01 |
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 23 | 1.80e-01 | 0.161000 | 5.41e-01 |
CLEC7A (Dectin-1) induces NFAT activation | 11 | 3.56e-01 | 0.161000 | 6.95e-01 |
Collagen chain trimerization | 39 | 8.31e-02 | -0.160000 | 3.62e-01 |
NOD1/2 Signaling Pathway | 36 | 9.63e-02 | -0.160000 | 4.02e-01 |
Activation of IRF3, IRF7 mediated by TBK1, IKBKE | 17 | 2.53e-01 | -0.160000 | 6.19e-01 |
FRS-mediated FGFR3 signaling | 14 | 3.01e-01 | 0.160000 | 6.55e-01 |
Synthesis of PIPs at the early endosome membrane | 16 | 2.70e-01 | -0.159000 | 6.38e-01 |
Transport of connexons to the plasma membrane | 14 | 3.02e-01 | 0.159000 | 6.55e-01 |
Metabolism of amino acids and derivatives | 320 | 1.04e-06 | 0.159000 | 3.57e-05 |
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | 24 | 1.77e-01 | 0.159000 | 5.39e-01 |
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | 24 | 1.77e-01 | 0.159000 | 5.39e-01 |
Defective homologous recombination repair (HRR) due to BRCA1 loss of function | 24 | 1.77e-01 | 0.159000 | 5.39e-01 |
Defective homologous recombination repair (HRR) due to PALB2 loss of function | 24 | 1.77e-01 | 0.159000 | 5.39e-01 |
Mitochondrial tRNA aminoacylation | 21 | 2.07e-01 | -0.159000 | 5.68e-01 |
NRAGE signals death through JNK | 56 | 3.97e-02 | -0.159000 | 2.33e-01 |
Tryptophan catabolism | 12 | 3.41e-01 | -0.159000 | 6.87e-01 |
TP53 Regulates Transcription of Cell Death Genes | 41 | 7.91e-02 | -0.159000 | 3.52e-01 |
Translesion synthesis by POLK | 17 | 2.58e-01 | 0.158000 | 6.24e-01 |
The activation of arylsulfatases | 10 | 3.86e-01 | -0.158000 | 7.14e-01 |
Metabolism of Angiotensinogen to Angiotensins | 15 | 2.89e-01 | -0.158000 | 6.47e-01 |
Sulfur amino acid metabolism | 23 | 1.89e-01 | -0.158000 | 5.41e-01 |
G-protein mediated events | 49 | 5.58e-02 | -0.158000 | 2.81e-01 |
Antimicrobial peptides | 30 | 1.35e-01 | 0.158000 | 4.69e-01 |
Neutrophil degranulation | 444 | 1.38e-08 | -0.157000 | 5.53e-07 |
Estrogen-dependent gene expression | 93 | 8.79e-03 | 0.157000 | 7.99e-02 |
RNA Polymerase III Chain Elongation | 18 | 2.48e-01 | 0.157000 | 6.15e-01 |
Pyruvate metabolism and Citric Acid (TCA) cycle | 51 | 5.24e-02 | -0.157000 | 2.72e-01 |
Complex I biogenesis | 51 | 5.28e-02 | 0.157000 | 2.72e-01 |
N-glycan antennae elongation in the medial/trans-Golgi | 20 | 2.26e-01 | -0.157000 | 5.96e-01 |
Protein ubiquitination | 64 | 3.07e-02 | 0.156000 | 2.00e-01 |
Beta-oxidation of very long chain fatty acids | 10 | 3.93e-01 | -0.156000 | 7.20e-01 |
Glutathione synthesis and recycling | 11 | 3.72e-01 | -0.156000 | 7.02e-01 |
Metabolism of folate and pterines | 17 | 2.69e-01 | -0.155000 | 6.38e-01 |
Immune System | 1683 | 1.33e-25 | -0.155000 | 1.41e-23 |
Transport of Mature mRNA Derived from an Intronless Transcript | 42 | 8.49e-02 | -0.154000 | 3.67e-01 |
Purine catabolism | 13 | 3.38e-01 | 0.154000 | 6.87e-01 |
Sensory perception of sweet, bitter, and umami (glutamate) taste | 13 | 3.39e-01 | -0.153000 | 6.87e-01 |
Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 13 | 3.39e-01 | -0.153000 | 6.87e-01 |
FRS-mediated FGFR2 signaling | 16 | 2.91e-01 | 0.153000 | 6.47e-01 |
RNA Polymerase III Transcription Initiation From Type 3 Promoter | 28 | 1.63e-01 | 0.152000 | 5.14e-01 |
Transport of inorganic cations/anions and amino acids/oligopeptides | 71 | 2.67e-02 | -0.152000 | 1.85e-01 |
Transport of Mature mRNAs Derived from Intronless Transcripts | 43 | 8.52e-02 | -0.152000 | 3.67e-01 |
Signal regulatory protein family interactions | 12 | 3.63e-01 | -0.152000 | 7.00e-01 |
Nucleotide biosynthesis | 12 | 3.63e-01 | -0.152000 | 7.00e-01 |
RUNX2 regulates osteoblast differentiation | 23 | 2.09e-01 | -0.151000 | 5.69e-01 |
DAG and IP3 signaling | 37 | 1.11e-01 | -0.151000 | 4.22e-01 |
Formation of the cornified envelope | 30 | 1.52e-01 | -0.151000 | 4.96e-01 |
Keratinization | 30 | 1.52e-01 | -0.151000 | 4.96e-01 |
Signaling by FGFR2 in disease | 34 | 1.27e-01 | 0.151000 | 4.54e-01 |
Acyl chain remodelling of PG | 12 | 3.68e-01 | -0.150000 | 7.00e-01 |
tRNA Aminoacylation | 42 | 9.22e-02 | -0.150000 | 3.91e-01 |
Glycerophospholipid biosynthesis | 105 | 7.89e-03 | -0.150000 | 7.51e-02 |
G0 and Early G1 | 25 | 1.94e-01 | -0.150000 | 5.44e-01 |
Pyroptosis | 23 | 2.14e-01 | -0.150000 | 5.76e-01 |
Transcriptional Regulation by NPAS4 | 31 | 1.50e-01 | 0.150000 | 4.93e-01 |
TICAM1-dependent activation of IRF3/IRF7 | 12 | 3.70e-01 | -0.149000 | 7.00e-01 |
Signaling by Insulin receptor | 65 | 3.74e-02 | -0.149000 | 2.25e-01 |
Regulation of NF-kappa B signaling | 18 | 2.74e-01 | -0.149000 | 6.40e-01 |
MHC class II antigen presentation | 98 | 1.09e-02 | -0.149000 | 9.17e-02 |
Drug ADME | 60 | 4.64e-02 | -0.149000 | 2.57e-01 |
HDMs demethylate histones | 21 | 2.39e-01 | -0.149000 | 6.05e-01 |
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 33 | 1.40e-01 | 0.149000 | 4.80e-01 |
Pyruvate metabolism | 27 | 1.82e-01 | -0.148000 | 5.41e-01 |
Chondroitin sulfate/dermatan sulfate metabolism | 45 | 8.52e-02 | -0.148000 | 3.67e-01 |
Vitamin B5 (pantothenate) metabolism | 17 | 2.90e-01 | -0.148000 | 6.47e-01 |
Downregulation of SMAD2/3:SMAD4 transcriptional activity | 30 | 1.62e-01 | 0.148000 | 5.14e-01 |
Rev-mediated nuclear export of HIV RNA | 35 | 1.31e-01 | -0.147000 | 4.64e-01 |
STAT3 nuclear events downstream of ALK signaling | 10 | 4.21e-01 | -0.147000 | 7.34e-01 |
Synthesis of pyrophosphates in the cytosol | 10 | 4.21e-01 | -0.147000 | 7.34e-01 |
Meiotic recombination | 27 | 1.87e-01 | 0.147000 | 5.41e-01 |
Transport of the SLBP independent Mature mRNA | 35 | 1.34e-01 | -0.147000 | 4.68e-01 |
Adaptive Immune System | 672 | 1.25e-10 | -0.146000 | 5.44e-09 |
RORA activates gene expression | 18 | 2.87e-01 | -0.145000 | 6.47e-01 |
SLC-mediated transmembrane transport | 161 | 1.52e-03 | -0.145000 | 2.00e-02 |
CREB1 phosphorylation through the activation of Adenylate Cyclase | 10 | 4.29e-01 | -0.145000 | 7.35e-01 |
Transport of the SLBP Dependant Mature mRNA | 36 | 1.34e-01 | -0.144000 | 4.68e-01 |
GRB2:SOS provides linkage to MAPK signaling for Integrins | 12 | 3.88e-01 | -0.144000 | 7.16e-01 |
RAF-independent MAPK1/3 activation | 22 | 2.43e-01 | 0.144000 | 6.09e-01 |
Regulation of IFNG signaling | 13 | 3.69e-01 | -0.144000 | 7.00e-01 |
Depolymerization of the Nuclear Lamina | 15 | 3.37e-01 | -0.143000 | 6.87e-01 |
Platelet degranulation | 111 | 9.20e-03 | -0.143000 | 8.13e-02 |
Negative regulation of FGFR4 signaling | 22 | 2.45e-01 | 0.143000 | 6.12e-01 |
SHC-mediated cascade:FGFR4 | 11 | 4.11e-01 | 0.143000 | 7.33e-01 |
Nuclear signaling by ERBB4 | 29 | 1.83e-01 | -0.143000 | 5.41e-01 |
RND1 GTPase cycle | 38 | 1.27e-01 | 0.143000 | 4.54e-01 |
Synthesis of PC | 24 | 2.28e-01 | -0.142000 | 5.97e-01 |
Synthesis of bile acids and bile salts | 26 | 2.09e-01 | 0.142000 | 5.69e-01 |
Defective pyroptosis | 20 | 2.71e-01 | 0.142000 | 6.38e-01 |
Adrenaline,noradrenaline inhibits insulin secretion | 24 | 2.30e-01 | 0.142000 | 5.97e-01 |
Peroxisomal lipid metabolism | 26 | 2.13e-01 | -0.141000 | 5.75e-01 |
KSRP (KHSRP) binds and destabilizes mRNA | 17 | 3.14e-01 | -0.141000 | 6.68e-01 |
Impaired BRCA2 binding to PALB2 | 23 | 2.41e-01 | 0.141000 | 6.08e-01 |
Regulation of localization of FOXO transcription factors | 12 | 3.98e-01 | 0.141000 | 7.24e-01 |
HIV Transcription Initiation | 45 | 1.02e-01 | 0.141000 | 4.04e-01 |
RNA Polymerase II HIV Promoter Escape | 45 | 1.02e-01 | 0.141000 | 4.04e-01 |
RNA Polymerase II Promoter Escape | 45 | 1.02e-01 | 0.141000 | 4.04e-01 |
RNA Polymerase II Transcription Initiation | 45 | 1.02e-01 | 0.141000 | 4.04e-01 |
RNA Polymerase II Transcription Initiation And Promoter Clearance | 45 | 1.02e-01 | 0.141000 | 4.04e-01 |
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 45 | 1.02e-01 | 0.141000 | 4.04e-01 |
RET signaling | 32 | 1.69e-01 | -0.141000 | 5.24e-01 |
NoRC negatively regulates rRNA expression | 53 | 7.73e-02 | 0.140000 | 3.47e-01 |
Iron uptake and transport | 55 | 7.22e-02 | -0.140000 | 3.35e-01 |
Signaling by Erythropoietin | 24 | 2.36e-01 | -0.140000 | 6.03e-01 |
Chemokine receptors bind chemokines | 37 | 1.42e-01 | -0.140000 | 4.82e-01 |
Signaling by FGFR2 IIIa TM | 19 | 2.92e-01 | 0.140000 | 6.49e-01 |
Nuclear Events (kinase and transcription factor activation) | 57 | 6.94e-02 | 0.139000 | 3.32e-01 |
Mismatch Repair | 14 | 3.68e-01 | 0.139000 | 7.00e-01 |
Miscellaneous transport and binding events | 21 | 2.70e-01 | -0.139000 | 6.38e-01 |
Calnexin/calreticulin cycle | 26 | 2.24e-01 | -0.138000 | 5.92e-01 |
Synthesis of Leukotrienes (LT) and Eoxins (EX) | 12 | 4.09e-01 | -0.138000 | 7.33e-01 |
Response to elevated platelet cytosolic Ca2+ | 115 | 1.09e-02 | -0.138000 | 9.17e-02 |
Diseases associated with O-glycosylation of proteins | 56 | 7.54e-02 | -0.137000 | 3.44e-01 |
RHOU GTPase cycle | 39 | 1.39e-01 | -0.137000 | 4.78e-01 |
NEP/NS2 Interacts with the Cellular Export Machinery | 32 | 1.80e-01 | -0.137000 | 5.41e-01 |
Stimuli-sensing channels | 75 | 4.06e-02 | -0.137000 | 2.36e-01 |
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 13 | 3.94e-01 | 0.137000 | 7.20e-01 |
Eicosanoid ligand-binding receptors | 14 | 3.76e-01 | -0.137000 | 7.05e-01 |
InlB-mediated entry of Listeria monocytogenes into host cell | 14 | 3.78e-01 | -0.136000 | 7.06e-01 |
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 72 | 4.61e-02 | -0.136000 | 2.57e-01 |
G beta:gamma signalling through PI3Kgamma | 21 | 2.81e-01 | -0.136000 | 6.44e-01 |
Unblocking of NMDA receptors, glutamate binding and activation | 20 | 2.94e-01 | 0.136000 | 6.49e-01 |
N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 35 | 1.66e-01 | -0.135000 | 5.19e-01 |
Phospholipid metabolism | 183 | 1.62e-03 | -0.135000 | 2.02e-02 |
CTLA4 inhibitory signaling | 19 | 3.08e-01 | -0.135000 | 6.63e-01 |
Processing of SMDT1 | 15 | 3.65e-01 | 0.135000 | 7.00e-01 |
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 32 | 1.87e-01 | -0.135000 | 5.41e-01 |
Regulation of Glucokinase by Glucokinase Regulatory Protein | 32 | 1.87e-01 | -0.135000 | 5.41e-01 |
Phase 0 - rapid depolarisation | 24 | 2.54e-01 | 0.135000 | 6.19e-01 |
Elastic fibre formation | 40 | 1.42e-01 | -0.134000 | 4.82e-01 |
The canonical retinoid cycle in rods (twilight vision) | 12 | 4.21e-01 | -0.134000 | 7.34e-01 |
FRS-mediated FGFR1 signaling | 15 | 3.69e-01 | 0.134000 | 7.00e-01 |
Signaling by FLT3 ITD and TKD mutants | 15 | 3.70e-01 | 0.134000 | 7.00e-01 |
Diseases of glycosylation | 128 | 9.29e-03 | -0.133000 | 8.15e-02 |
Ras activation upon Ca2+ influx through NMDA receptor | 18 | 3.28e-01 | 0.133000 | 6.83e-01 |
NS1 Mediated Effects on Host Pathways | 40 | 1.46e-01 | -0.133000 | 4.88e-01 |
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 89 | 3.04e-02 | -0.133000 | 2.00e-01 |
Recognition of DNA damage by PCNA-containing replication complex | 30 | 2.08e-01 | 0.133000 | 5.68e-01 |
Metabolism of RNA | 694 | 2.98e-09 | 0.133000 | 1.26e-07 |
Vpr-mediated nuclear import of PICs | 34 | 1.81e-01 | -0.133000 | 5.41e-01 |
Platelet activation, signaling and aggregation | 229 | 5.63e-04 | -0.132000 | 1.01e-02 |
SHC1 events in ERBB2 signaling | 20 | 3.06e-01 | -0.132000 | 6.61e-01 |
CRMPs in Sema3A signaling | 15 | 3.76e-01 | -0.132000 | 7.05e-01 |
Cytosolic sulfonation of small molecules | 18 | 3.33e-01 | -0.132000 | 6.87e-01 |
YAP1- and WWTR1 (TAZ)-stimulated gene expression | 11 | 4.50e-01 | 0.132000 | 7.53e-01 |
WNT ligand biogenesis and trafficking | 17 | 3.48e-01 | 0.132000 | 6.91e-01 |
Endosomal Sorting Complex Required For Transport (ESCRT) | 30 | 2.13e-01 | 0.132000 | 5.75e-01 |
Effects of PIP2 hydrolysis | 24 | 2.67e-01 | -0.131000 | 6.35e-01 |
Signaling by PDGF | 54 | 9.63e-02 | -0.131000 | 4.02e-01 |
TNFR2 non-canonical NF-kB pathway | 90 | 3.22e-02 | -0.131000 | 2.04e-01 |
Pyrimidine salvage | 10 | 4.75e-01 | -0.131000 | 7.71e-01 |
Signaling by NTRK2 (TRKB) | 23 | 2.79e-01 | -0.131000 | 6.43e-01 |
Downstream signaling of activated FGFR3 | 19 | 3.25e-01 | 0.130000 | 6.80e-01 |
Metabolic disorders of biological oxidation enzymes | 24 | 2.70e-01 | -0.130000 | 6.38e-01 |
TRAF6 mediated NF-kB activation | 23 | 2.81e-01 | -0.130000 | 6.44e-01 |
Bacterial Infection Pathways | 65 | 7.04e-02 | -0.130000 | 3.33e-01 |
RNA Polymerase I Transcription Termination | 30 | 2.19e-01 | 0.130000 | 5.85e-01 |
Killing mechanisms | 10 | 4.79e-01 | -0.129000 | 7.71e-01 |
WNT5:FZD7-mediated leishmania damping | 10 | 4.79e-01 | -0.129000 | 7.71e-01 |
ERBB2 Activates PTK6 Signaling | 11 | 4.59e-01 | -0.129000 | 7.59e-01 |
ADP signalling through P2Y purinoceptor 1 | 21 | 3.08e-01 | -0.129000 | 6.63e-01 |
Cytochrome c-mediated apoptotic response | 13 | 4.22e-01 | -0.129000 | 7.34e-01 |
Downstream signaling of activated FGFR2 | 21 | 3.10e-01 | 0.128000 | 6.65e-01 |
Transcription of E2F targets under negative control by DREAM complex | 18 | 3.48e-01 | -0.128000 | 6.91e-01 |
Physiological factors | 10 | 4.86e-01 | 0.127000 | 7.75e-01 |
Signaling by Leptin | 11 | 4.66e-01 | 0.127000 | 7.65e-01 |
Regulation of TP53 Activity through Methylation | 19 | 3.41e-01 | -0.126000 | 6.87e-01 |
Death Receptor Signaling | 149 | 7.87e-03 | -0.126000 | 7.51e-02 |
EGFR downregulation | 29 | 2.40e-01 | -0.126000 | 6.06e-01 |
Signaling by VEGF | 105 | 2.63e-02 | -0.126000 | 1.83e-01 |
IRF3-mediated induction of type I IFN | 12 | 4.52e-01 | -0.125000 | 7.53e-01 |
ER-Phagosome pathway | 79 | 5.50e-02 | -0.125000 | 2.79e-01 |
Asparagine N-linked glycosylation | 281 | 3.25e-04 | -0.125000 | 6.18e-03 |
Interactions of Rev with host cellular proteins | 37 | 1.90e-01 | -0.124000 | 5.41e-01 |
Cell death signalling via NRAGE, NRIF and NADE | 73 | 6.64e-02 | -0.124000 | 3.23e-01 |
Signaling by ALK | 26 | 2.74e-01 | -0.124000 | 6.40e-01 |
Diseases of metabolism | 210 | 2.00e-03 | -0.124000 | 2.41e-02 |
Synthesis of PIPs at the late endosome membrane | 11 | 4.77e-01 | -0.124000 | 7.71e-01 |
Interleukin-6 family signaling | 22 | 3.15e-01 | 0.124000 | 6.68e-01 |
NFE2L2 regulating anti-oxidant/detoxification enzymes | 15 | 4.07e-01 | 0.124000 | 7.33e-01 |
Negative regulation of MET activity | 20 | 3.41e-01 | -0.123000 | 6.87e-01 |
G alpha (12/13) signalling events | 71 | 7.35e-02 | -0.123000 | 3.38e-01 |
Activation of G protein gated Potassium channels | 21 | 3.30e-01 | 0.123000 | 6.83e-01 |
G protein gated Potassium channels | 21 | 3.30e-01 | 0.123000 | 6.83e-01 |
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 21 | 3.30e-01 | 0.123000 | 6.83e-01 |
Clathrin-mediated endocytosis | 133 | 1.47e-02 | -0.123000 | 1.18e-01 |
IL-6-type cytokine receptor ligand interactions | 15 | 4.11e-01 | 0.123000 | 7.33e-01 |
B-WICH complex positively regulates rRNA expression | 38 | 1.92e-01 | 0.122000 | 5.42e-01 |
Nuclear Envelope Breakdown | 53 | 1.25e-01 | -0.122000 | 4.50e-01 |
Downstream signaling of activated FGFR1 | 21 | 3.35e-01 | 0.122000 | 6.87e-01 |
Interactions of Vpr with host cellular proteins | 37 | 2.01e-01 | -0.121000 | 5.59e-01 |
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 15 | 4.16e-01 | -0.121000 | 7.34e-01 |
Basigin interactions | 22 | 3.25e-01 | -0.121000 | 6.80e-01 |
Signaling by FGFR4 in disease | 10 | 5.07e-01 | 0.121000 | 7.89e-01 |
Cytokine Signaling in Immune system | 603 | 4.10e-07 | -0.121000 | 1.52e-05 |
COPI-independent Golgi-to-ER retrograde traffic | 45 | 1.60e-01 | 0.121000 | 5.11e-01 |
Signaling by EGFR | 48 | 1.47e-01 | -0.121000 | 4.90e-01 |
Interleukin-20 family signaling | 14 | 4.35e-01 | -0.121000 | 7.39e-01 |
Negative epigenetic regulation of rRNA expression | 56 | 1.19e-01 | 0.120000 | 4.41e-01 |
Receptor-type tyrosine-protein phosphatases | 13 | 4.53e-01 | 0.120000 | 7.53e-01 |
RUNX2 regulates bone development | 29 | 2.63e-01 | -0.120000 | 6.29e-01 |
SARS-CoV-1 activates/modulates innate immune responses | 40 | 1.89e-01 | -0.120000 | 5.41e-01 |
MAPK targets/ Nuclear events mediated by MAP kinases | 31 | 2.48e-01 | 0.120000 | 6.15e-01 |
Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 10 | 5.12e-01 | 0.120000 | 7.92e-01 |
Regulation of FOXO transcriptional activity by acetylation | 10 | 5.15e-01 | 0.119000 | 7.94e-01 |
Synthesis of substrates in N-glycan biosythesis | 57 | 1.21e-01 | -0.119000 | 4.47e-01 |
VxPx cargo-targeting to cilium | 17 | 3.99e-01 | -0.118000 | 7.25e-01 |
Chaperonin-mediated protein folding | 78 | 7.14e-02 | 0.118000 | 3.35e-01 |
Vesicle-mediated transport | 617 | 5.96e-07 | -0.118000 | 2.15e-05 |
NPAS4 regulates expression of target genes | 19 | 3.74e-01 | 0.118000 | 7.03e-01 |
CD209 (DC-SIGN) signaling | 20 | 3.62e-01 | -0.118000 | 7.00e-01 |
Intrinsic Pathway for Apoptosis | 54 | 1.35e-01 | -0.118000 | 4.69e-01 |
PKA activation in glucagon signalling | 15 | 4.31e-01 | -0.117000 | 7.36e-01 |
Regulation of MECP2 expression and activity | 29 | 2.74e-01 | -0.117000 | 6.40e-01 |
Listeria monocytogenes entry into host cells | 18 | 3.89e-01 | -0.117000 | 7.16e-01 |
TBC/RABGAPs | 44 | 1.79e-01 | -0.117000 | 5.39e-01 |
Ion transport by P-type ATPases | 43 | 1.86e-01 | 0.117000 | 5.41e-01 |
DDX58/IFIH1-mediated induction of interferon-alpha/beta | 66 | 1.02e-01 | -0.117000 | 4.04e-01 |
Transport of small molecules | 540 | 4.06e-06 | -0.116000 | 1.23e-04 |
Activation of BAD and translocation to mitochondria | 15 | 4.36e-01 | 0.116000 | 7.41e-01 |
SARS-CoV-1 Infection | 137 | 2.01e-02 | 0.115000 | 1.50e-01 |
Inwardly rectifying K+ channels | 24 | 3.30e-01 | 0.115000 | 6.83e-01 |
Defective Intrinsic Pathway for Apoptosis | 21 | 3.63e-01 | -0.115000 | 7.00e-01 |
Regulation of signaling by CBL | 22 | 3.52e-01 | -0.115000 | 6.94e-01 |
DNA Damage/Telomere Stress Induced Senescence | 34 | 2.47e-01 | 0.115000 | 6.15e-01 |
Assembly Of The HIV Virion | 16 | 4.27e-01 | 0.115000 | 7.35e-01 |
Molecules associated with elastic fibres | 33 | 2.55e-01 | -0.114000 | 6.21e-01 |
Hemostasis | 504 | 1.15e-05 | -0.114000 | 3.05e-04 |
Autophagy | 139 | 2.02e-02 | 0.114000 | 1.50e-01 |
Ion channel transport | 137 | 2.13e-02 | -0.114000 | 1.55e-01 |
SUMOylation of SUMOylation proteins | 35 | 2.44e-01 | -0.114000 | 6.10e-01 |
Nuclear import of Rev protein | 34 | 2.53e-01 | -0.113000 | 6.19e-01 |
Nervous system development | 517 | 1.14e-05 | 0.113000 | 3.05e-04 |
PI Metabolism | 79 | 8.30e-02 | -0.113000 | 3.62e-01 |
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 17 | 4.21e-01 | -0.113000 | 7.34e-01 |
Sphingolipid de novo biosynthesis | 36 | 2.43e-01 | 0.112000 | 6.10e-01 |
Macroautophagy | 124 | 3.10e-02 | 0.112000 | 2.00e-01 |
Signaling by FGFR4 | 32 | 2.72e-01 | 0.112000 | 6.39e-01 |
Glycogen metabolism | 24 | 3.42e-01 | 0.112000 | 6.87e-01 |
Platelet sensitization by LDL | 17 | 4.24e-01 | -0.112000 | 7.34e-01 |
Initiation of Nuclear Envelope (NE) Reformation | 19 | 4.02e-01 | 0.111000 | 7.29e-01 |
FLT3 signaling in disease | 27 | 3.18e-01 | 0.111000 | 6.73e-01 |
Toll-like Receptor Cascades | 158 | 1.63e-02 | -0.111000 | 1.30e-01 |
Anchoring fibril formation | 12 | 5.08e-01 | -0.110000 | 7.89e-01 |
ABC-family proteins mediated transport | 90 | 7.12e-02 | -0.110000 | 3.35e-01 |
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 41 | 2.23e-01 | 0.110000 | 5.92e-01 |
Synthesis of PA | 32 | 2.82e-01 | -0.110000 | 6.44e-01 |
TRAF6-mediated induction of TAK1 complex within TLR4 complex | 16 | 4.47e-01 | -0.110000 | 7.53e-01 |
Uptake and actions of bacterial toxins | 25 | 3.42e-01 | -0.110000 | 6.87e-01 |
Transcriptional activation of mitochondrial biogenesis | 49 | 1.84e-01 | -0.110000 | 5.41e-01 |
RNA Polymerase I Promoter Clearance | 57 | 1.53e-01 | 0.109000 | 4.96e-01 |
RNA Polymerase I Transcription | 57 | 1.53e-01 | 0.109000 | 4.96e-01 |
Cytosolic tRNA aminoacylation | 24 | 3.55e-01 | -0.109000 | 6.95e-01 |
Negative regulation of FGFR3 signaling | 23 | 3.66e-01 | 0.109000 | 7.00e-01 |
Activation of GABAB receptors | 33 | 2.79e-01 | 0.109000 | 6.43e-01 |
GABA B receptor activation | 33 | 2.79e-01 | 0.109000 | 6.43e-01 |
Neurexins and neuroligins | 46 | 2.01e-01 | -0.109000 | 5.60e-01 |
Branched-chain amino acid catabolism | 21 | 3.89e-01 | -0.109000 | 7.16e-01 |
Axon guidance | 496 | 3.64e-05 | 0.109000 | 8.70e-04 |
Negative regulation of FGFR2 signaling | 25 | 3.48e-01 | 0.108000 | 6.91e-01 |
Sensory Perception | 159 | 1.85e-02 | 0.108000 | 1.43e-01 |
Regulated proteolysis of p75NTR | 11 | 5.34e-01 | -0.108000 | 8.04e-01 |
Signalling to ERKs | 33 | 2.82e-01 | -0.108000 | 6.44e-01 |
Potential therapeutics for SARS | 100 | 6.24e-02 | -0.108000 | 3.06e-01 |
Meiosis | 52 | 1.78e-01 | 0.108000 | 5.39e-01 |
VEGFA-VEGFR2 Pathway | 96 | 6.87e-02 | -0.108000 | 3.31e-01 |
Protein folding | 84 | 8.88e-02 | 0.107000 | 3.78e-01 |
Host Interactions of HIV factors | 127 | 3.67e-02 | -0.107000 | 2.24e-01 |
NOTCH4 Intracellular Domain Regulates Transcription | 19 | 4.18e-01 | 0.107000 | 7.34e-01 |
TICAM1, RIP1-mediated IKK complex recruitment | 19 | 4.19e-01 | 0.107000 | 7.34e-01 |
Metabolism of nitric oxide: NOS3 activation and regulation | 15 | 4.73e-01 | 0.107000 | 7.71e-01 |
p75 NTR receptor-mediated signalling | 93 | 7.51e-02 | -0.107000 | 3.44e-01 |
TP53 Regulates Transcription of Death Receptors and Ligands | 11 | 5.40e-01 | 0.107000 | 8.09e-01 |
Ca2+ pathway | 55 | 1.72e-01 | 0.106000 | 5.32e-01 |
Respiratory electron transport | 93 | 7.64e-02 | 0.106000 | 3.44e-01 |
Amine ligand-binding receptors | 11 | 5.43e-01 | 0.106000 | 8.12e-01 |
Keratan sulfate/keratin metabolism | 32 | 3.00e-01 | -0.106000 | 6.55e-01 |
Heme biosynthesis | 13 | 5.10e-01 | 0.106000 | 7.90e-01 |
CDC42 GTPase cycle | 146 | 2.82e-02 | -0.105000 | 1.90e-01 |
Chromosome Maintenance | 93 | 7.95e-02 | 0.105000 | 3.53e-01 |
Translation of Replicase and Assembly of the Replication Transcription Complex 9679504 | 12 | 5.28e-01 | 0.105000 | 8.01e-01 |
Interleukin-12 family signaling | 47 | 2.14e-01 | -0.105000 | 5.76e-01 |
APC-Cdc20 mediated degradation of Nek2A | 26 | 3.56e-01 | 0.105000 | 6.95e-01 |
CS/DS degradation | 11 | 5.49e-01 | -0.104000 | 8.17e-01 |
Rap1 signalling | 14 | 5.00e-01 | -0.104000 | 7.89e-01 |
Translation of Replicase and Assembly of the Replication Transcription Complex 9694676 | 13 | 5.18e-01 | 0.104000 | 7.96e-01 |
Formation of ATP by chemiosmotic coupling | 16 | 4.74e-01 | 0.103000 | 7.71e-01 |
Telomere Maintenance | 70 | 1.36e-01 | 0.103000 | 4.70e-01 |
Export of Viral Ribonucleoproteins from Nucleus | 33 | 3.06e-01 | -0.103000 | 6.61e-01 |
Processive synthesis on the C-strand of the telomere | 19 | 4.37e-01 | 0.103000 | 7.41e-01 |
RNA Polymerase II Pre-transcription Events | 77 | 1.19e-01 | 0.103000 | 4.41e-01 |
Signaling by high-kinase activity BRAF mutants | 32 | 3.14e-01 | -0.103000 | 6.68e-01 |
Mitophagy | 28 | 3.47e-01 | 0.103000 | 6.91e-01 |
Sphingolipid metabolism | 72 | 1.32e-01 | -0.103000 | 4.65e-01 |
Acyl chain remodelling of PE | 20 | 4.27e-01 | -0.103000 | 7.35e-01 |
Late endosomal microautophagy | 31 | 3.24e-01 | 0.102000 | 6.80e-01 |
O-glycosylation of TSR domain-containing proteins | 36 | 2.90e-01 | -0.102000 | 6.47e-01 |
Sealing of the nuclear envelope (NE) by ESCRT-III | 24 | 3.88e-01 | 0.102000 | 7.16e-01 |
SARS-CoV-1 targets host intracellular signalling and regulatory pathways | 16 | 4.83e-01 | 0.101000 | 7.72e-01 |
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 26 | 3.71e-01 | 0.101000 | 7.01e-01 |
Removal of the Flap Intermediate from the C-strand | 17 | 4.70e-01 | 0.101000 | 7.70e-01 |
Intrinsic Pathway of Fibrin Clot Formation | 12 | 5.44e-01 | 0.101000 | 8.12e-01 |
Amyloid fiber formation | 43 | 2.52e-01 | -0.101000 | 6.19e-01 |
Pentose phosphate pathway | 13 | 5.29e-01 | -0.101000 | 8.01e-01 |
Signaling by RAF1 mutants | 37 | 2.90e-01 | -0.101000 | 6.47e-01 |
ESR-mediated signaling | 158 | 2.99e-02 | 0.100000 | 1.99e-01 |
Assembly of the pre-replicative complex | 90 | 1.01e-01 | 0.100000 | 4.04e-01 |
Notch-HLH transcription pathway | 28 | 3.60e-01 | -0.099900 | 7.00e-01 |
Arachidonic acid metabolism | 37 | 2.95e-01 | -0.099600 | 6.49e-01 |
TAK1-dependent IKK and NF-kappa-B activation | 43 | 2.62e-01 | -0.098900 | 6.26e-01 |
G alpha (i) signalling events | 187 | 2.00e-02 | -0.098800 | 1.49e-01 |
EPHB-mediated forward signaling | 41 | 2.74e-01 | -0.098800 | 6.40e-01 |
Transcriptional Regulation by E2F6 | 34 | 3.20e-01 | 0.098700 | 6.74e-01 |
A tetrasaccharide linker sequence is required for GAG synthesis | 22 | 4.23e-01 | -0.098600 | 7.34e-01 |
ADP signalling through P2Y purinoceptor 12 | 17 | 4.82e-01 | 0.098500 | 7.72e-01 |
COPI-dependent Golgi-to-ER retrograde traffic | 88 | 1.11e-01 | -0.098300 | 4.22e-01 |
Membrane Trafficking | 581 | 5.53e-05 | -0.098200 | 1.30e-03 |
Interconversion of nucleotide di- and triphosphates | 27 | 3.79e-01 | 0.097900 | 7.06e-01 |
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 113 | 7.36e-02 | 0.097500 | 3.38e-01 |
Defects in vitamin and cofactor metabolism | 20 | 4.53e-01 | 0.097000 | 7.53e-01 |
Transport of Mature Transcript to Cytoplasm | 81 | 1.31e-01 | -0.097000 | 4.64e-01 |
RHO GTPases activate KTN1 | 10 | 5.96e-01 | -0.096800 | 8.50e-01 |
Senescence-Associated Secretory Phenotype (SASP) | 57 | 2.07e-01 | 0.096700 | 5.68e-01 |
mRNA Capping | 29 | 3.69e-01 | 0.096300 | 7.00e-01 |
Cilium Assembly | 187 | 2.34e-02 | 0.096300 | 1.67e-01 |
O-linked glycosylation | 89 | 1.17e-01 | -0.096200 | 4.39e-01 |
Infection with Mycobacterium tuberculosis | 27 | 3.89e-01 | -0.095800 | 7.16e-01 |
Platelet Aggregation (Plug Formation) | 32 | 3.50e-01 | -0.095600 | 6.91e-01 |
PKA-mediated phosphorylation of CREB | 18 | 4.84e-01 | -0.095400 | 7.72e-01 |
Extracellular matrix organization | 258 | 9.19e-03 | -0.094300 | 8.13e-02 |
Activation of NMDA receptors and postsynaptic events | 80 | 1.45e-01 | 0.094300 | 4.88e-01 |
RNA Pol II CTD phosphorylation and interaction with CE | 27 | 3.98e-01 | 0.094100 | 7.24e-01 |
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 27 | 3.98e-01 | 0.094100 | 7.24e-01 |
MASTL Facilitates Mitotic Progression | 10 | 6.08e-01 | 0.093700 | 8.54e-01 |
STING mediated induction of host immune responses | 15 | 5.30e-01 | -0.093700 | 8.01e-01 |
NRIF signals cell death from the nucleus | 16 | 5.18e-01 | 0.093300 | 7.96e-01 |
SUMOylation of transcription factors | 17 | 5.06e-01 | -0.093300 | 7.89e-01 |
Transcription of the HIV genome | 67 | 1.87e-01 | 0.093200 | 5.41e-01 |
Transport to the Golgi and subsequent modification | 168 | 3.73e-02 | -0.093200 | 2.25e-01 |
Intra-Golgi and retrograde Golgi-to-ER traffic | 187 | 2.83e-02 | -0.093100 | 1.90e-01 |
Peptide hormone metabolism | 56 | 2.30e-01 | -0.092800 | 5.97e-01 |
Prolactin receptor signaling | 11 | 5.98e-01 | -0.091900 | 8.50e-01 |
Signaling by BRAF and RAF1 fusions | 59 | 2.25e-01 | -0.091300 | 5.95e-01 |
Signaling by PDGFR in disease | 20 | 4.80e-01 | -0.091300 | 7.71e-01 |
Platelet calcium homeostasis | 23 | 4.49e-01 | -0.091300 | 7.53e-01 |
Long-term potentiation | 22 | 4.59e-01 | 0.091100 | 7.59e-01 |
Synthesis of IP2, IP, and Ins in the cytosol | 13 | 5.70e-01 | -0.091100 | 8.33e-01 |
mRNA 3’-end processing | 57 | 2.35e-01 | -0.091000 | 6.03e-01 |
Developmental Biology | 803 | 1.29e-05 | 0.091000 | 3.29e-04 |
Interleukin-12 signaling | 41 | 3.15e-01 | -0.090700 | 6.68e-01 |
Class I MHC mediated antigen processing & presentation | 346 | 4.20e-03 | -0.089800 | 4.62e-02 |
Lewis blood group biosynthesis | 10 | 6.23e-01 | 0.089700 | 8.60e-01 |
Transport of Mature mRNA derived from an Intron-Containing Transcript | 72 | 1.88e-01 | -0.089700 | 5.41e-01 |
Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 11 | 6.08e-01 | -0.089300 | 8.54e-01 |
Signaling by FGFR2 | 61 | 2.29e-01 | 0.089200 | 5.97e-01 |
Signaling by FGFR3 | 34 | 3.69e-01 | 0.089000 | 7.00e-01 |
Signaling by Receptor Tyrosine Kinases | 476 | 9.14e-04 | -0.089000 | 1.44e-02 |
Gamma carboxylation, hypusine formation and arylsulfatase activation | 33 | 3.78e-01 | -0.088800 | 7.06e-01 |
Gap-filling DNA repair synthesis and ligation in GG-NER | 25 | 4.43e-01 | 0.088700 | 7.48e-01 |
Thromboxane signalling through TP receptor | 20 | 4.92e-01 | -0.088700 | 7.80e-01 |
Synthesis, secretion, and deacylation of Ghrelin | 12 | 5.96e-01 | 0.088500 | 8.50e-01 |
SUMOylation of chromatin organization proteins | 57 | 2.49e-01 | -0.088300 | 6.16e-01 |
SLC transporter disorders | 71 | 1.99e-01 | -0.088300 | 5.55e-01 |
mRNA Splicing | 210 | 2.79e-02 | 0.088100 | 1.90e-01 |
Presynaptic phase of homologous DNA pairing and strand exchange | 38 | 3.49e-01 | 0.087800 | 6.91e-01 |
RND3 GTPase cycle | 37 | 3.56e-01 | 0.087700 | 6.95e-01 |
Growth hormone receptor signaling | 20 | 4.98e-01 | -0.087600 | 7.87e-01 |
FOXO-mediated transcription | 57 | 2.53e-01 | 0.087500 | 6.19e-01 |
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models | 18 | 5.22e-01 | -0.087200 | 7.98e-01 |
Neurodegenerative Diseases | 18 | 5.22e-01 | -0.087200 | 7.98e-01 |
Oncogenic MAPK signaling | 75 | 1.93e-01 | -0.087000 | 5.43e-01 |
MET activates RAP1 and RAC1 | 11 | 6.18e-01 | 0.086900 | 8.60e-01 |
Formation of Incision Complex in GG-NER | 43 | 3.25e-01 | 0.086800 | 6.80e-01 |
RUNX1 regulates transcription of genes involved in differentiation of HSCs | 72 | 2.04e-01 | 0.086600 | 5.62e-01 |
Processing of Capped Intronless Pre-mRNA | 29 | 4.21e-01 | -0.086300 | 7.34e-01 |
Downstream signal transduction | 28 | 4.30e-01 | -0.086100 | 7.36e-01 |
Signal amplification | 28 | 4.31e-01 | -0.086100 | 7.36e-01 |
Frs2-mediated activation | 12 | 6.08e-01 | -0.085500 | 8.54e-01 |
Formation of HIV-1 elongation complex containing HIV-1 Tat | 42 | 3.38e-01 | 0.085400 | 6.87e-01 |
HIV Transcription Elongation | 42 | 3.38e-01 | 0.085400 | 6.87e-01 |
Tat-mediated elongation of the HIV-1 transcript | 42 | 3.38e-01 | 0.085400 | 6.87e-01 |
GPCR downstream signalling | 384 | 4.24e-03 | -0.085200 | 4.62e-02 |
Nucleotide catabolism | 24 | 4.72e-01 | -0.084800 | 7.71e-01 |
NCAM1 interactions | 32 | 4.07e-01 | -0.084600 | 7.33e-01 |
mRNA decay by 3’ to 5’ exoribonuclease | 13 | 5.97e-01 | 0.084600 | 8.50e-01 |
Adenylate cyclase inhibitory pathway | 12 | 6.12e-01 | 0.084600 | 8.59e-01 |
G alpha (z) signalling events | 39 | 3.65e-01 | 0.083800 | 7.00e-01 |
Signaling by Interleukins | 394 | 4.43e-03 | -0.083700 | 4.73e-02 |
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 84 | 1.87e-01 | -0.083400 | 5.41e-01 |
RHO GTPases activate IQGAPs | 24 | 4.80e-01 | 0.083400 | 7.71e-01 |
The role of GTSE1 in G2/M progression after G2 checkpoint | 70 | 2.29e-01 | 0.083200 | 5.97e-01 |
Viral Messenger RNA Synthesis | 44 | 3.41e-01 | -0.083100 | 6.87e-01 |
ERBB2 Regulates Cell Motility | 13 | 6.06e-01 | -0.082700 | 8.54e-01 |
Regulation of TP53 Activity through Acetylation | 29 | 4.41e-01 | -0.082600 | 7.47e-01 |
mRNA Splicing - Minor Pathway | 50 | 3.13e-01 | 0.082600 | 6.68e-01 |
Anchoring of the basal body to the plasma membrane | 96 | 1.62e-01 | 0.082600 | 5.14e-01 |
Diseases of DNA repair | 48 | 3.24e-01 | 0.082300 | 6.80e-01 |
MAPK6/MAPK4 signaling | 83 | 1.96e-01 | 0.082200 | 5.47e-01 |
Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 22 | 5.07e-01 | -0.081700 | 7.89e-01 |
Formation of the Early Elongation Complex | 33 | 4.17e-01 | 0.081600 | 7.34e-01 |
Formation of the HIV-1 Early Elongation Complex | 33 | 4.17e-01 | 0.081600 | 7.34e-01 |
Vasopressin regulates renal water homeostasis via Aquaporins | 34 | 4.12e-01 | 0.081300 | 7.34e-01 |
Positive epigenetic regulation of rRNA expression | 53 | 3.06e-01 | 0.081300 | 6.61e-01 |
SHC-mediated cascade:FGFR2 | 14 | 5.99e-01 | 0.081200 | 8.51e-01 |
Cytoprotection by HMOX1 | 58 | 2.85e-01 | -0.081100 | 6.47e-01 |
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 24 | 4.92e-01 | 0.081100 | 7.80e-01 |
Defective B3GALTL causes PpS | 35 | 4.07e-01 | -0.081000 | 7.33e-01 |
Fanconi Anemia Pathway | 35 | 4.08e-01 | -0.080800 | 7.33e-01 |
Formation of RNA Pol II elongation complex | 56 | 2.97e-01 | 0.080600 | 6.50e-01 |
RNA Polymerase II Transcription Elongation | 56 | 2.97e-01 | 0.080600 | 6.50e-01 |
Deactivation of the beta-catenin transactivating complex | 39 | 3.85e-01 | 0.080500 | 7.13e-01 |
tRNA modification in the nucleus and cytosol | 43 | 3.62e-01 | 0.080300 | 7.00e-01 |
C-type lectin receptors (CLRs) | 123 | 1.24e-01 | -0.080300 | 4.50e-01 |
Signaling by cytosolic FGFR1 fusion mutants | 18 | 5.56e-01 | -0.080300 | 8.20e-01 |
Polymerase switching on the C-strand of the telomere | 26 | 4.81e-01 | 0.079900 | 7.71e-01 |
Opioid Signalling | 79 | 2.20e-01 | -0.079900 | 5.85e-01 |
GABA receptor activation | 41 | 3.76e-01 | 0.079900 | 7.05e-01 |
Integrin cell surface interactions | 74 | 2.36e-01 | -0.079800 | 6.03e-01 |
Signaling by FLT3 fusion proteins | 19 | 5.48e-01 | 0.079600 | 8.16e-01 |
Bile acid and bile salt metabolism | 30 | 4.52e-01 | 0.079300 | 7.53e-01 |
O-linked glycosylation of mucins | 44 | 3.63e-01 | -0.079300 | 7.00e-01 |
Rab regulation of trafficking | 119 | 1.36e-01 | -0.079300 | 4.70e-01 |
VEGFR2 mediated cell proliferation | 19 | 5.50e-01 | -0.079200 | 8.17e-01 |
mRNA Splicing - Major Pathway | 202 | 5.35e-02 | 0.078900 | 2.75e-01 |
Translocation of SLC2A4 (GLUT4) to the plasma membrane | 64 | 2.75e-01 | 0.078900 | 6.40e-01 |
Reproduction | 70 | 2.59e-01 | 0.078000 | 6.24e-01 |
Post-translational modification: synthesis of GPI-anchored proteins | 63 | 2.84e-01 | -0.078000 | 6.47e-01 |
GPER1 signaling | 38 | 4.06e-01 | -0.077900 | 7.33e-01 |
SHC-mediated cascade:FGFR3 | 12 | 6.41e-01 | 0.077600 | 8.70e-01 |
Sensory processing of sound by outer hair cells of the cochlea | 41 | 3.90e-01 | 0.077600 | 7.16e-01 |
Formation of HIV elongation complex in the absence of HIV Tat | 44 | 3.73e-01 | 0.077600 | 7.03e-01 |
Detoxification of Reactive Oxygen Species | 33 | 4.43e-01 | -0.077200 | 7.48e-01 |
Phase 4 - resting membrane potential | 11 | 6.58e-01 | 0.077100 | 8.80e-01 |
Regulation of BACH1 activity | 11 | 6.59e-01 | 0.076800 | 8.81e-01 |
Factors involved in megakaryocyte development and platelet production | 123 | 1.42e-01 | -0.076700 | 4.82e-01 |
Telomere C-strand (Lagging Strand) Synthesis | 34 | 4.41e-01 | 0.076400 | 7.47e-01 |
Retinoid metabolism and transport | 30 | 4.70e-01 | 0.076200 | 7.70e-01 |
EPH-Ephrin signaling | 86 | 2.23e-01 | -0.076100 | 5.92e-01 |
Signaling by NODAL | 13 | 6.37e-01 | 0.075500 | 8.70e-01 |
Diseases associated with glycosylation precursor biosynthesis | 15 | 6.13e-01 | -0.075400 | 8.59e-01 |
Pre-NOTCH Transcription and Translation | 40 | 4.10e-01 | 0.075300 | 7.33e-01 |
DNA Replication Pre-Initiation | 105 | 1.83e-01 | 0.075200 | 5.41e-01 |
Formation of TC-NER Pre-Incision Complex | 53 | 3.45e-01 | 0.075000 | 6.89e-01 |
Regulation of RUNX1 Expression and Activity | 18 | 5.84e-01 | -0.074600 | 8.41e-01 |
Recruitment of NuMA to mitotic centrosomes | 88 | 2.27e-01 | 0.074600 | 5.97e-01 |
Response of Mtb to phagocytosis | 23 | 5.37e-01 | -0.074400 | 8.07e-01 |
Post NMDA receptor activation events | 68 | 2.89e-01 | 0.074400 | 6.47e-01 |
Response to metal ions | 10 | 6.88e-01 | -0.073400 | 8.88e-01 |
Recycling pathway of L1 | 41 | 4.18e-01 | -0.073100 | 7.34e-01 |
ER to Golgi Anterograde Transport | 143 | 1.32e-01 | -0.073000 | 4.65e-01 |
Fc epsilon receptor (FCERI) signaling | 133 | 1.48e-01 | -0.072800 | 4.90e-01 |
Disorders of transmembrane transporters | 139 | 1.39e-01 | -0.072800 | 4.78e-01 |
Antiviral mechanism by IFN-stimulated genes | 79 | 2.64e-01 | -0.072800 | 6.29e-01 |
Paradoxical activation of RAF signaling by kinase inactive BRAF | 41 | 4.20e-01 | -0.072800 | 7.34e-01 |
Signaling by RAS mutants | 41 | 4.20e-01 | -0.072800 | 7.34e-01 |
Signaling by moderate kinase activity BRAF mutants | 41 | 4.20e-01 | -0.072800 | 7.34e-01 |
Signaling downstream of RAS mutants | 41 | 4.20e-01 | -0.072800 | 7.34e-01 |
Thrombin signalling through proteinase activated receptors (PARs) | 27 | 5.14e-01 | -0.072600 | 7.93e-01 |
Regulation of PLK1 Activity at G2/M Transition | 86 | 2.45e-01 | 0.072500 | 6.12e-01 |
Activation of HOX genes during differentiation | 66 | 3.11e-01 | 0.072200 | 6.65e-01 |
Activation of anterior HOX genes in hindbrain development during early embryogenesis | 66 | 3.11e-01 | 0.072200 | 6.65e-01 |
Aquaporin-mediated transport | 36 | 4.55e-01 | 0.072000 | 7.54e-01 |
IRAK2 mediated activation of TAK1 complex | 10 | 6.95e-01 | 0.071600 | 8.94e-01 |
Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 14 | 6.44e-01 | -0.071400 | 8.71e-01 |
Defective EXT2 causes exostoses 2 | 14 | 6.44e-01 | -0.071400 | 8.71e-01 |
Cargo trafficking to the periciliary membrane | 45 | 4.08e-01 | 0.071300 | 7.33e-01 |
Signaling by Retinoic Acid | 35 | 4.66e-01 | -0.071200 | 7.65e-01 |
RHOD GTPase cycle | 50 | 3.85e-01 | 0.071100 | 7.13e-01 |
Gap junction assembly | 21 | 5.74e-01 | 0.070800 | 8.37e-01 |
RMTs methylate histone arginines | 33 | 4.83e-01 | -0.070600 | 7.72e-01 |
Dual incision in TC-NER | 65 | 3.29e-01 | 0.070100 | 6.83e-01 |
RHO GTPases Activate WASPs and WAVEs | 35 | 4.77e-01 | -0.069500 | 7.71e-01 |
mTORC1-mediated signalling | 24 | 5.56e-01 | 0.069500 | 8.20e-01 |
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 12 | 6.77e-01 | 0.069500 | 8.87e-01 |
Visual phototransduction | 61 | 3.52e-01 | 0.068900 | 6.94e-01 |
Constitutive Signaling by Aberrant PI3K in Cancer | 58 | 3.64e-01 | -0.068900 | 7.00e-01 |
PI3K events in ERBB2 signaling | 14 | 6.56e-01 | -0.068800 | 8.80e-01 |
DNA Damage Bypass | 46 | 4.21e-01 | 0.068600 | 7.34e-01 |
ISG15 antiviral mechanism | 71 | 3.18e-01 | -0.068600 | 6.73e-01 |
Gap-filling DNA repair synthesis and ligation in TC-NER | 64 | 3.43e-01 | 0.068500 | 6.87e-01 |
Metabolism of lipids | 610 | 4.02e-03 | -0.068500 | 4.55e-02 |
Negative regulation of NMDA receptor-mediated neuronal transmission | 18 | 6.15e-01 | 0.068400 | 8.59e-01 |
HATs acetylate histones | 83 | 2.83e-01 | 0.068300 | 6.45e-01 |
PIWI-interacting RNA (piRNA) biogenesis | 22 | 5.82e-01 | 0.067800 | 8.40e-01 |
Methylation | 12 | 6.84e-01 | 0.067800 | 8.88e-01 |
RNA polymerase II transcribes snRNA genes | 71 | 3.24e-01 | 0.067700 | 6.80e-01 |
IRS-related events triggered by IGF1R | 38 | 4.71e-01 | 0.067600 | 7.70e-01 |
Carnitine metabolism | 13 | 6.73e-01 | 0.067600 | 8.87e-01 |
FCERI mediated NF-kB activation | 83 | 2.88e-01 | -0.067500 | 6.47e-01 |
Acyl chain remodelling of PC | 20 | 6.02e-01 | -0.067400 | 8.52e-01 |
TCF dependent signaling in response to WNT | 161 | 1.42e-01 | 0.067100 | 4.82e-01 |
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 12 | 6.87e-01 | -0.067100 | 8.88e-01 |
Synaptic adhesion-like molecules | 19 | 6.14e-01 | 0.066900 | 8.59e-01 |
VEGFR2 mediated vascular permeability | 27 | 5.48e-01 | -0.066900 | 8.16e-01 |
AUF1 (hnRNP D0) binds and destabilizes mRNA | 53 | 4.01e-01 | 0.066700 | 7.28e-01 |
Constitutive Signaling by EGFRvIII | 15 | 6.55e-01 | -0.066700 | 8.80e-01 |
Signaling by EGFRvIII in Cancer | 15 | 6.55e-01 | -0.066700 | 8.80e-01 |
Downregulation of ERBB2 signaling | 27 | 5.50e-01 | 0.066400 | 8.17e-01 |
Formation of WDR5-containing histone-modifying complexes | 42 | 4.57e-01 | -0.066400 | 7.57e-01 |
Activation of the pre-replicative complex | 31 | 5.23e-01 | 0.066300 | 7.98e-01 |
TP53 Regulates Transcription of DNA Repair Genes | 61 | 3.74e-01 | 0.065800 | 7.03e-01 |
RHOA GTPase cycle | 143 | 1.75e-01 | -0.065700 | 5.39e-01 |
G alpha (q) signalling events | 137 | 1.85e-01 | -0.065700 | 5.41e-01 |
Nuclear Envelope (NE) Reassembly | 68 | 3.49e-01 | 0.065600 | 6.91e-01 |
Surfactant metabolism | 20 | 6.13e-01 | 0.065400 | 8.59e-01 |
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | 13 | 6.83e-01 | -0.065300 | 8.88e-01 |
Negative regulation of the PI3K/AKT network | 91 | 2.83e-01 | -0.065200 | 6.45e-01 |
Toll Like Receptor 7/8 (TLR7/8) Cascade | 102 | 2.56e-01 | -0.065100 | 6.22e-01 |
Ovarian tumor domain proteases | 36 | 5.00e-01 | -0.065000 | 7.89e-01 |
Signaling by TGFB family members | 113 | 2.33e-01 | 0.065000 | 6.00e-01 |
Chondroitin sulfate biosynthesis | 16 | 6.53e-01 | -0.064900 | 8.80e-01 |
Base Excision Repair | 51 | 4.24e-01 | 0.064800 | 7.34e-01 |
Dopamine Neurotransmitter Release Cycle | 22 | 5.99e-01 | 0.064800 | 8.51e-01 |
Toll Like Receptor 4 (TLR4) Cascade | 138 | 1.90e-01 | -0.064700 | 5.41e-01 |
Negative regulation of FGFR1 signaling | 25 | 5.76e-01 | 0.064500 | 8.37e-01 |
Sialic acid metabolism | 27 | 5.63e-01 | -0.064300 | 8.26e-01 |
Cellular responses to stress | 696 | 4.05e-03 | 0.064200 | 4.55e-02 |
G beta:gamma signalling through PLC beta | 16 | 6.57e-01 | -0.064200 | 8.80e-01 |
Non-integrin membrane-ECM interactions | 55 | 4.11e-01 | 0.064100 | 7.33e-01 |
Nephrin family interactions | 20 | 6.20e-01 | 0.064100 | 8.60e-01 |
NOTCH1 Intracellular Domain Regulates Transcription | 47 | 4.48e-01 | 0.064100 | 7.53e-01 |
Signaling by ERBB2 TMD/JMD mutants | 20 | 6.21e-01 | -0.063900 | 8.60e-01 |
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 36 | 5.08e-01 | 0.063800 | 7.89e-01 |
Metabolism of fat-soluble vitamins | 33 | 5.26e-01 | 0.063800 | 8.01e-01 |
Alpha-protein kinase 1 signaling pathway | 11 | 7.16e-01 | 0.063400 | 9.08e-01 |
Early SARS-CoV-2 Infection Events | 33 | 5.30e-01 | -0.063200 | 8.01e-01 |
ATF6 (ATF6-alpha) activates chaperones | 12 | 7.05e-01 | -0.063200 | 9.02e-01 |
Resolution of D-Loop Structures | 33 | 5.33e-01 | -0.062700 | 8.04e-01 |
Resolution of Abasic Sites (AP sites) | 38 | 5.07e-01 | -0.062300 | 7.89e-01 |
Cellular responses to stimuli | 706 | 5.02e-03 | 0.062300 | 5.28e-02 |
Signaling by GPCR | 429 | 2.75e-02 | -0.062200 | 1.89e-01 |
NOTCH2 Activation and Transmission of Signal to the Nucleus | 22 | 6.15e-01 | 0.062000 | 8.59e-01 |
G-protein activation | 19 | 6.40e-01 | -0.061900 | 8.70e-01 |
CTNNB1 S33 mutants aren’t phosphorylated | 15 | 6.79e-01 | 0.061700 | 8.87e-01 |
CTNNB1 S37 mutants aren’t phosphorylated | 15 | 6.79e-01 | 0.061700 | 8.87e-01 |
CTNNB1 S45 mutants aren’t phosphorylated | 15 | 6.79e-01 | 0.061700 | 8.87e-01 |
CTNNB1 T41 mutants aren’t phosphorylated | 15 | 6.79e-01 | 0.061700 | 8.87e-01 |
Signaling by CTNNB1 phospho-site mutants | 15 | 6.79e-01 | 0.061700 | 8.87e-01 |
Signaling by GSK3beta mutants | 15 | 6.79e-01 | 0.061700 | 8.87e-01 |
MyD88-independent TLR4 cascade | 107 | 2.71e-01 | -0.061600 | 6.38e-01 |
TRIF(TICAM1)-mediated TLR4 signaling | 107 | 2.71e-01 | -0.061600 | 6.38e-01 |
N-Glycan antennae elongation | 13 | 7.01e-01 | 0.061500 | 9.00e-01 |
RHOQ GTPase cycle | 57 | 4.24e-01 | -0.061200 | 7.34e-01 |
Triglyceride catabolism | 16 | 6.73e-01 | -0.060900 | 8.87e-01 |
SARS-CoV-2 Infection | 266 | 8.81e-02 | -0.060900 | 3.77e-01 |
TGF-beta receptor signaling activates SMADs | 45 | 4.80e-01 | 0.060800 | 7.71e-01 |
SUMOylation of RNA binding proteins | 47 | 4.73e-01 | -0.060600 | 7.71e-01 |
SARS-CoV Infections | 384 | 4.26e-02 | -0.060400 | 2.44e-01 |
Class B/2 (Secretin family receptors) | 59 | 4.28e-01 | 0.059700 | 7.35e-01 |
Signaling by FGFR1 in disease | 32 | 5.60e-01 | 0.059600 | 8.23e-01 |
Toll Like Receptor 9 (TLR9) Cascade | 105 | 2.93e-01 | -0.059400 | 6.49e-01 |
Signal transduction by L1 | 21 | 6.38e-01 | -0.059400 | 8.70e-01 |
Signaling by CSF3 (G-CSF) | 29 | 5.81e-01 | -0.059200 | 8.40e-01 |
Defective homologous recombination repair (HRR) due to BRCA2 loss of function | 39 | 5.23e-01 | 0.059100 | 7.98e-01 |
Diseases of DNA Double-Strand Break Repair | 39 | 5.23e-01 | 0.059100 | 7.98e-01 |
Glutathione conjugation | 30 | 5.76e-01 | 0.059100 | 8.37e-01 |
TCR signaling | 106 | 2.94e-01 | -0.059000 | 6.49e-01 |
Transcriptional regulation by RUNX1 | 169 | 1.86e-01 | 0.059000 | 5.41e-01 |
Pausing and recovery of Tat-mediated HIV elongation | 30 | 5.78e-01 | 0.058800 | 8.37e-01 |
Tat-mediated HIV elongation arrest and recovery | 30 | 5.78e-01 | 0.058800 | 8.37e-01 |
Signaling by ERBB4 | 52 | 4.64e-01 | -0.058700 | 7.65e-01 |
Lysine catabolism | 11 | 7.38e-01 | -0.058400 | 9.14e-01 |
Separation of Sister Chromatids | 176 | 1.85e-01 | 0.058000 | 5.41e-01 |
Mitotic Prophase | 89 | 3.45e-01 | -0.058000 | 6.89e-01 |
Activation of kainate receptors upon glutamate binding | 24 | 6.23e-01 | 0.058000 | 8.60e-01 |
Cell-extracellular matrix interactions | 18 | 6.71e-01 | -0.057800 | 8.87e-01 |
G alpha (s) signalling events | 91 | 3.41e-01 | -0.057800 | 6.87e-01 |
RAC1 GTPase cycle | 173 | 1.91e-01 | -0.057700 | 5.41e-01 |
Resolution of Sister Chromatid Cohesion | 113 | 2.91e-01 | 0.057600 | 6.47e-01 |
Mitotic Telophase/Cytokinesis | 13 | 7.20e-01 | 0.057500 | 9.08e-01 |
Golgi-to-ER retrograde transport | 121 | 2.75e-01 | -0.057500 | 6.40e-01 |
PCP/CE pathway | 88 | 3.53e-01 | -0.057300 | 6.95e-01 |
Mitotic Metaphase and Anaphase | 220 | 1.45e-01 | 0.057100 | 4.88e-01 |
TP53 Regulates Transcription of Cell Cycle Genes | 44 | 5.12e-01 | -0.057100 | 7.92e-01 |
Signaling by FGFR | 70 | 4.10e-01 | 0.057000 | 7.33e-01 |
Glucagon signaling in metabolic regulation | 26 | 6.16e-01 | -0.056900 | 8.59e-01 |
Regulation of PTEN gene transcription | 59 | 4.51e-01 | 0.056700 | 7.53e-01 |
Mitotic Anaphase | 219 | 1.49e-01 | 0.056700 | 4.91e-01 |
RNA Polymerase I Transcription Initiation | 47 | 5.03e-01 | 0.056500 | 7.89e-01 |
PERK regulates gene expression | 32 | 5.80e-01 | 0.056500 | 8.40e-01 |
MyD88 dependent cascade initiated on endosome | 101 | 3.27e-01 | -0.056500 | 6.82e-01 |
Loss of Nlp from mitotic centrosomes | 68 | 4.22e-01 | 0.056300 | 7.34e-01 |
Loss of proteins required for interphase microtubule organization from the centrosome | 68 | 4.22e-01 | 0.056300 | 7.34e-01 |
Activation of RAC1 | 11 | 7.46e-01 | -0.056300 | 9.17e-01 |
TP53 Regulates Metabolic Genes | 80 | 3.85e-01 | 0.056200 | 7.13e-01 |
RNA Polymerase III Abortive And Retractive Initiation | 41 | 5.35e-01 | 0.056100 | 8.04e-01 |
RNA Polymerase III Transcription | 41 | 5.35e-01 | 0.056100 | 8.04e-01 |
ABC transporter disorders | 68 | 4.25e-01 | -0.056000 | 7.35e-01 |
APC/C:Cdc20 mediated degradation of Cyclin B | 24 | 6.36e-01 | 0.055800 | 8.70e-01 |
Cross-presentation of soluble exogenous antigens (endosomes) | 46 | 5.14e-01 | -0.055700 | 7.93e-01 |
Hedgehog ‘off’ state | 105 | 3.26e-01 | 0.055500 | 6.82e-01 |
HS-GAG biosynthesis | 25 | 6.33e-01 | -0.055200 | 8.67e-01 |
Interleukin-6 signaling | 11 | 7.52e-01 | 0.055100 | 9.19e-01 |
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 12 | 7.41e-01 | 0.055100 | 9.16e-01 |
Dissolution of Fibrin Clot | 10 | 7.63e-01 | -0.055000 | 9.24e-01 |
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 30 | 6.03e-01 | 0.054800 | 8.53e-01 |
Formation of Fibrin Clot (Clotting Cascade) | 21 | 6.64e-01 | 0.054800 | 8.83e-01 |
CLEC7A (Dectin-1) signaling | 96 | 3.54e-01 | -0.054700 | 6.95e-01 |
Organelle biogenesis and maintenance | 272 | 1.21e-01 | 0.054700 | 4.47e-01 |
RAC2 GTPase cycle | 85 | 3.85e-01 | -0.054600 | 7.13e-01 |
Negative regulation of MAPK pathway | 42 | 5.41e-01 | 0.054500 | 8.11e-01 |
Cellular response to chemical stress | 184 | 2.03e-01 | -0.054400 | 5.62e-01 |
Toll Like Receptor 3 (TLR3) Cascade | 103 | 3.41e-01 | -0.054300 | 6.87e-01 |
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 64 | 4.53e-01 | 0.054200 | 7.53e-01 |
SHC-mediated cascade:FGFR1 | 13 | 7.35e-01 | 0.054100 | 9.14e-01 |
Gap junction trafficking | 32 | 5.96e-01 | -0.054100 | 8.50e-01 |
NOTCH4 Activation and Transmission of Signal to the Nucleus | 11 | 7.57e-01 | 0.054000 | 9.19e-01 |
Incretin synthesis, secretion, and inactivation | 13 | 7.38e-01 | 0.053700 | 9.14e-01 |
Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 13 | 7.38e-01 | 0.053700 | 9.14e-01 |
Regulation of lipid metabolism by PPARalpha | 107 | 3.43e-01 | -0.053100 | 6.87e-01 |
Inositol phosphate metabolism | 45 | 5.38e-01 | -0.053100 | 8.08e-01 |
Interleukin-37 signaling | 20 | 6.81e-01 | -0.053000 | 8.88e-01 |
PKA activation | 16 | 7.14e-01 | -0.052800 | 9.08e-01 |
RA biosynthesis pathway | 15 | 7.23e-01 | 0.052800 | 9.08e-01 |
Peroxisomal protein import | 57 | 4.93e-01 | -0.052500 | 7.80e-01 |
Cellular response to heat stress | 96 | 3.79e-01 | 0.052000 | 7.06e-01 |
RNA Polymerase II Transcription Termination | 66 | 4.66e-01 | -0.051900 | 7.65e-01 |
Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 30 | 6.24e-01 | 0.051700 | 8.60e-01 |
Gastrulation | 85 | 4.14e-01 | 0.051300 | 7.34e-01 |
Centrosome maturation | 80 | 4.28e-01 | 0.051200 | 7.35e-01 |
Recruitment of mitotic centrosome proteins and complexes | 80 | 4.28e-01 | 0.051200 | 7.35e-01 |
Mitochondrial calcium ion transport | 22 | 6.80e-01 | 0.050900 | 8.87e-01 |
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 57 | 5.08e-01 | 0.050700 | 7.89e-01 |
Constitutive Signaling by NOTCH1 PEST Domain Mutants | 57 | 5.08e-01 | 0.050700 | 7.89e-01 |
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 57 | 5.08e-01 | 0.050700 | 7.89e-01 |
Signaling by NOTCH1 PEST Domain Mutants in Cancer | 57 | 5.08e-01 | 0.050700 | 7.89e-01 |
Signaling by NOTCH1 in Cancer | 57 | 5.08e-01 | 0.050700 | 7.89e-01 |
Semaphorin interactions | 63 | 4.87e-01 | -0.050700 | 7.75e-01 |
SUMO E3 ligases SUMOylate target proteins | 162 | 2.69e-01 | -0.050400 | 6.38e-01 |
Homologous DNA Pairing and Strand Exchange | 41 | 5.77e-01 | 0.050400 | 8.37e-01 |
Signaling by FGFR in disease | 53 | 5.26e-01 | 0.050300 | 8.01e-01 |
Signaling by NTRKs | 127 | 3.32e-01 | -0.049900 | 6.85e-01 |
Nuclear events stimulated by ALK signaling in cancer | 18 | 7.15e-01 | -0.049800 | 9.08e-01 |
HIV elongation arrest and recovery | 32 | 6.27e-01 | 0.049600 | 8.62e-01 |
Pausing and recovery of HIV elongation | 32 | 6.27e-01 | 0.049600 | 8.62e-01 |
MicroRNA (miRNA) biogenesis | 24 | 6.74e-01 | 0.049600 | 8.87e-01 |
RHO GTPases Activate Formins | 127 | 3.35e-01 | 0.049500 | 6.87e-01 |
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 100 | 3.94e-01 | -0.049400 | 7.20e-01 |
Regulation of TP53 Activity | 150 | 2.98e-01 | -0.049300 | 6.51e-01 |
PI3K/AKT Signaling in Cancer | 85 | 4.33e-01 | -0.049200 | 7.39e-01 |
Signaling by MET | 75 | 4.62e-01 | -0.049200 | 7.62e-01 |
Abortive elongation of HIV-1 transcript in the absence of Tat | 23 | 6.85e-01 | 0.048800 | 8.88e-01 |
Switching of origins to a post-replicative state | 89 | 4.29e-01 | 0.048600 | 7.35e-01 |
HIV Infection | 223 | 2.13e-01 | -0.048500 | 5.75e-01 |
Potassium Channels | 57 | 5.27e-01 | 0.048400 | 8.01e-01 |
HCMV Infection | 100 | 4.03e-01 | 0.048400 | 7.30e-01 |
Nucleotide salvage | 21 | 7.01e-01 | -0.048400 | 9.00e-01 |
Neurotransmitter release cycle | 41 | 5.92e-01 | 0.048300 | 8.50e-01 |
G beta:gamma signalling through CDC42 | 16 | 7.38e-01 | -0.048300 | 9.14e-01 |
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 36 | 6.18e-01 | -0.048100 | 8.60e-01 |
SARS-CoV-2 targets host intracellular signalling and regulatory pathways | 12 | 7.73e-01 | 0.048000 | 9.29e-01 |
Degradation of beta-catenin by the destruction complex | 83 | 4.50e-01 | 0.047900 | 7.53e-01 |
Cytochrome P450 - arranged by substrate type | 34 | 6.30e-01 | -0.047700 | 8.65e-01 |
Downstream signaling events of B Cell Receptor (BCR) | 79 | 4.65e-01 | 0.047600 | 7.65e-01 |
Vif-mediated degradation of APOBEC3G | 52 | 5.53e-01 | 0.047500 | 8.19e-01 |
Association of TriC/CCT with target proteins during biosynthesis | 35 | 6.27e-01 | 0.047400 | 8.62e-01 |
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 37 | 6.19e-01 | 0.047300 | 8.60e-01 |
Caspase-mediated cleavage of cytoskeletal proteins | 12 | 7.77e-01 | -0.047100 | 9.30e-01 |
ALK mutants bind TKIs | 11 | 7.88e-01 | 0.046900 | 9.32e-01 |
Signaling by EGFR in Cancer | 24 | 6.91e-01 | -0.046900 | 8.91e-01 |
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 50 | 5.67e-01 | 0.046800 | 8.30e-01 |
Diseases of programmed cell death | 48 | 5.75e-01 | -0.046800 | 8.37e-01 |
RAB GEFs exchange GTP for GDP on RABs | 87 | 4.53e-01 | -0.046500 | 7.53e-01 |
FGFR2 alternative splicing | 24 | 6.93e-01 | 0.046500 | 8.93e-01 |
Post-translational protein modification | 1207 | 7.03e-03 | -0.046400 | 6.82e-02 |
PPARA activates gene expression | 105 | 4.11e-01 | -0.046400 | 7.33e-01 |
Heme signaling | 44 | 5.95e-01 | -0.046400 | 8.50e-01 |
Gap junction trafficking and regulation | 34 | 6.40e-01 | -0.046300 | 8.70e-01 |
Signaling by WNT in cancer | 28 | 6.72e-01 | 0.046200 | 8.87e-01 |
GABA synthesis, release, reuptake and degradation | 15 | 7.57e-01 | -0.046200 | 9.19e-01 |
MET activates PTK2 signaling | 30 | 6.62e-01 | -0.046200 | 8.82e-01 |
DNA Replication | 130 | 3.64e-01 | 0.046100 | 7.00e-01 |
Uptake and function of anthrax toxins | 11 | 7.91e-01 | -0.046100 | 9.32e-01 |
tRNA processing in the nucleus | 59 | 5.42e-01 | -0.045900 | 8.11e-01 |
Ribavirin ADME | 10 | 8.02e-01 | -0.045900 | 9.36e-01 |
Regulation of RUNX3 expression and activity | 55 | 5.57e-01 | -0.045800 | 8.21e-01 |
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 40 | 6.22e-01 | 0.045000 | 8.60e-01 |
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 19 | 7.35e-01 | 0.044900 | 9.14e-01 |
Signaling by Ligand-Responsive EGFR Variants in Cancer | 19 | 7.35e-01 | 0.044900 | 9.14e-01 |
Transmission across Chemical Synapses | 198 | 2.77e-01 | 0.044900 | 6.42e-01 |
Regulation of CDH11 Expression and Function | 27 | 6.88e-01 | -0.044700 | 8.88e-01 |
NCAM signaling for neurite out-growth | 53 | 5.75e-01 | -0.044600 | 8.37e-01 |
Adherens junctions interactions | 45 | 6.06e-01 | 0.044500 | 8.54e-01 |
ER Quality Control Compartment (ERQC) | 21 | 7.26e-01 | -0.044300 | 9.08e-01 |
Phase II - Conjugation of compounds | 69 | 5.28e-01 | 0.044000 | 8.01e-01 |
Tie2 Signaling | 15 | 7.68e-01 | -0.043900 | 9.25e-01 |
HCMV Early Events | 77 | 5.06e-01 | 0.043900 | 7.89e-01 |
Neurotransmitter receptors and postsynaptic signal transmission | 147 | 3.60e-01 | 0.043700 | 7.00e-01 |
Regulated Necrosis | 53 | 5.82e-01 | -0.043700 | 8.40e-01 |
DNA Damage Recognition in GG-NER | 38 | 6.41e-01 | 0.043700 | 8.70e-01 |
Signaling by FGFR1 | 40 | 6.34e-01 | 0.043600 | 8.68e-01 |
Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 23 | 7.19e-01 | -0.043400 | 9.08e-01 |
RHOF GTPase cycle | 39 | 6.40e-01 | -0.043400 | 8.70e-01 |
Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 78 | 5.08e-01 | 0.043300 | 7.89e-01 |
Gene Silencing by RNA | 79 | 5.08e-01 | 0.043100 | 7.89e-01 |
Nuclear Receptor transcription pathway | 39 | 6.42e-01 | 0.043000 | 8.70e-01 |
Signaling by ALK fusions and activated point mutants | 54 | 5.84e-01 | -0.043000 | 8.41e-01 |
Signaling by ALK in cancer | 54 | 5.84e-01 | -0.043000 | 8.41e-01 |
Cyclin A/B1/B2 associated events during G2/M transition | 22 | 7.28e-01 | -0.042800 | 9.11e-01 |
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 32 | 6.77e-01 | 0.042500 | 8.87e-01 |
mRNA decay by 5’ to 3’ exoribonuclease | 15 | 7.76e-01 | -0.042400 | 9.30e-01 |
Mitochondrial protein import | 63 | 5.61e-01 | 0.042300 | 8.24e-01 |
Global Genome Nucleotide Excision Repair (GG-NER) | 84 | 5.03e-01 | 0.042300 | 7.89e-01 |
Signaling by WNT | 245 | 2.57e-01 | 0.042100 | 6.22e-01 |
FLT3 Signaling | 37 | 6.58e-01 | -0.042000 | 8.80e-01 |
Activation of BH3-only proteins | 29 | 6.96e-01 | -0.041900 | 8.95e-01 |
Transport of vitamins, nucleosides, and related molecules | 31 | 6.87e-01 | -0.041800 | 8.88e-01 |
Signaling by the B Cell Receptor (BCR) | 113 | 4.47e-01 | -0.041400 | 7.53e-01 |
Postmitotic nuclear pore complex (NPC) reformation | 27 | 7.10e-01 | -0.041300 | 9.07e-01 |
IGF1R signaling cascade | 39 | 6.56e-01 | 0.041200 | 8.80e-01 |
Constitutive Signaling by AKT1 E17K in Cancer | 26 | 7.18e-01 | -0.040900 | 9.08e-01 |
Formation of apoptosome | 11 | 8.16e-01 | -0.040600 | 9.45e-01 |
Glutamate and glutamine metabolism | 11 | 8.16e-01 | -0.040600 | 9.45e-01 |
Regulation of the apoptosome activity | 11 | 8.16e-01 | -0.040600 | 9.45e-01 |
Orc1 removal from chromatin | 68 | 5.65e-01 | 0.040300 | 8.29e-01 |
G2/M Transition | 186 | 3.54e-01 | 0.039500 | 6.95e-01 |
MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 108 | 4.79e-01 | -0.039500 | 7.71e-01 |
Toll Like Receptor TLR6:TLR2 Cascade | 108 | 4.79e-01 | -0.039500 | 7.71e-01 |
Acyl chain remodelling of PI | 11 | 8.21e-01 | 0.039400 | 9.45e-01 |
RAB geranylgeranylation | 57 | 6.08e-01 | 0.039300 | 8.54e-01 |
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 15 | 7.92e-01 | 0.039300 | 9.32e-01 |
Interleukin-1 signaling | 110 | 4.78e-01 | -0.039200 | 7.71e-01 |
MAP2K and MAPK activation | 36 | 6.85e-01 | -0.039100 | 8.88e-01 |
ERKs are inactivated | 13 | 8.08e-01 | -0.038900 | 9.42e-01 |
Cristae formation | 29 | 7.17e-01 | 0.038900 | 9.08e-01 |
Processing of DNA double-strand break ends | 61 | 6.01e-01 | 0.038800 | 8.51e-01 |
PTEN Regulation | 137 | 4.34e-01 | 0.038700 | 7.39e-01 |
Myogenesis | 22 | 7.54e-01 | 0.038600 | 9.19e-01 |
Interleukin-1 family signaling | 138 | 4.35e-01 | -0.038600 | 7.39e-01 |
SUMOylation | 168 | 3.90e-01 | -0.038500 | 7.16e-01 |
Netrin-1 signaling | 42 | 6.67e-01 | 0.038400 | 8.85e-01 |
Regulation of HSF1-mediated heat shock response | 78 | 5.58e-01 | 0.038400 | 8.21e-01 |
Synthesis of very long-chain fatty acyl-CoAs | 19 | 7.73e-01 | 0.038200 | 9.29e-01 |
Transcriptional regulation by RUNX2 | 115 | 4.81e-01 | -0.038100 | 7.71e-01 |
Toll Like Receptor 2 (TLR2) Cascade | 109 | 4.92e-01 | -0.038100 | 7.80e-01 |
Toll Like Receptor TLR1:TLR2 Cascade | 109 | 4.92e-01 | -0.038100 | 7.80e-01 |
APC/C:Cdc20 mediated degradation of Securin | 66 | 5.94e-01 | 0.038000 | 8.50e-01 |
Nucleotide Excision Repair | 110 | 4.93e-01 | 0.037900 | 7.80e-01 |
Autodegradation of Cdh1 by Cdh1:APC/C | 64 | 6.01e-01 | 0.037800 | 8.51e-01 |
Mitotic Prometaphase | 190 | 3.69e-01 | 0.037800 | 7.00e-01 |
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 14 | 8.07e-01 | 0.037800 | 9.41e-01 |
Resolution of D-loop Structures through Holliday Junction Intermediates | 32 | 7.12e-01 | -0.037800 | 9.07e-01 |
RIPK1-mediated regulated necrosis | 30 | 7.22e-01 | 0.037600 | 9.08e-01 |
Regulation of necroptotic cell death | 30 | 7.22e-01 | 0.037600 | 9.08e-01 |
Mitochondrial biogenesis | 85 | 5.52e-01 | -0.037400 | 8.18e-01 |
Presynaptic function of Kainate receptors | 17 | 7.91e-01 | -0.037200 | 9.32e-01 |
Ubiquitin-dependent degradation of Cyclin D | 50 | 6.51e-01 | 0.037000 | 8.77e-01 |
Synthesis of glycosylphosphatidylinositol (GPI) | 18 | 7.86e-01 | -0.036900 | 9.32e-01 |
Activation of gene expression by SREBF (SREBP) | 42 | 6.80e-01 | 0.036800 | 8.87e-01 |
SUMOylation of intracellular receptors | 27 | 7.43e-01 | 0.036500 | 9.17e-01 |
Acetylcholine Neurotransmitter Release Cycle | 13 | 8.22e-01 | -0.036100 | 9.45e-01 |
Telomere Extension By Telomerase | 21 | 7.77e-01 | 0.035700 | 9.30e-01 |
Keratan sulfate biosynthesis | 26 | 7.53e-01 | 0.035700 | 9.19e-01 |
Transcriptional regulation of white adipocyte differentiation | 82 | 5.78e-01 | -0.035600 | 8.37e-01 |
Glycogen breakdown (glycogenolysis) | 14 | 8.18e-01 | -0.035500 | 9.45e-01 |
COPI-mediated anterograde transport | 92 | 5.56e-01 | -0.035500 | 8.20e-01 |
Extension of Telomeres | 49 | 6.68e-01 | 0.035400 | 8.85e-01 |
Processing of Capped Intron-Containing Pre-mRNA | 278 | 3.11e-01 | 0.035400 | 6.65e-01 |
ADORA2B mediated anti-inflammatory cytokines production | 36 | 7.16e-01 | -0.035100 | 9.08e-01 |
Regulation of gene expression by Hypoxia-inducible Factor | 10 | 8.48e-01 | 0.035100 | 9.64e-01 |
RHOB GTPase cycle | 66 | 6.23e-01 | 0.035100 | 8.60e-01 |
Circadian Clock | 66 | 6.24e-01 | 0.034900 | 8.60e-01 |
MAP3K8 (TPL2)-dependent MAPK1/3 activation | 16 | 8.10e-01 | -0.034700 | 9.43e-01 |
Ub-specific processing proteases | 157 | 4.54e-01 | 0.034700 | 7.53e-01 |
Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 25 | 7.65e-01 | -0.034600 | 9.25e-01 |
Reduction of cytosolic Ca++ levels | 10 | 8.50e-01 | 0.034600 | 9.65e-01 |
S Phase | 159 | 4.52e-01 | 0.034600 | 7.53e-01 |
NOTCH3 Intracellular Domain Regulates Transcription | 22 | 7.80e-01 | -0.034400 | 9.32e-01 |
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | 10 | 8.51e-01 | -0.034400 | 9.65e-01 |
HDR through Single Strand Annealing (SSA) | 35 | 7.25e-01 | -0.034300 | 9.08e-01 |
Glucagon-type ligand receptors | 20 | 7.90e-01 | 0.034300 | 9.32e-01 |
Endogenous sterols | 21 | 7.86e-01 | -0.034200 | 9.32e-01 |
Regulation of activated PAK-2p34 by proteasome mediated degradation | 48 | 6.84e-01 | 0.034000 | 8.88e-01 |
RNA Polymerase III Transcription Initiation | 36 | 7.24e-01 | 0.034000 | 9.08e-01 |
Metabolism of water-soluble vitamins and cofactors | 110 | 5.48e-01 | -0.033200 | 8.16e-01 |
DNA Double-Strand Break Repair | 130 | 5.16e-01 | -0.033000 | 7.94e-01 |
Degradation of DVL | 55 | 6.74e-01 | 0.032800 | 8.87e-01 |
Class A/1 (Rhodopsin-like receptors) | 156 | 4.80e-01 | -0.032800 | 7.71e-01 |
Regulation of PTEN stability and activity | 67 | 6.45e-01 | 0.032600 | 8.71e-01 |
Transcriptional regulation by RUNX3 | 94 | 5.87e-01 | 0.032500 | 8.43e-01 |
Negative regulation of FLT3 | 14 | 8.34e-01 | -0.032400 | 9.55e-01 |
Late Phase of HIV Life Cycle | 132 | 5.20e-01 | 0.032400 | 7.98e-01 |
Termination of translesion DNA synthesis | 31 | 7.55e-01 | 0.032400 | 9.19e-01 |
Impaired BRCA2 binding to RAD51 | 33 | 7.48e-01 | 0.032300 | 9.17e-01 |
G2/M DNA damage checkpoint | 58 | 6.71e-01 | 0.032300 | 8.87e-01 |
Energy dependent regulation of mTOR by LKB1-AMPK | 28 | 7.68e-01 | 0.032200 | 9.25e-01 |
RAF activation | 34 | 7.45e-01 | -0.032200 | 9.17e-01 |
Interleukin-4 and Interleukin-13 signaling | 93 | 5.93e-01 | -0.032100 | 8.50e-01 |
Tight junction interactions | 17 | 8.19e-01 | 0.032000 | 9.45e-01 |
RAC3 GTPase cycle | 87 | 6.08e-01 | -0.031800 | 8.54e-01 |
Synthesis of DNA | 118 | 5.52e-01 | 0.031800 | 8.18e-01 |
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 34 | 7.49e-01 | -0.031800 | 9.17e-01 |
AURKA Activation by TPX2 | 71 | 6.45e-01 | 0.031600 | 8.71e-01 |
Antigen processing: Ubiquitination & Proteasome degradation | 285 | 3.59e-01 | -0.031600 | 7.00e-01 |
NOTCH3 Activation and Transmission of Signal to the Nucleus | 25 | 7.85e-01 | 0.031500 | 9.32e-01 |
Mitotic G2-G2/M phases | 188 | 4.59e-01 | 0.031400 | 7.59e-01 |
Norepinephrine Neurotransmitter Release Cycle | 15 | 8.35e-01 | -0.031100 | 9.55e-01 |
Regulation of CDH11 function | 10 | 8.65e-01 | 0.030900 | 9.70e-01 |
EML4 and NUDC in mitotic spindle formation | 104 | 5.87e-01 | 0.030900 | 8.43e-01 |
Transcriptional regulation of granulopoiesis | 35 | 7.52e-01 | 0.030800 | 9.19e-01 |
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 26 | 7.86e-01 | 0.030700 | 9.32e-01 |
Cellular response to hypoxia | 72 | 6.57e-01 | 0.030300 | 8.80e-01 |
KEAP1-NFE2L2 pathway | 102 | 6.00e-01 | -0.030000 | 8.51e-01 |
Oxidative Stress Induced Senescence | 70 | 6.65e-01 | 0.029900 | 8.85e-01 |
Viral Infection Pathways | 668 | 1.92e-01 | 0.029700 | 5.42e-01 |
Cell-cell junction organization | 64 | 6.82e-01 | 0.029600 | 8.88e-01 |
Processive synthesis on the lagging strand | 15 | 8.44e-01 | -0.029400 | 9.61e-01 |
Suppression of phagosomal maturation | 13 | 8.54e-01 | 0.029400 | 9.66e-01 |
Disease | 1490 | 6.05e-02 | -0.029400 | 2.99e-01 |
Syndecan interactions | 26 | 7.96e-01 | -0.029300 | 9.33e-01 |
Nicotinate metabolism | 27 | 7.96e-01 | -0.028800 | 9.33e-01 |
Regulation of APC/C activators between G1/S and early anaphase | 78 | 6.66e-01 | -0.028300 | 8.85e-01 |
Sensory processing of sound | 59 | 7.07e-01 | 0.028300 | 9.05e-01 |
SARS-CoV-2-host interactions | 177 | 5.18e-01 | 0.028200 | 7.96e-01 |
DNA Double Strand Break Response | 44 | 7.47e-01 | 0.028100 | 9.17e-01 |
Cell junction organization | 89 | 6.49e-01 | 0.027900 | 8.76e-01 |
Transcriptional regulation by small RNAs | 54 | 7.26e-01 | 0.027600 | 9.08e-01 |
GLI3 is processed to GLI3R by the proteasome | 57 | 7.19e-01 | -0.027600 | 9.08e-01 |
PCNA-Dependent Long Patch Base Excision Repair | 21 | 8.27e-01 | -0.027500 | 9.50e-01 |
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 53 | 7.30e-01 | 0.027400 | 9.12e-01 |
SCF(Skp2)-mediated degradation of p27/p21 | 59 | 7.18e-01 | 0.027200 | 9.08e-01 |
APC/C-mediated degradation of cell cycle proteins | 85 | 6.68e-01 | -0.027000 | 8.85e-01 |
Regulation of mitotic cell cycle | 85 | 6.68e-01 | -0.027000 | 8.85e-01 |
Diseases of mitotic cell cycle | 38 | 7.76e-01 | 0.026700 | 9.30e-01 |
M Phase | 347 | 3.94e-01 | 0.026700 | 7.20e-01 |
L1CAM interactions | 104 | 6.41e-01 | 0.026500 | 8.70e-01 |
RHO GTPase cycle | 420 | 3.54e-01 | -0.026400 | 6.95e-01 |
AKT phosphorylates targets in the cytosol | 14 | 8.66e-01 | -0.026100 | 9.70e-01 |
Cyclin D associated events in G1 | 47 | 7.57e-01 | -0.026100 | 9.19e-01 |
G1 Phase | 47 | 7.57e-01 | -0.026100 | 9.19e-01 |
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 71 | 7.09e-01 | 0.025600 | 9.06e-01 |
Signaling by NOTCH4 | 81 | 6.93e-01 | 0.025300 | 8.93e-01 |
Ion homeostasis | 46 | 7.66e-01 | -0.025300 | 9.25e-01 |
RHOV GTPase cycle | 34 | 7.99e-01 | 0.025200 | 9.35e-01 |
HDR through MMEJ (alt-NHEJ) | 12 | 8.80e-01 | -0.025100 | 9.76e-01 |
G2/M Checkpoints | 127 | 6.25e-01 | 0.025100 | 8.61e-01 |
Sensory processing of sound by inner hair cells of the cochlea | 55 | 7.47e-01 | 0.025100 | 9.17e-01 |
Platelet Adhesion to exposed collagen | 11 | 8.86e-01 | 0.024900 | 9.77e-01 |
CDK-mediated phosphorylation and removal of Cdc6 | 70 | 7.19e-01 | 0.024900 | 9.08e-01 |
Unwinding of DNA | 12 | 8.82e-01 | -0.024800 | 9.76e-01 |
Defective B3GAT3 causes JDSSDHD | 17 | 8.60e-01 | 0.024800 | 9.67e-01 |
Mitotic Spindle Checkpoint | 105 | 6.63e-01 | 0.024600 | 8.83e-01 |
Regulation of Apoptosis | 51 | 7.65e-01 | 0.024200 | 9.25e-01 |
Diseases associated with glycosaminoglycan metabolism | 38 | 7.98e-01 | -0.024000 | 9.35e-01 |
eNOS activation | 11 | 8.91e-01 | 0.023800 | 9.78e-01 |
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 43 | 7.89e-01 | 0.023600 | 9.32e-01 |
RHOJ GTPase cycle | 53 | 7.68e-01 | -0.023400 | 9.25e-01 |
Pre-NOTCH Expression and Processing | 56 | 7.62e-01 | -0.023400 | 9.24e-01 |
Cell Cycle Checkpoints | 243 | 5.32e-01 | 0.023300 | 8.03e-01 |
Oncogene Induced Senescence | 33 | 8.17e-01 | -0.023200 | 9.45e-01 |
Regulation of RAS by GAPs | 65 | 7.46e-01 | 0.023200 | 9.17e-01 |
Negative regulation of NOTCH4 signaling | 54 | 7.69e-01 | 0.023100 | 9.25e-01 |
Insulin receptor signalling cascade | 40 | 8.01e-01 | 0.023000 | 9.36e-01 |
Leading Strand Synthesis | 14 | 8.82e-01 | 0.023000 | 9.76e-01 |
Polymerase switching | 14 | 8.82e-01 | 0.023000 | 9.76e-01 |
rRNA processing in the mitochondrion | 10 | 9.01e-01 | 0.022700 | 9.78e-01 |
Hedgehog ‘on’ state | 82 | 7.23e-01 | -0.022700 | 9.08e-01 |
Mitotic G1 phase and G1/S transition | 145 | 6.41e-01 | -0.022400 | 8.70e-01 |
Muscle contraction | 161 | 6.24e-01 | -0.022400 | 8.60e-01 |
APC/C:Cdc20 mediated degradation of mitotic proteins | 73 | 7.41e-01 | 0.022400 | 9.16e-01 |
Somitogenesis | 50 | 7.85e-01 | -0.022300 | 9.32e-01 |
IRS-mediated signalling | 35 | 8.20e-01 | 0.022200 | 9.45e-01 |
Asymmetric localization of PCP proteins | 62 | 7.64e-01 | -0.022100 | 9.24e-01 |
Regulation of TP53 Degradation | 35 | 8.21e-01 | -0.022100 | 9.45e-01 |
MAPK family signaling cascades | 281 | 5.26e-01 | 0.022000 | 8.01e-01 |
ERK/MAPK targets | 22 | 8.59e-01 | 0.021900 | 9.67e-01 |
SUMOylation of DNA damage response and repair proteins | 77 | 7.41e-01 | 0.021800 | 9.16e-01 |
Autodegradation of the E3 ubiquitin ligase COP1 | 49 | 7.92e-01 | 0.021800 | 9.32e-01 |
RHO GTPase Effectors | 247 | 5.58e-01 | 0.021700 | 8.21e-01 |
p75NTR recruits signalling complexes | 13 | 8.93e-01 | 0.021600 | 9.78e-01 |
Aflatoxin activation and detoxification | 12 | 8.99e-01 | 0.021300 | 9.78e-01 |
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 16 | 8.83e-01 | -0.021200 | 9.76e-01 |
Phosphorylation of the APC/C | 20 | 8.70e-01 | -0.021200 | 9.72e-01 |
Nucleotide-like (purinergic) receptors | 15 | 8.87e-01 | 0.021200 | 9.77e-01 |
CASP8 activity is inhibited | 10 | 9.08e-01 | -0.021200 | 9.78e-01 |
Dimerization of procaspase-8 | 10 | 9.08e-01 | -0.021200 | 9.78e-01 |
Regulation by c-FLIP | 10 | 9.08e-01 | -0.021200 | 9.78e-01 |
Degradation of GLI1 by the proteasome | 57 | 7.83e-01 | -0.021100 | 9.32e-01 |
MyD88 cascade initiated on plasma membrane | 94 | 7.26e-01 | -0.021000 | 9.08e-01 |
Toll Like Receptor 10 (TLR10) Cascade | 94 | 7.26e-01 | -0.021000 | 9.08e-01 |
Toll Like Receptor 5 (TLR5) Cascade | 94 | 7.26e-01 | -0.021000 | 9.08e-01 |
IKK complex recruitment mediated by RIP1 | 23 | 8.62e-01 | 0.020900 | 9.69e-01 |
NIK–>noncanonical NF-kB signaling | 57 | 7.86e-01 | -0.020800 | 9.32e-01 |
Integration of energy metabolism | 88 | 7.36e-01 | -0.020800 | 9.14e-01 |
Activation of SMO | 16 | 8.86e-01 | 0.020800 | 9.77e-01 |
Formation of paraxial mesoderm | 62 | 7.77e-01 | -0.020800 | 9.30e-01 |
Protein-protein interactions at synapses | 69 | 7.66e-01 | -0.020700 | 9.25e-01 |
ATF4 activates genes in response to endoplasmic reticulum stress | 27 | 8.53e-01 | 0.020600 | 9.66e-01 |
Dectin-1 mediated noncanonical NF-kB signaling | 58 | 7.88e-01 | -0.020500 | 9.32e-01 |
The citric acid (TCA) cycle and respiratory electron transport | 160 | 6.60e-01 | 0.020200 | 8.81e-01 |
Glyoxylate metabolism and glycine degradation | 23 | 8.68e-01 | 0.020000 | 9.71e-01 |
Regulation of mRNA stability by proteins that bind AU-rich elements | 87 | 7.49e-01 | 0.019900 | 9.17e-01 |
p130Cas linkage to MAPK signaling for integrins | 12 | 9.05e-01 | -0.019800 | 9.78e-01 |
Regulation of insulin secretion | 61 | 7.90e-01 | -0.019700 | 9.32e-01 |
Metabolism of proteins | 1653 | 1.89e-01 | 0.019600 | 5.41e-01 |
Regulation of beta-cell development | 20 | 8.80e-01 | -0.019600 | 9.76e-01 |
Homology Directed Repair | 101 | 7.35e-01 | -0.019500 | 9.14e-01 |
Signaling by Non-Receptor Tyrosine Kinases | 51 | 8.12e-01 | 0.019300 | 9.43e-01 |
Signaling by PTK6 | 51 | 8.12e-01 | 0.019300 | 9.43e-01 |
Cardiac conduction | 96 | 7.45e-01 | 0.019300 | 9.17e-01 |
Metabolism | 1756 | 1.85e-01 | -0.019200 | 5.41e-01 |
Hh mutants are degraded by ERAD | 53 | 8.09e-01 | -0.019200 | 9.42e-01 |
Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 14 | 9.01e-01 | -0.019100 | 9.78e-01 |
Platelet homeostasis | 72 | 7.81e-01 | -0.019000 | 9.32e-01 |
Condensation of Prophase Chromosomes | 20 | 8.84e-01 | -0.018900 | 9.76e-01 |
G beta:gamma signalling through BTK | 14 | 9.04e-01 | -0.018700 | 9.78e-01 |
TICAM1,TRAF6-dependent induction of TAK1 complex | 11 | 9.15e-01 | -0.018700 | 9.82e-01 |
Deadenylation of mRNA | 22 | 8.80e-01 | -0.018600 | 9.76e-01 |
MTOR signalling | 40 | 8.44e-01 | -0.018000 | 9.61e-01 |
Regulation of TP53 Expression and Degradation | 36 | 8.52e-01 | -0.018000 | 9.65e-01 |
Protein localization | 155 | 7.03e-01 | -0.017800 | 9.01e-01 |
Intracellular signaling by second messengers | 280 | 6.20e-01 | -0.017300 | 8.60e-01 |
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 17 | 9.02e-01 | -0.017200 | 9.78e-01 |
Metabolism of porphyrins | 21 | 8.91e-01 | 0.017200 | 9.78e-01 |
Generic Transcription Pathway | 1092 | 3.42e-01 | 0.017200 | 6.87e-01 |
Signaling by NOTCH1 | 72 | 8.02e-01 | 0.017100 | 9.36e-01 |
Metabolism of nucleotides | 81 | 7.94e-01 | -0.016800 | 9.33e-01 |
Cell-Cell communication | 120 | 7.54e-01 | 0.016500 | 9.19e-01 |
RNA Polymerase II Transcription | 1210 | 3.37e-01 | 0.016500 | 6.87e-01 |
Defective B3GALT6 causes EDSP2 and SEMDJL1 | 17 | 9.07e-01 | 0.016300 | 9.78e-01 |
Defective CFTR causes cystic fibrosis | 58 | 8.32e-01 | -0.016100 | 9.53e-01 |
Interleukin-7 signaling | 19 | 9.04e-01 | 0.016100 | 9.78e-01 |
DNA strand elongation | 32 | 8.79e-01 | -0.015500 | 9.76e-01 |
Constitutive Signaling by Overexpressed ERBB2 | 11 | 9.29e-01 | 0.015500 | 9.83e-01 |
Dual Incision in GG-NER | 41 | 8.65e-01 | 0.015300 | 9.70e-01 |
MET receptor recycling | 10 | 9.33e-01 | 0.015300 | 9.83e-01 |
RHOG GTPase cycle | 71 | 8.25e-01 | 0.015200 | 9.48e-01 |
RHOH GTPase cycle | 33 | 8.82e-01 | 0.014900 | 9.76e-01 |
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 49 | 8.60e-01 | 0.014600 | 9.67e-01 |
p53-Independent DNA Damage Response | 49 | 8.60e-01 | 0.014600 | 9.67e-01 |
p53-Independent G1/S DNA damage checkpoint | 49 | 8.60e-01 | 0.014600 | 9.67e-01 |
Signaling by NOTCH | 179 | 7.37e-01 | -0.014600 | 9.14e-01 |
Degradation of GLI2 by the proteasome | 57 | 8.51e-01 | -0.014400 | 9.65e-01 |
FGFR1 mutant receptor activation | 25 | 9.01e-01 | 0.014300 | 9.78e-01 |
Neuronal System | 282 | 6.83e-01 | 0.014100 | 8.88e-01 |
Signal Transduction | 2081 | 3.01e-01 | -0.014000 | 6.55e-01 |
Fatty acyl-CoA biosynthesis | 31 | 8.94e-01 | -0.013900 | 9.78e-01 |
APC truncation mutants have impaired AXIN binding | 14 | 9.30e-01 | 0.013600 | 9.83e-01 |
AXIN missense mutants destabilize the destruction complex | 14 | 9.30e-01 | 0.013600 | 9.83e-01 |
Signaling by AMER1 mutants | 14 | 9.30e-01 | 0.013600 | 9.83e-01 |
Signaling by APC mutants | 14 | 9.30e-01 | 0.013600 | 9.83e-01 |
Signaling by AXIN mutants | 14 | 9.30e-01 | 0.013600 | 9.83e-01 |
Truncations of AMER1 destabilize the destruction complex | 14 | 9.30e-01 | 0.013600 | 9.83e-01 |
Biological oxidations | 141 | 7.83e-01 | 0.013500 | 9.32e-01 |
Fatty acid metabolism | 142 | 7.88e-01 | -0.013100 | 9.32e-01 |
Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 70 | 8.50e-01 | 0.013100 | 9.65e-01 |
Cellular Senescence | 133 | 7.95e-01 | 0.013100 | 9.33e-01 |
Aberrant regulation of mitotic cell cycle due to RB1 defects | 36 | 8.92e-01 | 0.013100 | 9.78e-01 |
Interleukin-17 signaling | 67 | 8.54e-01 | -0.013000 | 9.66e-01 |
BMAL1:CLOCK,NPAS2 activates circadian gene expression | 25 | 9.10e-01 | 0.013000 | 9.80e-01 |
Phase I - Functionalization of compounds | 67 | 8.56e-01 | 0.012900 | 9.66e-01 |
RNA Polymerase III Transcription Initiation From Type 1 Promoter | 28 | 9.06e-01 | -0.012800 | 9.78e-01 |
HDACs deacetylate histones | 37 | 8.93e-01 | 0.012800 | 9.78e-01 |
tRNA processing | 109 | 8.18e-01 | 0.012800 | 9.45e-01 |
Signaling by Nuclear Receptors | 218 | 7.46e-01 | 0.012800 | 9.17e-01 |
Defective B4GALT7 causes EDS, progeroid type | 17 | 9.28e-01 | 0.012600 | 9.83e-01 |
SCF-beta-TrCP mediated degradation of Emi1 | 53 | 8.74e-01 | -0.012600 | 9.75e-01 |
Spry regulation of FGF signaling | 16 | 9.32e-01 | 0.012400 | 9.83e-01 |
Regulation of ornithine decarboxylase (ODC) | 49 | 8.82e-01 | 0.012200 | 9.76e-01 |
Signaling by NOTCH2 | 32 | 9.05e-01 | -0.012200 | 9.78e-01 |
Signaling by TGF-beta Receptor Complex | 90 | 8.42e-01 | 0.012200 | 9.61e-01 |
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 88 | 8.44e-01 | 0.012100 | 9.61e-01 |
Amplification of signal from the kinetochores | 88 | 8.44e-01 | 0.012100 | 9.61e-01 |
HuR (ELAVL1) binds and stabilizes mRNA | 10 | 9.48e-01 | 0.012000 | 9.90e-01 |
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 95 | 8.40e-01 | -0.012000 | 9.60e-01 |
HDR through Homologous Recombination (HRR) | 65 | 8.71e-01 | -0.011700 | 9.72e-01 |
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 17 | 9.34e-01 | -0.011700 | 9.83e-01 |
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 17 | 9.34e-01 | -0.011700 | 9.83e-01 |
Hedgehog ligand biogenesis | 60 | 8.76e-01 | -0.011600 | 9.76e-01 |
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 74 | 8.65e-01 | 0.011500 | 9.70e-01 |
activated TAK1 mediates p38 MAPK activation | 23 | 9.25e-01 | -0.011300 | 9.83e-01 |
Beta-catenin phosphorylation cascade | 17 | 9.36e-01 | 0.011200 | 9.84e-01 |
Transcriptional Regulation by VENTX | 39 | 9.04e-01 | -0.011100 | 9.78e-01 |
GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | 52 | 8.91e-01 | 0.011000 | 9.78e-01 |
Cyclin A:Cdk2-associated events at S phase entry | 83 | 8.66e-01 | -0.010700 | 9.70e-01 |
UCH proteinases | 85 | 8.68e-01 | -0.010400 | 9.71e-01 |
Acyl chain remodelling of PS | 15 | 9.45e-01 | 0.010400 | 9.89e-01 |
HCMV Late Events | 60 | 8.92e-01 | -0.010100 | 9.78e-01 |
Cytosolic sensors of pathogen-associated DNA | 63 | 8.90e-01 | -0.010100 | 9.78e-01 |
DARPP-32 events | 22 | 9.35e-01 | 0.010000 | 9.84e-01 |
Synthesis of PIPs at the plasma membrane | 51 | 9.01e-01 | -0.010000 | 9.78e-01 |
Vpu mediated degradation of CD4 | 50 | 9.02e-01 | 0.010000 | 9.78e-01 |
Metabolism of vitamins and cofactors | 159 | 8.29e-01 | -0.009940 | 9.51e-01 |
SUMOylation of transcription cofactors | 44 | 9.09e-01 | -0.009940 | 9.79e-01 |
Lagging Strand Synthesis | 20 | 9.39e-01 | -0.009910 | 9.85e-01 |
Signaling by ERBB2 ECD mutants | 16 | 9.46e-01 | -0.009820 | 9.89e-01 |
Voltage gated Potassium channels | 20 | 9.41e-01 | 0.009630 | 9.85e-01 |
MAP kinase activation | 63 | 8.95e-01 | 0.009600 | 9.78e-01 |
MET promotes cell motility | 40 | 9.20e-01 | -0.009220 | 9.83e-01 |
Chromatin modifying enzymes | 204 | 8.22e-01 | -0.009160 | 9.45e-01 |
Chromatin organization | 204 | 8.22e-01 | -0.009160 | 9.45e-01 |
PKMTs methylate histone lysines | 42 | 9.18e-01 | 0.009140 | 9.83e-01 |
Signaling by NOTCH3 | 46 | 9.15e-01 | 0.009110 | 9.82e-01 |
Gene expression (Transcription) | 1369 | 5.84e-01 | 0.008900 | 8.41e-01 |
Prolonged ERK activation events | 14 | 9.55e-01 | -0.008740 | 9.93e-01 |
Signaling by ERBB2 | 47 | 9.18e-01 | 0.008660 | 9.83e-01 |
Neddylation | 227 | 8.35e-01 | 0.008060 | 9.55e-01 |
RND2 GTPase cycle | 37 | 9.33e-01 | 0.007990 | 9.83e-01 |
Signaling by ERBB2 in Cancer | 24 | 9.47e-01 | 0.007870 | 9.90e-01 |
G1/S Transition | 127 | 8.78e-01 | -0.007870 | 9.76e-01 |
Diseases of signal transduction by growth factor receptors and second messengers | 393 | 7.91e-01 | -0.007810 | 9.32e-01 |
Cell Cycle | 597 | 7.48e-01 | 0.007730 | 9.17e-01 |
Regulation of TP53 Activity through Phosphorylation | 86 | 9.02e-01 | -0.007660 | 9.78e-01 |
NF-kB is activated and signals survival | 13 | 9.62e-01 | 0.007660 | 9.98e-01 |
Infectious disease | 844 | 7.09e-01 | -0.007600 | 9.06e-01 |
Stabilization of p53 | 54 | 9.25e-01 | 0.007440 | 9.83e-01 |
p53-Dependent G1 DNA Damage Response | 62 | 9.21e-01 | -0.007320 | 9.83e-01 |
p53-Dependent G1/S DNA damage checkpoint | 62 | 9.21e-01 | -0.007320 | 9.83e-01 |
Termination of O-glycan biosynthesis | 14 | 9.62e-01 | -0.007270 | 9.98e-01 |
Transcriptional Regulation by MECP2 | 52 | 9.30e-01 | -0.007020 | 9.83e-01 |
p75NTR signals via NF-kB | 16 | 9.62e-01 | 0.006870 | 9.98e-01 |
Signaling by NTRK1 (TRKA) | 110 | 9.02e-01 | -0.006800 | 9.78e-01 |
Signaling by ERBB2 KD Mutants | 23 | 9.55e-01 | -0.006780 | 9.93e-01 |
Beta-catenin independent WNT signaling | 135 | 8.94e-01 | 0.006630 | 9.78e-01 |
AKT phosphorylates targets in the nucleus | 10 | 9.71e-01 | 0.006560 | 9.99e-01 |
Prostacyclin signalling through prostacyclin receptor | 15 | 9.66e-01 | -0.006420 | 9.99e-01 |
FOXO-mediated transcription of cell death genes | 15 | 9.67e-01 | -0.006120 | 9.99e-01 |
Regulation of Expression and Function of Type II Classical Cadherins | 29 | 9.55e-01 | 0.006110 | 9.93e-01 |
Regulation of Homotypic Cell-Cell Adhesion | 29 | 9.55e-01 | 0.006110 | 9.93e-01 |
Aberrant regulation of mitotic exit in cancer due to RB1 defects | 20 | 9.62e-01 | 0.006110 | 9.98e-01 |
Serotonin Neurotransmitter Release Cycle | 17 | 9.65e-01 | 0.006100 | 9.99e-01 |
Extra-nuclear estrogen signaling | 69 | 9.32e-01 | 0.005950 | 9.83e-01 |
G1/S DNA Damage Checkpoints | 63 | 9.36e-01 | -0.005860 | 9.84e-01 |
Glycogen storage diseases | 14 | 9.70e-01 | -0.005710 | 9.99e-01 |
SUMOylation of DNA methylation proteins | 16 | 9.70e-01 | 0.005450 | 9.99e-01 |
Signaling by Rho GTPases, Miro GTPases and RHOBTB3 | 618 | 8.21e-01 | -0.005340 | 9.45e-01 |
ATF6 (ATF6-alpha) activates chaperone genes | 10 | 9.77e-01 | -0.005200 | 9.99e-01 |
HIV Life Cycle | 145 | 9.14e-01 | 0.005170 | 9.82e-01 |
Downstream TCR signaling | 85 | 9.36e-01 | -0.005010 | 9.84e-01 |
Epigenetic regulation of gene expression | 134 | 9.23e-01 | 0.004840 | 9.83e-01 |
Transcriptional Regulation by TP53 | 341 | 8.79e-01 | -0.004800 | 9.76e-01 |
Signaling by Hedgehog | 139 | 9.24e-01 | 0.004700 | 9.83e-01 |
Inactivation of CSF3 (G-CSF) signaling | 24 | 9.69e-01 | -0.004620 | 9.99e-01 |
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 72 | 9.49e-01 | -0.004370 | 9.90e-01 |
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 22 | 9.72e-01 | 0.004340 | 9.99e-01 |
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 20 | 9.73e-01 | 0.004320 | 9.99e-01 |
Degradation of AXIN | 53 | 9.64e-01 | 0.003620 | 9.99e-01 |
RAF/MAP kinase cascade | 240 | 9.24e-01 | -0.003580 | 9.83e-01 |
Removal of the Flap Intermediate | 14 | 9.82e-01 | -0.003540 | 9.99e-01 |
Common Pathway of Fibrin Clot Formation | 11 | 9.84e-01 | 0.003460 | 9.99e-01 |
Nicotinamide salvaging | 16 | 9.81e-01 | -0.003440 | 9.99e-01 |
MAPK3 (ERK1) activation | 10 | 9.86e-01 | -0.003310 | 9.99e-01 |
GPCR ligand binding | 221 | 9.37e-01 | -0.003070 | 9.84e-01 |
Metabolism of polyamines | 57 | 9.69e-01 | 0.002970 | 9.99e-01 |
Activation of NF-kappaB in B cells | 65 | 9.67e-01 | -0.002950 | 9.99e-01 |
Cell Cycle, Mitotic | 486 | 9.14e-01 | 0.002870 | 9.82e-01 |
PIP3 activates AKT signaling | 244 | 9.40e-01 | 0.002820 | 9.85e-01 |
Glutamate Neurotransmitter Release Cycle | 22 | 9.82e-01 | 0.002790 | 9.99e-01 |
PI3K Cascade | 31 | 9.79e-01 | 0.002790 | 9.99e-01 |
Activated NTRK2 signals through FRS2 and FRS3 | 10 | 9.88e-01 | 0.002780 | 9.99e-01 |
RUNX3 regulates NOTCH signaling | 14 | 9.86e-01 | 0.002740 | 9.99e-01 |
Nonhomologous End-Joining (NHEJ) | 35 | 9.80e-01 | 0.002490 | 9.99e-01 |
Signaling by Rho GTPases | 603 | 9.18e-01 | -0.002470 | 9.83e-01 |
Metabolism of steroids | 122 | 9.66e-01 | 0.002230 | 9.99e-01 |
DNA Repair | 281 | 9.49e-01 | -0.002210 | 9.90e-01 |
Metabolism of non-coding RNA | 53 | 9.79e-01 | 0.002090 | 9.99e-01 |
snRNP Assembly | 53 | 9.79e-01 | 0.002090 | 9.99e-01 |
Activated NOTCH1 Transmits Signal to the Nucleus | 30 | 9.85e-01 | -0.002020 | 9.99e-01 |
Metabolism of cofactors | 18 | 9.89e-01 | 0.001790 | 9.99e-01 |
Class I peroxisomal membrane protein import | 19 | 9.90e-01 | 0.001720 | 9.99e-01 |
Inactivation of APC/C via direct inhibition of the APC/C complex | 21 | 9.89e-01 | -0.001680 | 9.99e-01 |
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 21 | 9.89e-01 | -0.001680 | 9.99e-01 |
Nuclear events mediated by NFE2L2 | 77 | 9.80e-01 | 0.001660 | 9.99e-01 |
Activation of ATR in response to replication stress | 33 | 9.87e-01 | -0.001640 | 9.99e-01 |
Apoptosis | 164 | 9.73e-01 | 0.001540 | 9.99e-01 |
Lysosphingolipid and LPA receptors | 10 | 9.93e-01 | -0.001500 | 9.99e-01 |
E2F mediated regulation of DNA replication | 22 | 9.91e-01 | -0.001410 | 9.99e-01 |
Phase 2 - plateau phase | 10 | 9.94e-01 | -0.001400 | 9.99e-01 |
Deubiquitination | 229 | 9.71e-01 | 0.001400 | 9.99e-01 |
Hh mutants abrogate ligand secretion | 55 | 9.87e-01 | -0.001290 | 9.99e-01 |
Cyclin E associated events during G1/S transition | 81 | 9.86e-01 | 0.001110 | 9.99e-01 |
Deadenylation-dependent mRNA decay | 50 | 9.89e-01 | 0.001110 | 9.99e-01 |
MAPK1/MAPK3 signaling | 246 | 9.82e-01 | 0.000826 | 9.99e-01 |
Regulation of RUNX2 expression and activity | 70 | 9.91e-01 | -0.000791 | 9.99e-01 |
ECM proteoglycans | 65 | 9.92e-01 | 0.000724 | 9.99e-01 |
Synthesis of IP3 and IP4 in the cytosol | 24 | 9.96e-01 | -0.000622 | 9.99e-01 |
Disassembly of the destruction complex and recruitment of AXIN to the membrane | 27 | 9.96e-01 | 0.000586 | 9.99e-01 |
Purine salvage | 12 | 9.97e-01 | 0.000530 | 9.99e-01 |
Regulation of innate immune responses to cytosolic DNA | 14 | 9.98e-01 | -0.000422 | 9.99e-01 |
RHOC GTPase cycle | 70 | 9.95e-01 | -0.000393 | 9.99e-01 |
Peptide ligand-binding receptors | 89 | 9.95e-01 | 0.000387 | 9.99e-01 |
Kinesins | 49 | 9.98e-01 | 0.000214 | 9.99e-01 |
Programmed Cell Death | 192 | 9.96e-01 | -0.000212 | 9.99e-01 |
RNA Polymerase III Transcription Initiation From Type 2 Promoter | 27 | 9.99e-01 | -0.000174 | 9.99e-01 |
Regulation of cholesterol biosynthesis by SREBP (SREBF) | 55 | 9.99e-01 | 0.000121 | 9.99e-01 |
SARS-CoV-1 modulates host translation machinery
1107 | |
---|---|
set | SARS-CoV-1 modulates host translation machinery |
setSize | 36 |
pANOVA | 5.31e-15 |
s.dist | 0.753 |
p.adjustANOVA | 2.92e-13 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
EEF1A1 | 7895 |
FAU | 7867 |
RPS7 | 7855 |
RPS11 | 7841 |
RPS3A | 7827 |
RPS15A | 7639 |
RPS27A | 7636 |
RPS5 | 7614 |
RPS6 | 7516 |
RPS10 | 7438 |
RPS13 | 7341 |
RPSA | 7336 |
RPS23 | 7279 |
RPS20 | 7274 |
RPS8 | 7231 |
RPS17 | 6977 |
RPS3 | 6842 |
RPS15 | 6811 |
HNRNPA1 | 6806 |
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
EEF1A1 | 7895 |
FAU | 7867 |
RPS7 | 7855 |
RPS11 | 7841 |
RPS3A | 7827 |
RPS15A | 7639 |
RPS27A | 7636 |
RPS5 | 7614 |
RPS6 | 7516 |
RPS10 | 7438 |
RPS13 | 7341 |
RPSA | 7336 |
RPS23 | 7279 |
RPS20 | 7274 |
RPS8 | 7231 |
RPS17 | 6977 |
RPS3 | 6842 |
RPS15 | 6811 |
HNRNPA1 | 6806 |
RPS24 | 6802 |
RPS19 | 6640 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
RPS29 | 6283 |
RPS28 | 6238 |
RPS16 | 6124 |
RPS12 | 6075 |
RPS9 | 5735 |
RPS21 | 5653 |
RPS18 | 5530 |
RPS4X | 5267 |
RPS2 | 4768 |
RPS4Y1 | 1782 |
RPS26 | -1698 |
Peptide chain elongation
859 | |
---|---|
set | Peptide chain elongation |
setSize | 87 |
pANOVA | 3.14e-32 |
s.dist | 0.732 |
p.adjustANOVA | 1.16e-29 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
EEF1A1 | 7895 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
EEF1A1 | 7895 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
RPS13 | 7341 |
RPSA | 7336 |
RPL31 | 7281 |
RPL35A | 7280 |
RPS23 | 7279 |
RPS20 | 7274 |
RPL22 | 7262 |
RPL26 | 7242 |
RPS8 | 7231 |
RPL7A | 7219 |
RPL41 | 7187 |
RPL32 | 7125 |
RPL21 | 7065 |
RPL6 | 7045 |
RPL14 | 7019 |
RPL10 | 7017 |
RPS17 | 6977 |
RPL8 | 6975 |
RPL19 | 6903 |
RPL37 | 6857 |
RPS3 | 6842 |
RPL23 | 6817 |
RPS15 | 6811 |
RPS24 | 6802 |
RPL18 | 6774 |
RPL13A | 6760 |
RPL37A | 6664 |
RPS19 | 6640 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
RPL36 | 6383 |
RPL11 | 6366 |
RPL23A | 6332 |
RPLP2 | 6284 |
RPS29 | 6283 |
RPS28 | 6238 |
RPL24 | 6202 |
RPL3 | 6179 |
RPLP1 | 6158 |
RPL27 | 6127 |
RPS16 | 6124 |
RPS12 | 6075 |
RPL12 | 6004 |
RPL13 | 5974 |
RPL35 | 5831 |
RPS9 | 5735 |
RPL10A | 5726 |
UBA52 | 5692 |
RPS21 | 5653 |
RPL38 | 5646 |
RPS18 | 5530 |
RPL27A | 5467 |
RPL36AL | 5427 |
RPL36A | 5413 |
RPS4X | 5267 |
RPS2 | 4768 |
RPLP0 | 4642 |
RPL39L | 3498 |
RPL26L1 | 3493 |
RPL28 | 2504 |
EEF2 | 2348 |
RPL9 | 2110 |
RPS4Y1 | 1782 |
RPS26 | -1698 |
RPL22L1 | -2079 |
Eukaryotic Translation Elongation
373 | |
---|---|
set | Eukaryotic Translation Elongation |
setSize | 92 |
pANOVA | 3.56e-33 |
s.dist | 0.723 |
p.adjustANOVA | 2.7e-30 |
Top enriched genes
GeneID | Gene Rank |
---|---|
EEF1B2 | 8168 |
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
EEF1A1 | 7895 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
EEF1D | 7618 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
GeneID | Gene Rank |
---|---|
EEF1B2 | 8168 |
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
EEF1A1 | 7895 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
EEF1D | 7618 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
RPS13 | 7341 |
RPSA | 7336 |
RPL31 | 7281 |
RPL35A | 7280 |
RPS23 | 7279 |
RPS20 | 7274 |
RPL22 | 7262 |
RPL26 | 7242 |
RPS8 | 7231 |
RPL7A | 7219 |
RPL41 | 7187 |
RPL32 | 7125 |
RPL21 | 7065 |
RPL6 | 7045 |
RPL14 | 7019 |
RPL10 | 7017 |
RPS17 | 6977 |
RPL8 | 6975 |
EEF1A1P5 | 6945 |
RPL19 | 6903 |
RPL37 | 6857 |
RPS3 | 6842 |
RPL23 | 6817 |
RPS15 | 6811 |
RPS24 | 6802 |
RPL18 | 6774 |
RPL13A | 6760 |
RPL37A | 6664 |
RPS19 | 6640 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
RPL36 | 6383 |
RPL11 | 6366 |
RPL23A | 6332 |
EEF1G | 6286 |
RPLP2 | 6284 |
RPS29 | 6283 |
RPS28 | 6238 |
RPL24 | 6202 |
RPL3 | 6179 |
RPLP1 | 6158 |
RPL27 | 6127 |
RPS16 | 6124 |
RPS12 | 6075 |
RPL12 | 6004 |
RPL13 | 5974 |
RPL35 | 5831 |
RPS9 | 5735 |
RPL10A | 5726 |
UBA52 | 5692 |
RPS21 | 5653 |
RPL38 | 5646 |
RPS18 | 5530 |
RPL27A | 5467 |
RPL36AL | 5427 |
RPL36A | 5413 |
RPS4X | 5267 |
RPS2 | 4768 |
RPLP0 | 4642 |
RPL39L | 3498 |
RPL26L1 | 3493 |
RPL28 | 2504 |
EEF2 | 2348 |
RPL9 | 2110 |
RPS4Y1 | 1782 |
RPS26 | -1698 |
RPL22L1 | -2079 |
EEF1A2 | -4965 |
Classical antibody-mediated complement activation
202 | |
---|---|
set | Classical antibody-mediated complement activation |
setSize | 13 |
pANOVA | 7.28e-06 |
s.dist | -0.718 |
p.adjustANOVA | 0.000208 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IGHG4 | -8636 |
IGLC1 | -8528 |
IGLC3 | -8412 |
IGLC2 | -7870 |
IGHG2 | -6973 |
IGHG1 | -6890 |
C1QC | -6479 |
C1R | -5803 |
C1QA | -5746 |
C1QB | -5638 |
IGHG3 | -4982 |
C1S | -3589 |
IGKC | -1151 |
GeneID | Gene Rank |
---|---|
IGHG4 | -8636 |
IGLC1 | -8528 |
IGLC3 | -8412 |
IGLC2 | -7870 |
IGHG2 | -6973 |
IGHG1 | -6890 |
C1QC | -6479 |
C1R | -5803 |
C1QA | -5746 |
C1QB | -5638 |
IGHG3 | -4982 |
C1S | -3589 |
IGKC | -1151 |
Viral mRNA Translation
1435 | |
---|---|
set | Viral mRNA Translation |
setSize | 87 |
pANOVA | 5.89e-31 |
s.dist | 0.717 |
p.adjustANOVA | 1.46e-28 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
RPS13 | 7341 |
RPSA | 7336 |
RPL31 | 7281 |
RPL35A | 7280 |
RPS23 | 7279 |
RPS20 | 7274 |
RPL22 | 7262 |
RPL26 | 7242 |
RPS8 | 7231 |
RPL7A | 7219 |
RPL41 | 7187 |
RPL32 | 7125 |
RPL21 | 7065 |
RPL6 | 7045 |
RPL14 | 7019 |
RPL10 | 7017 |
RPS17 | 6977 |
RPL8 | 6975 |
RPL19 | 6903 |
RPL37 | 6857 |
RPS3 | 6842 |
RPL23 | 6817 |
RPS15 | 6811 |
RPS24 | 6802 |
RPL18 | 6774 |
RPL13A | 6760 |
RPL37A | 6664 |
RPS19 | 6640 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
RPL36 | 6383 |
RPL11 | 6366 |
RPL23A | 6332 |
RPLP2 | 6284 |
RPS29 | 6283 |
RPS28 | 6238 |
RPL24 | 6202 |
RPL3 | 6179 |
RPLP1 | 6158 |
RPL27 | 6127 |
RPS16 | 6124 |
RPS12 | 6075 |
RPL12 | 6004 |
RPL13 | 5974 |
RPL35 | 5831 |
RPS9 | 5735 |
RPL10A | 5726 |
UBA52 | 5692 |
RPS21 | 5653 |
RPL38 | 5646 |
RPS18 | 5530 |
RPL27A | 5467 |
RPL36AL | 5427 |
RPL36A | 5413 |
RPS4X | 5267 |
RPS2 | 4768 |
RPLP0 | 4642 |
RPL39L | 3498 |
RPL26L1 | 3493 |
GRSF1 | 3175 |
RPL28 | 2504 |
RPL9 | 2110 |
RPS4Y1 | 1782 |
RPS26 | -1698 |
RPL22L1 | -2079 |
DNAJC3 | -4428 |
Selenocysteine synthesis
1153 | |
---|---|
set | Selenocysteine synthesis |
setSize | 91 |
pANOVA | 1.02e-30 |
s.dist | 0.698 |
p.adjustANOVA | 2.15e-28 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
RPS13 | 7341 |
RPSA | 7336 |
RPL31 | 7281 |
RPL35A | 7280 |
RPS23 | 7279 |
RPS20 | 7274 |
RPL22 | 7262 |
RPL26 | 7242 |
RPS8 | 7231 |
RPL7A | 7219 |
RPL41 | 7187 |
RPL32 | 7125 |
RPL21 | 7065 |
RPL6 | 7045 |
RPL14 | 7019 |
RPL10 | 7017 |
RPS17 | 6977 |
RPL8 | 6975 |
RPL19 | 6903 |
RPL37 | 6857 |
RPS3 | 6842 |
RPL23 | 6817 |
RPS15 | 6811 |
RPS24 | 6802 |
RPL18 | 6774 |
RPL13A | 6760 |
RPL37A | 6664 |
RPS19 | 6640 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
RPL36 | 6383 |
RPL11 | 6366 |
RPL23A | 6332 |
RPLP2 | 6284 |
RPS29 | 6283 |
RPS28 | 6238 |
RPL24 | 6202 |
RPL3 | 6179 |
RPLP1 | 6158 |
RPL27 | 6127 |
RPS16 | 6124 |
RPS12 | 6075 |
RPL12 | 6004 |
RPL13 | 5974 |
RPL35 | 5831 |
RPS9 | 5735 |
RPL10A | 5726 |
UBA52 | 5692 |
RPS21 | 5653 |
RPL38 | 5646 |
RPS18 | 5530 |
RPL27A | 5467 |
RPL36AL | 5427 |
RPL36A | 5413 |
RPS4X | 5267 |
RPS2 | 4768 |
RPLP0 | 4642 |
EEFSEC | 4290 |
SARS1 | 3834 |
RPL39L | 3498 |
RPL26L1 | 3493 |
PSTK | 2532 |
RPL28 | 2504 |
RPL9 | 2110 |
RPS4Y1 | 1782 |
SEPSECS | 923 |
SECISBP2 | -758 |
RPS26 | -1698 |
RPL22L1 | -2079 |
SEPHS2 | -2160 |
Formation of a pool of free 40S subunits
418 | |
---|---|
set | Formation of a pool of free 40S subunits |
setSize | 99 |
pANOVA | 3.64e-33 |
s.dist | 0.697 |
p.adjustANOVA | 2.7e-30 |
Top enriched genes
GeneID | Gene Rank |
---|---|
EIF3E | 8452 |
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
GeneID | Gene Rank |
---|---|
EIF3E | 8452 |
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
RPS13 | 7341 |
RPSA | 7336 |
EIF3H | 7291 |
RPL31 | 7281 |
RPL35A | 7280 |
RPS23 | 7279 |
RPS20 | 7274 |
RPL22 | 7262 |
RPL26 | 7242 |
RPS8 | 7231 |
RPL7A | 7219 |
RPL41 | 7187 |
RPL32 | 7125 |
RPL21 | 7065 |
RPL6 | 7045 |
RPL14 | 7019 |
RPL10 | 7017 |
RPS17 | 6977 |
RPL8 | 6975 |
RPL19 | 6903 |
RPL37 | 6857 |
RPS3 | 6842 |
RPL23 | 6817 |
RPS15 | 6811 |
RPS24 | 6802 |
RPL18 | 6774 |
RPL13A | 6760 |
EIF3L | 6741 |
RPL37A | 6664 |
RPS19 | 6640 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
RPL36 | 6383 |
RPL11 | 6366 |
EIF3I | 6339 |
RPL23A | 6332 |
RPLP2 | 6284 |
RPS29 | 6283 |
RPS28 | 6238 |
RPL24 | 6202 |
RPL3 | 6179 |
RPLP1 | 6158 |
RPL27 | 6127 |
RPS16 | 6124 |
RPS12 | 6075 |
RPL12 | 6004 |
RPL13 | 5974 |
RPL35 | 5831 |
EIF3G | 5826 |
RPS9 | 5735 |
RPL10A | 5726 |
UBA52 | 5692 |
RPS21 | 5653 |
RPL38 | 5646 |
RPS18 | 5530 |
RPL27A | 5467 |
EIF3M | 5460 |
RPL36AL | 5427 |
RPL36A | 5413 |
RPS4X | 5267 |
EIF1AX | 5062 |
RPS2 | 4768 |
RPLP0 | 4642 |
EIF3D | 4594 |
EIF3C | 4357 |
EIF3A | 3808 |
RPL39L | 3498 |
RPL26L1 | 3493 |
RPL28 | 2504 |
RPL9 | 2110 |
RPS4Y1 | 1782 |
EIF3F | 1625 |
EIF3J | 131 |
EIF3K | -171 |
RPS26 | -1698 |
RPL22L1 | -2079 |
EIF3B | -4075 |
Eukaryotic Translation Termination
375 | |
---|---|
set | Eukaryotic Translation Termination |
setSize | 91 |
pANOVA | 1e-28 |
s.dist | 0.674 |
p.adjustANOVA | 1.48e-26 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
RPS13 | 7341 |
RPSA | 7336 |
RPL31 | 7281 |
RPL35A | 7280 |
RPS23 | 7279 |
RPS20 | 7274 |
RPL22 | 7262 |
RPL26 | 7242 |
RPS8 | 7231 |
RPL7A | 7219 |
RPL41 | 7187 |
RPL32 | 7125 |
RPL21 | 7065 |
RPL6 | 7045 |
RPL14 | 7019 |
RPL10 | 7017 |
RPS17 | 6977 |
RPL8 | 6975 |
RPL19 | 6903 |
RPL37 | 6857 |
RPS3 | 6842 |
RPL23 | 6817 |
RPS15 | 6811 |
RPS24 | 6802 |
RPL18 | 6774 |
RPL13A | 6760 |
RPL37A | 6664 |
RPS19 | 6640 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
RPL36 | 6383 |
RPL11 | 6366 |
RPL23A | 6332 |
RPLP2 | 6284 |
RPS29 | 6283 |
RPS28 | 6238 |
RPL24 | 6202 |
RPL3 | 6179 |
RPLP1 | 6158 |
RPL27 | 6127 |
RPS16 | 6124 |
RPS12 | 6075 |
RPL12 | 6004 |
RPL13 | 5974 |
RPL35 | 5831 |
RPS9 | 5735 |
RPL10A | 5726 |
UBA52 | 5692 |
RPS21 | 5653 |
RPL38 | 5646 |
RPS18 | 5530 |
RPL27A | 5467 |
RPL36AL | 5427 |
RPL36A | 5413 |
RPS4X | 5267 |
TRMT112 | 4781 |
RPS2 | 4768 |
RPLP0 | 4642 |
RPL39L | 3498 |
RPL26L1 | 3493 |
RPL28 | 2504 |
RPL9 | 2110 |
RPS4Y1 | 1782 |
ETF1 | 1473 |
RPS26 | -1698 |
GSPT2 | -1934 |
RPL22L1 | -2079 |
GSPT1 | -3107 |
APEH | -3547 |
N6AMT1 | -8009 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
789 | |
---|---|
set | Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) |
setSize | 93 |
pANOVA | 1.44e-28 |
s.dist | 0.664 |
p.adjustANOVA | 1.94e-26 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
RPS13 | 7341 |
RPSA | 7336 |
RPL31 | 7281 |
RPL35A | 7280 |
RPS23 | 7279 |
RPS20 | 7274 |
RPL22 | 7262 |
RPL26 | 7242 |
RPS8 | 7231 |
RPL7A | 7219 |
RPL41 | 7187 |
RPL32 | 7125 |
RPL21 | 7065 |
RPL6 | 7045 |
RPL14 | 7019 |
RPL10 | 7017 |
RPS17 | 6977 |
RPL8 | 6975 |
RPL19 | 6903 |
RPL37 | 6857 |
RPS3 | 6842 |
RPL23 | 6817 |
RPS15 | 6811 |
RPS24 | 6802 |
RPL18 | 6774 |
RPL13A | 6760 |
RPL37A | 6664 |
RPS19 | 6640 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
RPL36 | 6383 |
RPL11 | 6366 |
RPL23A | 6332 |
RPLP2 | 6284 |
RPS29 | 6283 |
RPS28 | 6238 |
RPL24 | 6202 |
RPL3 | 6179 |
RPLP1 | 6158 |
RPL27 | 6127 |
RPS16 | 6124 |
RPS12 | 6075 |
RPL12 | 6004 |
RPL13 | 5974 |
RPL35 | 5831 |
RPS9 | 5735 |
RPL10A | 5726 |
UBA52 | 5692 |
RPS21 | 5653 |
RPL38 | 5646 |
RPS18 | 5530 |
RPL27A | 5467 |
RPL36AL | 5427 |
RPL36A | 5413 |
RPS4X | 5267 |
RPS2 | 4768 |
RPLP0 | 4642 |
PABPC1 | 3810 |
RPL39L | 3498 |
RPL26L1 | 3493 |
RPL28 | 2504 |
RPL9 | 2110 |
NCBP2 | 1938 |
RPS4Y1 | 1782 |
ETF1 | 1473 |
NCBP1 | 254 |
RPS26 | -1698 |
GSPT2 | -1934 |
RPL22L1 | -2079 |
GSPT1 | -3107 |
UPF1 | -3377 |
EIF4G1 | -5229 |
L13a-mediated translational silencing of Ceruloplasmin expression
627 | |
---|---|
set | L13a-mediated translational silencing of Ceruloplasmin expression |
setSize | 109 |
pANOVA | 2.87e-32 |
s.dist | 0.655 |
p.adjustANOVA | 1.16e-29 |
Top enriched genes
GeneID | Gene Rank |
---|---|
EIF3E | 8452 |
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
EIF4A2 | 7536 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
GeneID | Gene Rank |
---|---|
EIF3E | 8452 |
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
EIF4A2 | 7536 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
RPS13 | 7341 |
RPSA | 7336 |
EIF3H | 7291 |
RPL31 | 7281 |
RPL35A | 7280 |
RPS23 | 7279 |
RPS20 | 7274 |
RPL22 | 7262 |
RPL26 | 7242 |
RPS8 | 7231 |
RPL7A | 7219 |
RPL41 | 7187 |
RPL32 | 7125 |
RPL21 | 7065 |
RPL6 | 7045 |
RPL14 | 7019 |
RPL10 | 7017 |
RPS17 | 6977 |
RPL8 | 6975 |
RPL19 | 6903 |
RPL37 | 6857 |
RPS3 | 6842 |
RPL23 | 6817 |
RPS15 | 6811 |
RPS24 | 6802 |
RPL18 | 6774 |
RPL13A | 6760 |
EIF3L | 6741 |
RPL37A | 6664 |
RPS19 | 6640 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
RPL36 | 6383 |
RPL11 | 6366 |
EIF3I | 6339 |
RPL23A | 6332 |
RPLP2 | 6284 |
RPS29 | 6283 |
RPS28 | 6238 |
RPL24 | 6202 |
EIF2S2 | 6188 |
RPL3 | 6179 |
RPLP1 | 6158 |
EIF4B | 6154 |
RPL27 | 6127 |
RPS16 | 6124 |
RPS12 | 6075 |
RPL12 | 6004 |
RPL13 | 5974 |
RPL35 | 5831 |
EIF3G | 5826 |
RPS9 | 5735 |
RPL10A | 5726 |
UBA52 | 5692 |
RPS21 | 5653 |
RPL38 | 5646 |
RPS18 | 5530 |
RPL27A | 5467 |
EIF3M | 5460 |
RPL36AL | 5427 |
RPL36A | 5413 |
EIF2S1 | 5338 |
RPS4X | 5267 |
EIF1AX | 5062 |
RPS2 | 4768 |
RPLP0 | 4642 |
EIF3D | 4594 |
EIF3C | 4357 |
PABPC1 | 3810 |
EIF3A | 3808 |
RPL39L | 3498 |
RPL26L1 | 3493 |
RPL28 | 2504 |
RPL9 | 2110 |
RPS4Y1 | 1782 |
EIF3F | 1625 |
EIF3J | 131 |
EIF4E | -1 |
EIF3K | -171 |
EIF4H | -348 |
EIF2S3 | -1224 |
RPS26 | -1698 |
EIF4A1 | -2064 |
RPL22L1 | -2079 |
EIF3B | -4075 |
EIF4G1 | -5229 |
Formation of the ternary complex, and subsequently, the 43S complex
426 | |
---|---|
set | Formation of the ternary complex, and subsequently, the 43S complex |
setSize | 51 |
pANOVA | 1.17e-15 |
s.dist | 0.648 |
p.adjustANOVA | 6.66e-14 |
Top enriched genes
GeneID | Gene Rank |
---|---|
EIF3E | 8452 |
RPS14 | 8115 |
FAU | 7867 |
RPS7 | 7855 |
RPS11 | 7841 |
RPS3A | 7827 |
RPS15A | 7639 |
RPS27A | 7636 |
RPS5 | 7614 |
RPS6 | 7516 |
RPS10 | 7438 |
RPS13 | 7341 |
RPSA | 7336 |
EIF3H | 7291 |
RPS23 | 7279 |
RPS20 | 7274 |
RPS8 | 7231 |
RPS17 | 6977 |
RPS3 | 6842 |
RPS15 | 6811 |
GeneID | Gene Rank |
---|---|
EIF3E | 8452 |
RPS14 | 8115 |
FAU | 7867 |
RPS7 | 7855 |
RPS11 | 7841 |
RPS3A | 7827 |
RPS15A | 7639 |
RPS27A | 7636 |
RPS5 | 7614 |
RPS6 | 7516 |
RPS10 | 7438 |
RPS13 | 7341 |
RPSA | 7336 |
EIF3H | 7291 |
RPS23 | 7279 |
RPS20 | 7274 |
RPS8 | 7231 |
RPS17 | 6977 |
RPS3 | 6842 |
RPS15 | 6811 |
RPS24 | 6802 |
EIF3L | 6741 |
RPS19 | 6640 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
EIF3I | 6339 |
RPS29 | 6283 |
RPS28 | 6238 |
EIF2S2 | 6188 |
RPS16 | 6124 |
RPS12 | 6075 |
EIF3G | 5826 |
RPS9 | 5735 |
RPS21 | 5653 |
RPS18 | 5530 |
EIF3M | 5460 |
EIF2S1 | 5338 |
RPS4X | 5267 |
EIF1AX | 5062 |
RPS2 | 4768 |
EIF3D | 4594 |
EIF3C | 4357 |
EIF3A | 3808 |
RPS4Y1 | 1782 |
EIF3F | 1625 |
EIF3J | 131 |
EIF3K | -171 |
EIF2S3 | -1224 |
RPS26 | -1698 |
EIF3B | -4075 |
Response of EIF2AK4 (GCN2) to amino acid deficiency
1091 | |
---|---|
set | Response of EIF2AK4 (GCN2) to amino acid deficiency |
setSize | 99 |
pANOVA | 1.61e-28 |
s.dist | 0.644 |
p.adjustANOVA | 1.99e-26 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ATF3 | 8618 |
CEBPG | 8422 |
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
GeneID | Gene Rank |
---|---|
ATF3 | 8618 |
CEBPG | 8422 |
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
RPS13 | 7341 |
RPSA | 7336 |
RPL31 | 7281 |
RPL35A | 7280 |
RPS23 | 7279 |
RPS20 | 7274 |
RPL22 | 7262 |
RPL26 | 7242 |
RPS8 | 7231 |
RPL7A | 7219 |
RPL41 | 7187 |
RPL32 | 7125 |
RPL21 | 7065 |
RPL6 | 7045 |
RPL14 | 7019 |
RPL10 | 7017 |
RPS17 | 6977 |
RPL8 | 6975 |
RPL19 | 6903 |
RPL37 | 6857 |
RPS3 | 6842 |
RPL23 | 6817 |
RPS15 | 6811 |
RPS24 | 6802 |
RPL18 | 6774 |
RPL13A | 6760 |
RPL37A | 6664 |
RPS19 | 6640 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
RPL36 | 6383 |
RPL11 | 6366 |
RPL23A | 6332 |
RPLP2 | 6284 |
RPS29 | 6283 |
RPS28 | 6238 |
RPL24 | 6202 |
EIF2S2 | 6188 |
RPL3 | 6179 |
RPLP1 | 6158 |
RPL27 | 6127 |
RPS16 | 6124 |
RPS12 | 6075 |
RPL12 | 6004 |
RPL13 | 5974 |
RPL35 | 5831 |
RPS9 | 5735 |
RPL10A | 5726 |
UBA52 | 5692 |
RPS21 | 5653 |
RPL38 | 5646 |
RPS18 | 5530 |
RPL27A | 5467 |
RPL36AL | 5427 |
RPL36A | 5413 |
EIF2S1 | 5338 |
RPS4X | 5267 |
RPS2 | 4768 |
RPLP0 | 4642 |
RPL39L | 3498 |
RPL26L1 | 3493 |
ATF4 | 3224 |
RPL28 | 2504 |
RPL9 | 2110 |
RPS4Y1 | 1782 |
EIF2AK4 | 1141 |
IMPACT | -699 |
ATF2 | -1057 |
CEBPB | -1165 |
EIF2S3 | -1224 |
RPS26 | -1698 |
RPL22L1 | -2079 |
ASNS | -2422 |
DDIT3 | -2701 |
TRIB3 | -6269 |
GCN1 | -7265 |
GTP hydrolysis and joining of the 60S ribosomal subunit
464 | |
---|---|
set | GTP hydrolysis and joining of the 60S ribosomal subunit |
setSize | 110 |
pANOVA | 2.01e-31 |
s.dist | 0.643 |
p.adjustANOVA | 5.95e-29 |
Top enriched genes
GeneID | Gene Rank |
---|---|
EIF3E | 8452 |
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
EIF4A2 | 7536 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
GeneID | Gene Rank |
---|---|
EIF3E | 8452 |
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
EIF4A2 | 7536 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
RPS13 | 7341 |
RPSA | 7336 |
EIF3H | 7291 |
RPL31 | 7281 |
RPL35A | 7280 |
RPS23 | 7279 |
RPS20 | 7274 |
RPL22 | 7262 |
RPL26 | 7242 |
RPS8 | 7231 |
RPL7A | 7219 |
RPL41 | 7187 |
RPL32 | 7125 |
RPL21 | 7065 |
RPL6 | 7045 |
RPL14 | 7019 |
RPL10 | 7017 |
RPS17 | 6977 |
RPL8 | 6975 |
RPL19 | 6903 |
RPL37 | 6857 |
RPS3 | 6842 |
RPL23 | 6817 |
RPS15 | 6811 |
RPS24 | 6802 |
RPL18 | 6774 |
RPL13A | 6760 |
EIF3L | 6741 |
RPL37A | 6664 |
RPS19 | 6640 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
RPL36 | 6383 |
RPL11 | 6366 |
EIF3I | 6339 |
RPL23A | 6332 |
RPLP2 | 6284 |
RPS29 | 6283 |
RPS28 | 6238 |
RPL24 | 6202 |
EIF2S2 | 6188 |
RPL3 | 6179 |
RPLP1 | 6158 |
EIF4B | 6154 |
RPL27 | 6127 |
RPS16 | 6124 |
RPS12 | 6075 |
RPL12 | 6004 |
RPL13 | 5974 |
RPL35 | 5831 |
EIF3G | 5826 |
RPS9 | 5735 |
RPL10A | 5726 |
UBA52 | 5692 |
RPS21 | 5653 |
RPL38 | 5646 |
RPS18 | 5530 |
RPL27A | 5467 |
EIF3M | 5460 |
RPL36AL | 5427 |
RPL36A | 5413 |
EIF2S1 | 5338 |
RPS4X | 5267 |
EIF1AX | 5062 |
RPS2 | 4768 |
RPLP0 | 4642 |
EIF3D | 4594 |
EIF3C | 4357 |
EIF3A | 3808 |
RPL39L | 3498 |
RPL26L1 | 3493 |
EIF5B | 3048 |
RPL28 | 2504 |
RPL9 | 2110 |
RPS4Y1 | 1782 |
EIF3F | 1625 |
EIF3J | 131 |
EIF4E | -1 |
EIF3K | -171 |
EIF4H | -348 |
EIF2S3 | -1224 |
RPS26 | -1698 |
EIF4A1 | -2064 |
RPL22L1 | -2079 |
EIF3B | -4075 |
EIF5 | -4979 |
EIF4G1 | -5229 |
FCGR activation
385 | |
---|---|
set | FCGR activation |
setSize | 20 |
pANOVA | 7.34e-07 |
s.dist | -0.639 |
p.adjustANOVA | 2.59e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IGHG4 | -8636 |
IGLC1 | -8528 |
IGLC3 | -8412 |
FCGR2A | -8279 |
FCGR1A | -8113 |
FCGR3A | -7985 |
IGLC2 | -7870 |
HCK | -7733 |
SYK | -7142 |
IGHG2 | -6973 |
FGR | -6972 |
IGHG1 | -6890 |
CD247 | -6839 |
SRC | -5305 |
IGHG3 | -4982 |
LYN | -4370 |
FYN | -1654 |
IGKC | -1151 |
YES1 | 1029 |
CD3G | 6329 |
GeneID | Gene Rank |
---|---|
IGHG4 | -8636 |
IGLC1 | -8528 |
IGLC3 | -8412 |
FCGR2A | -8279 |
FCGR1A | -8113 |
FCGR3A | -7985 |
IGLC2 | -7870 |
HCK | -7733 |
SYK | -7142 |
IGHG2 | -6973 |
FGR | -6972 |
IGHG1 | -6890 |
CD247 | -6839 |
SRC | -5305 |
IGHG3 | -4982 |
LYN | -4370 |
FYN | -1654 |
IGKC | -1151 |
YES1 | 1029 |
CD3G | 6329 |
Creation of C4 and C2 activators
230 | |
---|---|
set | Creation of C4 and C2 activators |
setSize | 16 |
pANOVA | 1.28e-05 |
s.dist | -0.63 |
p.adjustANOVA | 0.000329 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IGHG4 | -8636 |
IGLC1 | -8528 |
IGLC3 | -8412 |
IGLC2 | -7870 |
IGHG2 | -6973 |
IGHG1 | -6890 |
C1QC | -6479 |
MASP2 | -5886 |
C1R | -5803 |
C1QA | -5746 |
C1QB | -5638 |
IGHG3 | -4982 |
C1S | -3589 |
MASP1 | -2834 |
IGKC | -1151 |
FCN1 | 2327 |
GeneID | Gene Rank |
---|---|
IGHG4 | -8636 |
IGLC1 | -8528 |
IGLC3 | -8412 |
IGLC2 | -7870 |
IGHG2 | -6973 |
IGHG1 | -6890 |
C1QC | -6479 |
MASP2 | -5886 |
C1R | -5803 |
C1QA | -5746 |
C1QB | -5638 |
IGHG3 | -4982 |
C1S | -3589 |
MASP1 | -2834 |
IGKC | -1151 |
FCN1 | 2327 |
Cap-dependent Translation Initiation
154 | |
---|---|
set | Cap-dependent Translation Initiation |
setSize | 117 |
pANOVA | 1.78e-29 |
s.dist | 0.603 |
p.adjustANOVA | 2.93e-27 |
Top enriched genes
GeneID | Gene Rank |
---|---|
EIF3E | 8452 |
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
EIF4A2 | 7536 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
GeneID | Gene Rank |
---|---|
EIF3E | 8452 |
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
EIF4A2 | 7536 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
RPS13 | 7341 |
RPSA | 7336 |
EIF3H | 7291 |
RPL31 | 7281 |
RPL35A | 7280 |
RPS23 | 7279 |
RPS20 | 7274 |
RPL22 | 7262 |
RPL26 | 7242 |
RPS8 | 7231 |
RPL7A | 7219 |
RPL41 | 7187 |
RPL32 | 7125 |
RPL21 | 7065 |
RPL6 | 7045 |
RPL14 | 7019 |
RPL10 | 7017 |
RPS17 | 6977 |
RPL8 | 6975 |
RPL19 | 6903 |
RPL37 | 6857 |
RPS3 | 6842 |
RPL23 | 6817 |
RPS15 | 6811 |
RPS24 | 6802 |
RPL18 | 6774 |
RPL13A | 6760 |
EIF3L | 6741 |
RPL37A | 6664 |
RPS19 | 6640 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
RPL36 | 6383 |
RPL11 | 6366 |
EIF3I | 6339 |
RPL23A | 6332 |
RPLP2 | 6284 |
RPS29 | 6283 |
RPS28 | 6238 |
RPL24 | 6202 |
EIF2S2 | 6188 |
RPL3 | 6179 |
RPLP1 | 6158 |
EIF4B | 6154 |
RPL27 | 6127 |
RPS16 | 6124 |
RPS12 | 6075 |
RPL12 | 6004 |
RPL13 | 5974 |
RPL35 | 5831 |
EIF3G | 5826 |
RPS9 | 5735 |
RPL10A | 5726 |
UBA52 | 5692 |
RPS21 | 5653 |
RPL38 | 5646 |
RPS18 | 5530 |
RPL27A | 5467 |
EIF3M | 5460 |
RPL36AL | 5427 |
RPL36A | 5413 |
EIF2S1 | 5338 |
RPS4X | 5267 |
EIF1AX | 5062 |
EIF2B3 | 4853 |
RPS2 | 4768 |
RPLP0 | 4642 |
EIF3D | 4594 |
EIF3C | 4357 |
PABPC1 | 3810 |
EIF3A | 3808 |
EIF2B2 | 3550 |
RPL39L | 3498 |
RPL26L1 | 3493 |
EIF5B | 3048 |
RPL28 | 2504 |
RPL9 | 2110 |
RPS4Y1 | 1782 |
EIF3F | 1625 |
EIF3J | 131 |
EIF4E | -1 |
EIF2B4 | -88 |
EIF3K | -171 |
EIF4H | -348 |
EIF2S3 | -1224 |
RPS26 | -1698 |
EIF4A1 | -2064 |
RPL22L1 | -2079 |
EIF4EBP1 | -3119 |
EIF3B | -4075 |
EIF2B5 | -4355 |
EIF5 | -4979 |
EIF4G1 | -5229 |
EIF2B1 | -6523 |
Eukaryotic Translation Initiation
374 | |
---|---|
set | Eukaryotic Translation Initiation |
setSize | 117 |
pANOVA | 1.78e-29 |
s.dist | 0.603 |
p.adjustANOVA | 2.93e-27 |
Top enriched genes
GeneID | Gene Rank |
---|---|
EIF3E | 8452 |
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
EIF4A2 | 7536 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
GeneID | Gene Rank |
---|---|
EIF3E | 8452 |
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
EIF4A2 | 7536 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
RPS13 | 7341 |
RPSA | 7336 |
EIF3H | 7291 |
RPL31 | 7281 |
RPL35A | 7280 |
RPS23 | 7279 |
RPS20 | 7274 |
RPL22 | 7262 |
RPL26 | 7242 |
RPS8 | 7231 |
RPL7A | 7219 |
RPL41 | 7187 |
RPL32 | 7125 |
RPL21 | 7065 |
RPL6 | 7045 |
RPL14 | 7019 |
RPL10 | 7017 |
RPS17 | 6977 |
RPL8 | 6975 |
RPL19 | 6903 |
RPL37 | 6857 |
RPS3 | 6842 |
RPL23 | 6817 |
RPS15 | 6811 |
RPS24 | 6802 |
RPL18 | 6774 |
RPL13A | 6760 |
EIF3L | 6741 |
RPL37A | 6664 |
RPS19 | 6640 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
RPL36 | 6383 |
RPL11 | 6366 |
EIF3I | 6339 |
RPL23A | 6332 |
RPLP2 | 6284 |
RPS29 | 6283 |
RPS28 | 6238 |
RPL24 | 6202 |
EIF2S2 | 6188 |
RPL3 | 6179 |
RPLP1 | 6158 |
EIF4B | 6154 |
RPL27 | 6127 |
RPS16 | 6124 |
RPS12 | 6075 |
RPL12 | 6004 |
RPL13 | 5974 |
RPL35 | 5831 |
EIF3G | 5826 |
RPS9 | 5735 |
RPL10A | 5726 |
UBA52 | 5692 |
RPS21 | 5653 |
RPL38 | 5646 |
RPS18 | 5530 |
RPL27A | 5467 |
EIF3M | 5460 |
RPL36AL | 5427 |
RPL36A | 5413 |
EIF2S1 | 5338 |
RPS4X | 5267 |
EIF1AX | 5062 |
EIF2B3 | 4853 |
RPS2 | 4768 |
RPLP0 | 4642 |
EIF3D | 4594 |
EIF3C | 4357 |
PABPC1 | 3810 |
EIF3A | 3808 |
EIF2B2 | 3550 |
RPL39L | 3498 |
RPL26L1 | 3493 |
EIF5B | 3048 |
RPL28 | 2504 |
RPL9 | 2110 |
RPS4Y1 | 1782 |
EIF3F | 1625 |
EIF3J | 131 |
EIF4E | -1 |
EIF2B4 | -88 |
EIF3K | -171 |
EIF4H | -348 |
EIF2S3 | -1224 |
RPS26 | -1698 |
EIF4A1 | -2064 |
RPL22L1 | -2079 |
EIF4EBP1 | -3119 |
EIF3B | -4075 |
EIF2B5 | -4355 |
EIF5 | -4979 |
EIF4G1 | -5229 |
EIF2B1 | -6523 |
SARS-CoV-2 modulates host translation machinery
1113 | |
---|---|
set | SARS-CoV-2 modulates host translation machinery |
setSize | 49 |
pANOVA | 3.7e-13 |
s.dist | 0.6 |
p.adjustANOVA | 1.66e-11 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
SMN1 | 7896 |
FAU | 7867 |
RPS7 | 7855 |
RPS11 | 7841 |
RPS3A | 7827 |
GEMIN5 | 7767 |
RPS15A | 7639 |
RPS27A | 7636 |
RPS5 | 7614 |
RPS6 | 7516 |
RPS10 | 7438 |
RPS13 | 7341 |
SNRPD1 | 7338 |
RPSA | 7336 |
RPS23 | 7279 |
RPS20 | 7274 |
RPS8 | 7231 |
RPS17 | 6977 |
RPS3 | 6842 |
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
SMN1 | 7896 |
FAU | 7867 |
RPS7 | 7855 |
RPS11 | 7841 |
RPS3A | 7827 |
GEMIN5 | 7767 |
RPS15A | 7639 |
RPS27A | 7636 |
RPS5 | 7614 |
RPS6 | 7516 |
RPS10 | 7438 |
RPS13 | 7341 |
SNRPD1 | 7338 |
RPSA | 7336 |
RPS23 | 7279 |
RPS20 | 7274 |
RPS8 | 7231 |
RPS17 | 6977 |
RPS3 | 6842 |
RPS15 | 6811 |
RPS24 | 6802 |
SNRPD2 | 6702 |
RPS19 | 6640 |
GEMIN8 | 6580 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
RPS29 | 6283 |
RPS28 | 6238 |
RPS16 | 6124 |
RPS12 | 6075 |
RPS9 | 5735 |
RPS21 | 5653 |
SNRPE | 5596 |
RPS18 | 5530 |
RPS4X | 5267 |
RPS2 | 4768 |
SNRPB | 4182 |
GEMIN6 | 1974 |
RPS4Y1 | 1782 |
SNRPG | 38 |
GEMIN2 | -209 |
SNRPD3 | -534 |
DDX20 | -1460 |
RPS26 | -1698 |
SNRPF | -2122 |
GEMIN4 | -3980 |
GEMIN7 | -5468 |
Expression and translocation of olfactory receptors
377 | |
---|---|
set | Expression and translocation of olfactory receptors |
setSize | 22 |
pANOVA | 1.34e-06 |
s.dist | 0.595 |
p.adjustANOVA | 4.52e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
OR6C75 | 8539 |
OR10H5 | 8370 |
OR6Y1 | 8313 |
OR2M3 | 8269 |
OR5A1 | 8245 |
OR2AT4 | 8150 |
OR7C1 | 8112 |
OR1D2 | 7908 |
OR5AN1 | 7649 |
OR14J1 | 7590 |
OR1I1 | 7498 |
OR5AS1 | 7423 |
OR4D9 | 7071 |
OR10G3 | 5658 |
OR52K1 | 4897 |
REEP1 | 4884 |
OR5A2 | 3846 |
OR8A1 | 2888 |
OR2A7 | -138 |
EBF1 | -1250 |
GeneID | Gene Rank |
---|---|
OR6C75 | 8539 |
OR10H5 | 8370 |
OR6Y1 | 8313 |
OR2M3 | 8269 |
OR5A1 | 8245 |
OR2AT4 | 8150 |
OR7C1 | 8112 |
OR1D2 | 7908 |
OR5AN1 | 7649 |
OR14J1 | 7590 |
OR1I1 | 7498 |
OR5AS1 | 7423 |
OR4D9 | 7071 |
OR10G3 | 5658 |
OR52K1 | 4897 |
REEP1 | 4884 |
OR5A2 | 3846 |
OR8A1 | 2888 |
OR2A7 | -138 |
EBF1 | -1250 |
LDB1 | -2420 |
OR2I1P | -8427 |
Translation initiation complex formation
1385 | |
---|---|
set | Translation initiation complex formation |
setSize | 58 |
pANOVA | 7.83e-15 |
s.dist | 0.59 |
p.adjustANOVA | 4.15e-13 |
Top enriched genes
GeneID | Gene Rank |
---|---|
EIF3E | 8452 |
RPS14 | 8115 |
FAU | 7867 |
RPS7 | 7855 |
RPS11 | 7841 |
RPS3A | 7827 |
RPS15A | 7639 |
RPS27A | 7636 |
RPS5 | 7614 |
EIF4A2 | 7536 |
RPS6 | 7516 |
RPS10 | 7438 |
RPS13 | 7341 |
RPSA | 7336 |
EIF3H | 7291 |
RPS23 | 7279 |
RPS20 | 7274 |
RPS8 | 7231 |
RPS17 | 6977 |
RPS3 | 6842 |
GeneID | Gene Rank |
---|---|
EIF3E | 8452 |
RPS14 | 8115 |
FAU | 7867 |
RPS7 | 7855 |
RPS11 | 7841 |
RPS3A | 7827 |
RPS15A | 7639 |
RPS27A | 7636 |
RPS5 | 7614 |
EIF4A2 | 7536 |
RPS6 | 7516 |
RPS10 | 7438 |
RPS13 | 7341 |
RPSA | 7336 |
EIF3H | 7291 |
RPS23 | 7279 |
RPS20 | 7274 |
RPS8 | 7231 |
RPS17 | 6977 |
RPS3 | 6842 |
RPS15 | 6811 |
RPS24 | 6802 |
EIF3L | 6741 |
RPS19 | 6640 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
EIF3I | 6339 |
RPS29 | 6283 |
RPS28 | 6238 |
EIF2S2 | 6188 |
EIF4B | 6154 |
RPS16 | 6124 |
RPS12 | 6075 |
EIF3G | 5826 |
RPS9 | 5735 |
RPS21 | 5653 |
RPS18 | 5530 |
EIF3M | 5460 |
EIF2S1 | 5338 |
RPS4X | 5267 |
EIF1AX | 5062 |
RPS2 | 4768 |
EIF3D | 4594 |
EIF3C | 4357 |
PABPC1 | 3810 |
EIF3A | 3808 |
RPS4Y1 | 1782 |
EIF3F | 1625 |
EIF3J | 131 |
EIF4E | -1 |
EIF3K | -171 |
EIF4H | -348 |
EIF2S3 | -1224 |
RPS26 | -1698 |
EIF4A1 | -2064 |
EIF3B | -4075 |
EIF4G1 | -5229 |
Mucopolysaccharidoses
726 | |
---|---|
set | Mucopolysaccharidoses |
setSize | 11 |
pANOVA | 0.000814 |
s.dist | -0.583 |
p.adjustANOVA | 0.0137 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IDUA | -8562 |
SGSH | -8225 |
GALNS | -8154 |
NAGLU | -7986 |
GNS | -7644 |
GLB1 | -7405 |
GUSB | -4019 |
HGSNAT | -3571 |
ARSB | -2772 |
IDS | 1201 |
HYAL1 | 1718 |
GeneID | Gene Rank |
---|---|
IDUA | -8562 |
SGSH | -8225 |
GALNS | -8154 |
NAGLU | -7986 |
GNS | -7644 |
GLB1 | -7405 |
GUSB | -4019 |
HGSNAT | -3571 |
ARSB | -2772 |
IDS | 1201 |
HYAL1 | 1718 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
51 | |
---|---|
set | Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S |
setSize | 59 |
pANOVA | 2.49e-14 |
s.dist | 0.573 |
p.adjustANOVA | 1.27e-12 |
Top enriched genes
GeneID | Gene Rank |
---|---|
EIF3E | 8452 |
RPS14 | 8115 |
FAU | 7867 |
RPS7 | 7855 |
RPS11 | 7841 |
RPS3A | 7827 |
RPS15A | 7639 |
RPS27A | 7636 |
RPS5 | 7614 |
EIF4A2 | 7536 |
RPS6 | 7516 |
RPS10 | 7438 |
RPS13 | 7341 |
RPSA | 7336 |
EIF3H | 7291 |
RPS23 | 7279 |
RPS20 | 7274 |
RPS8 | 7231 |
RPS17 | 6977 |
RPS3 | 6842 |
GeneID | Gene Rank |
---|---|
EIF3E | 8452 |
RPS14 | 8115 |
FAU | 7867 |
RPS7 | 7855 |
RPS11 | 7841 |
RPS3A | 7827 |
RPS15A | 7639 |
RPS27A | 7636 |
RPS5 | 7614 |
EIF4A2 | 7536 |
RPS6 | 7516 |
RPS10 | 7438 |
RPS13 | 7341 |
RPSA | 7336 |
EIF3H | 7291 |
RPS23 | 7279 |
RPS20 | 7274 |
RPS8 | 7231 |
RPS17 | 6977 |
RPS3 | 6842 |
RPS15 | 6811 |
RPS24 | 6802 |
EIF3L | 6741 |
RPS19 | 6640 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
EIF3I | 6339 |
RPS29 | 6283 |
RPS28 | 6238 |
EIF2S2 | 6188 |
EIF4B | 6154 |
RPS16 | 6124 |
RPS12 | 6075 |
EIF3G | 5826 |
RPS9 | 5735 |
RPS21 | 5653 |
RPS18 | 5530 |
EIF3M | 5460 |
EIF2S1 | 5338 |
RPS4X | 5267 |
EIF1AX | 5062 |
RPS2 | 4768 |
EIF3D | 4594 |
EIF3C | 4357 |
PABPC1 | 3810 |
EIF3A | 3808 |
RPS4Y1 | 1782 |
EIF3F | 1625 |
EIF3J | 131 |
EIF4E | -1 |
EIF3K | -171 |
EIF4H | -348 |
EIF2S3 | -1224 |
RPS26 | -1698 |
EIF4A1 | -2064 |
EIF4EBP1 | -3119 |
EIF3B | -4075 |
EIF4G1 | -5229 |
Ribosomal scanning and start codon recognition
1100 | |
---|---|
set | Ribosomal scanning and start codon recognition |
setSize | 58 |
pANOVA | 4.77e-14 |
s.dist | 0.572 |
p.adjustANOVA | 2.36e-12 |
Top enriched genes
GeneID | Gene Rank |
---|---|
EIF3E | 8452 |
RPS14 | 8115 |
FAU | 7867 |
RPS7 | 7855 |
RPS11 | 7841 |
RPS3A | 7827 |
RPS15A | 7639 |
RPS27A | 7636 |
RPS5 | 7614 |
EIF4A2 | 7536 |
RPS6 | 7516 |
RPS10 | 7438 |
RPS13 | 7341 |
RPSA | 7336 |
EIF3H | 7291 |
RPS23 | 7279 |
RPS20 | 7274 |
RPS8 | 7231 |
RPS17 | 6977 |
RPS3 | 6842 |
GeneID | Gene Rank |
---|---|
EIF3E | 8452 |
RPS14 | 8115 |
FAU | 7867 |
RPS7 | 7855 |
RPS11 | 7841 |
RPS3A | 7827 |
RPS15A | 7639 |
RPS27A | 7636 |
RPS5 | 7614 |
EIF4A2 | 7536 |
RPS6 | 7516 |
RPS10 | 7438 |
RPS13 | 7341 |
RPSA | 7336 |
EIF3H | 7291 |
RPS23 | 7279 |
RPS20 | 7274 |
RPS8 | 7231 |
RPS17 | 6977 |
RPS3 | 6842 |
RPS15 | 6811 |
RPS24 | 6802 |
EIF3L | 6741 |
RPS19 | 6640 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
EIF3I | 6339 |
RPS29 | 6283 |
RPS28 | 6238 |
EIF2S2 | 6188 |
EIF4B | 6154 |
RPS16 | 6124 |
RPS12 | 6075 |
EIF3G | 5826 |
RPS9 | 5735 |
RPS21 | 5653 |
RPS18 | 5530 |
EIF3M | 5460 |
EIF2S1 | 5338 |
RPS4X | 5267 |
EIF1AX | 5062 |
RPS2 | 4768 |
EIF3D | 4594 |
EIF3C | 4357 |
EIF3A | 3808 |
RPS4Y1 | 1782 |
EIF3F | 1625 |
EIF3J | 131 |
EIF4E | -1 |
EIF3K | -171 |
EIF4H | -348 |
EIF2S3 | -1224 |
RPS26 | -1698 |
EIF4A1 | -2064 |
EIF3B | -4075 |
EIF5 | -4979 |
EIF4G1 | -5229 |
Selenoamino acid metabolism
1152 | |
---|---|
set | Selenoamino acid metabolism |
setSize | 113 |
pANOVA | 1.1e-25 |
s.dist | 0.57 |
p.adjustANOVA | 1.25e-23 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
NNMT | 7703 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
NNMT | 7703 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
RPS13 | 7341 |
RPSA | 7336 |
RPL31 | 7281 |
RPL35A | 7280 |
RPS23 | 7279 |
RPS20 | 7274 |
RPL22 | 7262 |
RPL26 | 7242 |
RPS8 | 7231 |
RPL7A | 7219 |
RPL41 | 7187 |
RPL32 | 7125 |
RPL21 | 7065 |
RPL6 | 7045 |
INMT | 7044 |
RPL14 | 7019 |
RPL10 | 7017 |
RPS17 | 6977 |
RPL8 | 6975 |
RPL19 | 6903 |
RPL37 | 6857 |
RPS3 | 6842 |
RPL23 | 6817 |
RPS15 | 6811 |
RPS24 | 6802 |
RPL18 | 6774 |
RPL13A | 6760 |
RPL37A | 6664 |
RPS19 | 6640 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
RPL36 | 6383 |
RPL11 | 6366 |
RPL23A | 6332 |
RPLP2 | 6284 |
RPS29 | 6283 |
RPS28 | 6238 |
RPL24 | 6202 |
RPL3 | 6179 |
RPLP1 | 6158 |
RPL27 | 6127 |
RPS16 | 6124 |
RPS12 | 6075 |
RPL12 | 6004 |
AHCY | 5975 |
RPL13 | 5974 |
RPL35 | 5831 |
RPS9 | 5735 |
RPL10A | 5726 |
UBA52 | 5692 |
RPS21 | 5653 |
RPL38 | 5646 |
RPS18 | 5530 |
RPL27A | 5467 |
RPL36AL | 5427 |
RPL36A | 5413 |
RPS4X | 5267 |
KARS1 | 5213 |
RPS2 | 4768 |
RPLP0 | 4642 |
EEFSEC | 4290 |
SARS1 | 3834 |
PAPSS2 | 3667 |
AIMP2 | 3610 |
RPL39L | 3498 |
RPL26L1 | 3493 |
PSTK | 2532 |
RPL28 | 2504 |
AIMP1 | 2206 |
RPL9 | 2110 |
TXNRD1 | 2041 |
RPS4Y1 | 1782 |
DARS1 | 1745 |
EEF1E1 | 1291 |
EPRS1 | 1223 |
CTH | 950 |
SEPSECS | 923 |
GSR | 845 |
SECISBP2 | -758 |
RARS1 | -1084 |
RPS26 | -1698 |
QARS1 | -2009 |
RPL22L1 | -2079 |
SEPHS2 | -2160 |
CBS | -3375 |
PAPSS1 | -3844 |
LARS1 | -4554 |
HNMT | -4623 |
SCLY | -5320 |
IARS1 | -5557 |
MARS1 | -6086 |
Initial triggering of complement
569 | |
---|---|
set | Initial triggering of complement |
setSize | 24 |
pANOVA | 1.44e-06 |
s.dist | -0.568 |
p.adjustANOVA | 4.73e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IGHG4 | -8636 |
IGLC1 | -8528 |
IGLC3 | -8412 |
IGLC2 | -7870 |
C4B | -7038 |
IGHG2 | -6973 |
IGHG1 | -6890 |
C1QC | -6479 |
MASP2 | -5886 |
C1R | -5803 |
C1QA | -5746 |
CFB | -5644 |
C1QB | -5638 |
C2 | -5388 |
IGHG3 | -4982 |
CFD | -4354 |
C1S | -3589 |
CFP | -2891 |
MASP1 | -2834 |
C4A | -2719 |
GeneID | Gene Rank |
---|---|
IGHG4 | -8636 |
IGLC1 | -8528 |
IGLC3 | -8412 |
IGLC2 | -7870 |
C4B | -7038 |
IGHG2 | -6973 |
IGHG1 | -6890 |
C1QC | -6479 |
MASP2 | -5886 |
C1R | -5803 |
C1QA | -5746 |
CFB | -5644 |
C1QB | -5638 |
C2 | -5388 |
IGHG3 | -4982 |
CFD | -4354 |
C1S | -3589 |
CFP | -2891 |
MASP1 | -2834 |
C4A | -2719 |
C3 | -1816 |
IGKC | -1151 |
GZMM | -841 |
FCN1 | 2327 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
788 | |
---|---|
set | Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) |
setSize | 113 |
pANOVA | 3.45e-24 |
s.dist | 0.552 |
p.adjustANOVA | 3.19e-22 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
RPS13 | 7341 |
RPSA | 7336 |
RPL31 | 7281 |
RPL35A | 7280 |
RPS23 | 7279 |
RPS20 | 7274 |
RPL22 | 7262 |
RPL26 | 7242 |
RPS8 | 7231 |
RPL7A | 7219 |
RPL41 | 7187 |
RPL32 | 7125 |
RPL21 | 7065 |
RPL6 | 7045 |
RPL14 | 7019 |
RPL10 | 7017 |
RPS17 | 6977 |
RPL8 | 6975 |
RPL19 | 6903 |
RPL37 | 6857 |
RPS3 | 6842 |
RPL23 | 6817 |
RPS15 | 6811 |
RPS24 | 6802 |
RPL18 | 6774 |
RPL13A | 6760 |
RPL37A | 6664 |
RPS19 | 6640 |
PNRC2 | 6612 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
RPL36 | 6383 |
RPL11 | 6366 |
RPL23A | 6332 |
RPLP2 | 6284 |
RPS29 | 6283 |
RPS28 | 6238 |
RPL24 | 6202 |
RPL3 | 6179 |
RPLP1 | 6158 |
RPL27 | 6127 |
RPS16 | 6124 |
RPS12 | 6075 |
RPL12 | 6004 |
RPL13 | 5974 |
PPP2R2A | 5965 |
RPL35 | 5831 |
RBM8A | 5803 |
RPS9 | 5735 |
RPL10A | 5726 |
UBA52 | 5692 |
RPS21 | 5653 |
RPL38 | 5646 |
RPS18 | 5530 |
RPL27A | 5467 |
RPL36AL | 5427 |
RPL36A | 5413 |
RPS4X | 5267 |
MAGOH | 5248 |
RPS2 | 4768 |
RPLP0 | 4642 |
CASC3 | 4384 |
UPF2 | 4344 |
SMG8 | 3941 |
PABPC1 | 3810 |
RPL39L | 3498 |
RPL26L1 | 3493 |
DCP1A | 3001 |
MAGOHB | 2536 |
RPL28 | 2504 |
RPL9 | 2110 |
NCBP2 | 1938 |
RPS4Y1 | 1782 |
ETF1 | 1473 |
EIF4A3 | 376 |
NCBP1 | 254 |
PPP2CA | -267 |
SMG1 | -1662 |
RPS26 | -1698 |
GSPT2 | -1934 |
RPL22L1 | -2079 |
UPF3A | -2419 |
RNPS1 | -2524 |
UPF3B | -2837 |
GSPT1 | -3107 |
UPF1 | -3377 |
PPP2R1A | -3397 |
SMG7 | -3892 |
EIF4G1 | -5229 |
SMG6 | -5241 |
SMG5 | -7494 |
SMG9 | -8018 |
Nonsense-Mediated Decay (NMD)
790 | |
---|---|
set | Nonsense-Mediated Decay (NMD) |
setSize | 113 |
pANOVA | 3.45e-24 |
s.dist | 0.552 |
p.adjustANOVA | 3.19e-22 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
RPS13 | 7341 |
RPSA | 7336 |
RPL31 | 7281 |
RPL35A | 7280 |
RPS23 | 7279 |
RPS20 | 7274 |
RPL22 | 7262 |
RPL26 | 7242 |
RPS8 | 7231 |
RPL7A | 7219 |
RPL41 | 7187 |
RPL32 | 7125 |
RPL21 | 7065 |
RPL6 | 7045 |
RPL14 | 7019 |
RPL10 | 7017 |
RPS17 | 6977 |
RPL8 | 6975 |
RPL19 | 6903 |
RPL37 | 6857 |
RPS3 | 6842 |
RPL23 | 6817 |
RPS15 | 6811 |
RPS24 | 6802 |
RPL18 | 6774 |
RPL13A | 6760 |
RPL37A | 6664 |
RPS19 | 6640 |
PNRC2 | 6612 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
RPL36 | 6383 |
RPL11 | 6366 |
RPL23A | 6332 |
RPLP2 | 6284 |
RPS29 | 6283 |
RPS28 | 6238 |
RPL24 | 6202 |
RPL3 | 6179 |
RPLP1 | 6158 |
RPL27 | 6127 |
RPS16 | 6124 |
RPS12 | 6075 |
RPL12 | 6004 |
RPL13 | 5974 |
PPP2R2A | 5965 |
RPL35 | 5831 |
RBM8A | 5803 |
RPS9 | 5735 |
RPL10A | 5726 |
UBA52 | 5692 |
RPS21 | 5653 |
RPL38 | 5646 |
RPS18 | 5530 |
RPL27A | 5467 |
RPL36AL | 5427 |
RPL36A | 5413 |
RPS4X | 5267 |
MAGOH | 5248 |
RPS2 | 4768 |
RPLP0 | 4642 |
CASC3 | 4384 |
UPF2 | 4344 |
SMG8 | 3941 |
PABPC1 | 3810 |
RPL39L | 3498 |
RPL26L1 | 3493 |
DCP1A | 3001 |
MAGOHB | 2536 |
RPL28 | 2504 |
RPL9 | 2110 |
NCBP2 | 1938 |
RPS4Y1 | 1782 |
ETF1 | 1473 |
EIF4A3 | 376 |
NCBP1 | 254 |
PPP2CA | -267 |
SMG1 | -1662 |
RPS26 | -1698 |
GSPT2 | -1934 |
RPL22L1 | -2079 |
UPF3A | -2419 |
RNPS1 | -2524 |
UPF3B | -2837 |
GSPT1 | -3107 |
UPF1 | -3377 |
PPP2R1A | -3397 |
SMG7 | -3892 |
EIF4G1 | -5229 |
SMG6 | -5241 |
SMG5 | -7494 |
SMG9 | -8018 |
SRP-dependent cotranslational protein targeting to membrane
1132 | |
---|---|
set | SRP-dependent cotranslational protein targeting to membrane |
setSize | 110 |
pANOVA | 5.44e-23 |
s.dist | 0.545 |
p.adjustANOVA | 4.74e-21 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
GeneID | Gene Rank |
---|---|
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
RPS13 | 7341 |
RPSA | 7336 |
RPL31 | 7281 |
RPL35A | 7280 |
RPS23 | 7279 |
RPS20 | 7274 |
RPL22 | 7262 |
RPL26 | 7242 |
RPS8 | 7231 |
RPL7A | 7219 |
RPL41 | 7187 |
RPL32 | 7125 |
RPL21 | 7065 |
RPL6 | 7045 |
RPL14 | 7019 |
RPL10 | 7017 |
RPS17 | 6977 |
RPL8 | 6975 |
RPL19 | 6903 |
RPL37 | 6857 |
RPS3 | 6842 |
RPL23 | 6817 |
RPS15 | 6811 |
RPS24 | 6802 |
RPL18 | 6774 |
RPL13A | 6760 |
SEC11A | 6709 |
RPL37A | 6664 |
RPS19 | 6640 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
RPL36 | 6383 |
RPL11 | 6366 |
RPL23A | 6332 |
RPLP2 | 6284 |
RPS29 | 6283 |
RPS28 | 6238 |
RPL24 | 6202 |
RPL3 | 6179 |
RPLP1 | 6158 |
RPL27 | 6127 |
RPS16 | 6124 |
RPS12 | 6075 |
RPL12 | 6004 |
RPL13 | 5974 |
RPL35 | 5831 |
RPS9 | 5735 |
RPL10A | 5726 |
UBA52 | 5692 |
RPS21 | 5653 |
RPL38 | 5646 |
RPS18 | 5530 |
RPL27A | 5467 |
RPL36AL | 5427 |
RPL36A | 5413 |
RPS4X | 5267 |
RPS2 | 4768 |
RPLP0 | 4642 |
SRP19 | 3842 |
RPL39L | 3498 |
RPL26L1 | 3493 |
SEC11C | 2984 |
SSR2 | 2622 |
RPL28 | 2504 |
SEC61B | 2191 |
RPL9 | 2110 |
SRP54 | 2044 |
SPCS1 | 1948 |
RPS4Y1 | 1782 |
SRP14 | 1769 |
SRP9 | 1663 |
SRP68 | 1521 |
SPCS2 | 521 |
SEC61G | 90 |
SRP72 | 66 |
TRAM1 | -381 |
SSR3 | -1124 |
RPS26 | -1698 |
RPL22L1 | -2079 |
RPN1 | -2618 |
SPCS3 | -3327 |
SRPRB | -3381 |
SSR4 | -4034 |
SSR1 | -4223 |
SRPRA | -4424 |
DDOST | -5218 |
SEC61A2 | -7053 |
RPN2 | -7222 |
SEC61A1 | -7977 |
Scavenging of heme from plasma
1149 | |
---|---|
set | Scavenging of heme from plasma |
setSize | 14 |
pANOVA | 0.000659 |
s.dist | -0.526 |
p.adjustANOVA | 0.0114 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IGLC1 | -8528 |
IGLC3 | -8412 |
IGLC2 | -7870 |
APOL1 | -7818 |
JCHAIN | -7064 |
HP | -6427 |
LRP1 | -5611 |
CD163 | -5242 |
IGHA2 | -4762 |
HPX | -1382 |
IGHA1 | -1345 |
IGKC | -1151 |
HBB | 39 |
HBA1 | 1971 |
GeneID | Gene Rank |
---|---|
IGLC1 | -8528 |
IGLC3 | -8412 |
IGLC2 | -7870 |
APOL1 | -7818 |
JCHAIN | -7064 |
HP | -6427 |
LRP1 | -5611 |
CD163 | -5242 |
IGHA2 | -4762 |
HPX | -1382 |
IGHA1 | -1345 |
IGKC | -1151 |
HBB | 39 |
HBA1 | 1971 |
Gluconeogenesis
484 | |
---|---|
set | Gluconeogenesis |
setSize | 28 |
pANOVA | 1.69e-06 |
s.dist | -0.523 |
p.adjustANOVA | 5.33e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SLC37A2 | -8277 |
SLC37A4 | -8156 |
ENO3 | -7774 |
PCK1 | -7638 |
GPI | -7561 |
FBP1 | -7401 |
ALDOA | -6977 |
PCK2 | -6824 |
PGAM2 | -6437 |
GOT2 | -5869 |
SLC25A12 | -5730 |
PGK1 | -5692 |
SLC25A11 | -5563 |
G6PC3 | -5010 |
PC | -4958 |
ENO1 | -4444 |
SLC25A13 | -4301 |
TPI1 | -4271 |
MDH1 | -4174 |
ENO2 | -3984 |
GeneID | Gene Rank |
---|---|
SLC37A2 | -8277 |
SLC37A4 | -8156 |
ENO3 | -7774 |
PCK1 | -7638 |
GPI | -7561 |
FBP1 | -7401 |
ALDOA | -6977 |
PCK2 | -6824 |
PGAM2 | -6437 |
GOT2 | -5869 |
SLC25A12 | -5730 |
PGK1 | -5692 |
SLC25A11 | -5563 |
G6PC3 | -5010 |
PC | -4958 |
ENO1 | -4444 |
SLC25A13 | -4301 |
TPI1 | -4271 |
MDH1 | -4174 |
ENO2 | -3984 |
MDH2 | -3577 |
GAPDH | -2810 |
ALDOC | -1910 |
SLC25A10 | -1729 |
PGAM1 | -1600 |
GOT1 | -621 |
SLC25A1 | 2621 |
SLC37A1 | 4314 |
Olfactory Signaling Pathway
813 | |
---|---|
set | Olfactory Signaling Pathway |
setSize | 26 |
pANOVA | 5.38e-06 |
s.dist | 0.515 |
p.adjustANOVA | 0.000157 |
Top enriched genes
GeneID | Gene Rank |
---|---|
OR6C75 | 8539 |
OR10H5 | 8370 |
OR6Y1 | 8313 |
OR2M3 | 8269 |
OR5A1 | 8245 |
OR2AT4 | 8150 |
OR7C1 | 8112 |
OR1D2 | 7908 |
OR5AN1 | 7649 |
OR14J1 | 7590 |
OR1I1 | 7498 |
OR5AS1 | 7423 |
OR4D9 | 7071 |
ANO2 | 6956 |
OR10G3 | 5658 |
GNAL | 5098 |
OR52K1 | 4897 |
REEP1 | 4884 |
OR5A2 | 3846 |
OR8A1 | 2888 |
GeneID | Gene Rank |
---|---|
OR6C75 | 8539 |
OR10H5 | 8370 |
OR6Y1 | 8313 |
OR2M3 | 8269 |
OR5A1 | 8245 |
OR2AT4 | 8150 |
OR7C1 | 8112 |
OR1D2 | 7908 |
OR5AN1 | 7649 |
OR14J1 | 7590 |
OR1I1 | 7498 |
OR5AS1 | 7423 |
OR4D9 | 7071 |
ANO2 | 6956 |
OR10G3 | 5658 |
GNAL | 5098 |
OR52K1 | 4897 |
REEP1 | 4884 |
OR5A2 | 3846 |
OR8A1 | 2888 |
OR2A7 | -138 |
EBF1 | -1250 |
LDB1 | -2420 |
GNB1 | -2867 |
ADCY3 | -6582 |
OR2I1P | -8427 |
Trafficking and processing of endosomal TLR
1361 | |
---|---|
set | Trafficking and processing of endosomal TLR |
setSize | 12 |
pANOVA | 0.00205 |
s.dist | -0.514 |
p.adjustANOVA | 0.0244 |
Top enriched genes
GeneID | Gene Rank |
---|---|
LGMN | -8357 |
UNC93B1 | -8153 |
TLR8 | -8094 |
CTSB | -7112 |
CTSL | -7056 |
TLR7 | -4543 |
HSP90B1 | -3626 |
TLR9 | -3348 |
TLR3 | -2517 |
CTSS | -2175 |
CTSK | 766 |
CNPY3 | 917 |
GeneID | Gene Rank |
---|---|
LGMN | -8357 |
UNC93B1 | -8153 |
TLR8 | -8094 |
CTSB | -7112 |
CTSL | -7056 |
TLR7 | -4543 |
HSP90B1 | -3626 |
TLR9 | -3348 |
TLR3 | -2517 |
CTSS | -2175 |
CTSK | 766 |
CNPY3 | 917 |
Role of LAT2/NTAL/LAB on calcium mobilization
1101 | |
---|---|
set | Role of LAT2/NTAL/LAB on calcium mobilization |
setSize | 20 |
pANOVA | 9.59e-05 |
s.dist | -0.504 |
p.adjustANOVA | 0.00209 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IGLC1 | -8528 |
IGLC3 | -8412 |
SHC1 | -8297 |
LAT2 | -7999 |
IGLC2 | -7870 |
GRB2 | -7705 |
FCER1G | -7448 |
PIK3R2 | -7148 |
SYK | -7142 |
PDPK1 | -6798 |
GAB2 | -5858 |
LYN | -4370 |
MS4A2 | -2608 |
FYN | -1654 |
PIK3CB | -1354 |
IGKC | -1151 |
SOS1 | -828 |
PIK3CA | 1041 |
FCER1A | 3313 |
PIK3R1 | 3780 |
GeneID | Gene Rank |
---|---|
IGLC1 | -8528 |
IGLC3 | -8412 |
SHC1 | -8297 |
LAT2 | -7999 |
IGLC2 | -7870 |
GRB2 | -7705 |
FCER1G | -7448 |
PIK3R2 | -7148 |
SYK | -7142 |
PDPK1 | -6798 |
GAB2 | -5858 |
LYN | -4370 |
MS4A2 | -2608 |
FYN | -1654 |
PIK3CB | -1354 |
IGKC | -1151 |
SOS1 | -828 |
PIK3CA | 1041 |
FCER1A | 3313 |
PIK3R1 | 3780 |
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
760 | |
---|---|
set | Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters |
setSize | 19 |
pANOVA | 0.00016 |
s.dist | -0.5 |
p.adjustANOVA | 0.00321 |
Top enriched genes
GeneID | Gene Rank |
---|---|
AP2M1 | -8265 |
AP2A1 | -7882 |
AP1S1 | -7103 |
AP2A2 | -6946 |
AP1B1 | -6862 |
PACS1 | -6774 |
CD4 | -6660 |
AP2S1 | -6520 |
CD28 | -6042 |
AP1G1 | -5699 |
B2M | -5258 |
AP2B1 | -4237 |
ATP6V1H | -4078 |
AP1S2 | -3988 |
LCK | -2271 |
ARF1 | -1242 |
CD8B | -304 |
AP1M1 | -53 |
AP1S3 | 8087 |
GeneID | Gene Rank |
---|---|
AP2M1 | -8265 |
AP2A1 | -7882 |
AP1S1 | -7103 |
AP2A2 | -6946 |
AP1B1 | -6862 |
PACS1 | -6774 |
CD4 | -6660 |
AP2S1 | -6520 |
CD28 | -6042 |
AP1G1 | -5699 |
B2M | -5258 |
AP2B1 | -4237 |
ATP6V1H | -4078 |
AP1S2 | -3988 |
LCK | -2271 |
ARF1 | -1242 |
CD8B | -304 |
AP1M1 | -53 |
AP1S3 | 8087 |
SARS-CoV-2 modulates autophagy
1112 | |
---|---|
set | SARS-CoV-2 modulates autophagy |
setSize | 11 |
pANOVA | 0.0054 |
s.dist | -0.484 |
p.adjustANOVA | 0.0548 |
Top enriched genes
GeneID | Gene Rank |
---|---|
VPS39 | -8536 |
VPS16 | -8258 |
VPS18 | -7229 |
VPS41 | -6291 |
VPS33B | -5050 |
VPS45 | -4909 |
VPS11 | -4569 |
TUFM | -3581 |
VPS33A | -1716 |
MAP1LC3B | 1018 |
UVRAG | 3061 |
GeneID | Gene Rank |
---|---|
VPS39 | -8536 |
VPS16 | -8258 |
VPS18 | -7229 |
VPS41 | -6291 |
VPS33B | -5050 |
VPS45 | -4909 |
VPS11 | -4569 |
TUFM | -3581 |
VPS33A | -1716 |
MAP1LC3B | 1018 |
UVRAG | 3061 |
Transcriptional regulation of pluripotent stem cells
1381 | |
---|---|
set | Transcriptional regulation of pluripotent stem cells |
setSize | 16 |
pANOVA | 0.000897 |
s.dist | 0.48 |
p.adjustANOVA | 0.0143 |
Top enriched genes
GeneID | Gene Rank |
---|---|
FGF2 | 8518 |
SMAD2 | 7881 |
KLF4 | 7853 |
HIF3A | 7663 |
TSC22D1 | 7459 |
SMAD4 | 6719 |
EPHA1 | 6477 |
EPAS1 | 5688 |
GATA6 | 4628 |
FOXP1 | 3990 |
PBX1 | 3799 |
GSC | 3721 |
HHEX | 1691 |
STAT3 | -2894 |
NR6A1 | -3412 |
POU5F1 | -3506 |
GeneID | Gene Rank |
---|---|
FGF2 | 8518 |
SMAD2 | 7881 |
KLF4 | 7853 |
HIF3A | 7663 |
TSC22D1 | 7459 |
SMAD4 | 6719 |
EPHA1 | 6477 |
EPAS1 | 5688 |
GATA6 | 4628 |
FOXP1 | 3990 |
PBX1 | 3799 |
GSC | 3721 |
HHEX | 1691 |
STAT3 | -2894 |
NR6A1 | -3412 |
POU5F1 | -3506 |
Scavenging by Class A Receptors
1148 | |
---|---|
set | Scavenging by Class A Receptors |
setSize | 16 |
pANOVA | 0.000954 |
s.dist | -0.477 |
p.adjustANOVA | 0.0149 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SCARA5 | -7167 |
MARCO | -6924 |
FTL | -6137 |
COL1A1 | -5999 |
MSR1 | -5706 |
APOE | -5210 |
COL1A2 | -4914 |
COLEC12 | -4864 |
HSP90B1 | -3626 |
APOB | -3167 |
MASP1 | -2834 |
FTH1 | -2755 |
COL4A2 | -2649 |
CALR | -2533 |
COL3A1 | -1131 |
COL4A1 | -331 |
GeneID | Gene Rank |
---|---|
SCARA5 | -7167 |
MARCO | -6924 |
FTL | -6137 |
COL1A1 | -5999 |
MSR1 | -5706 |
APOE | -5210 |
COL1A2 | -4914 |
COLEC12 | -4864 |
HSP90B1 | -3626 |
APOB | -3167 |
MASP1 | -2834 |
FTH1 | -2755 |
COL4A2 | -2649 |
CALR | -2533 |
COL3A1 | -1131 |
COL4A1 | -331 |
WNT5A-dependent internalization of FZD2, FZD5 and ROR2
1445 | |
---|---|
set | WNT5A-dependent internalization of FZD2, FZD5 and ROR2 |
setSize | 13 |
pANOVA | 0.00345 |
s.dist | -0.468 |
p.adjustANOVA | 0.0394 |
Top enriched genes
GeneID | Gene Rank |
---|---|
FZD2 | -8502 |
AP2M1 | -8265 |
AP2A1 | -7882 |
WNT5A | -7808 |
AP2A2 | -6946 |
AP2S1 | -6520 |
CLTC | -4933 |
ROR2 | -4830 |
AP2B1 | -4237 |
FZD5 | -2287 |
ROR1 | 666 |
CLTA | 1755 |
CLTB | 7171 |
GeneID | Gene Rank |
---|---|
FZD2 | -8502 |
AP2M1 | -8265 |
AP2A1 | -7882 |
WNT5A | -7808 |
AP2A2 | -6946 |
AP2S1 | -6520 |
CLTC | -4933 |
ROR2 | -4830 |
AP2B1 | -4237 |
FZD5 | -2287 |
ROR1 | 666 |
CLTA | 1755 |
CLTB | 7171 |
ABC transporters in lipid homeostasis
3 | |
---|---|
set | ABC transporters in lipid homeostasis |
setSize | 12 |
pANOVA | 0.00506 |
s.dist | -0.467 |
p.adjustANOVA | 0.0529 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ABCA7 | -8406 |
ABCD1 | -8151 |
ABCA2 | -7643 |
PEX19 | -7563 |
ABCG1 | -6156 |
ABCA3 | -5921 |
ABCD3 | -5860 |
ABCA5 | -4265 |
ABCA9 | -956 |
PEX3 | 1515 |
ABCA6 | 2000 |
ABCA10 | 2944 |
GeneID | Gene Rank |
---|---|
ABCA7 | -8406 |
ABCD1 | -8151 |
ABCA2 | -7643 |
PEX19 | -7563 |
ABCG1 | -6156 |
ABCA3 | -5921 |
ABCD3 | -5860 |
ABCA5 | -4265 |
ABCA9 | -956 |
PEX3 | 1515 |
ABCA6 | 2000 |
ABCA10 | 2944 |
Interleukin-2 signaling
597 | |
---|---|
set | Interleukin-2 signaling |
setSize | 11 |
pANOVA | 0.00873 |
s.dist | -0.457 |
p.adjustANOVA | 0.0799 |
Top enriched genes
GeneID | Gene Rank |
---|---|
JAK3 | -8638 |
SHC1 | -8297 |
PTK2B | -7580 |
SYK | -7142 |
IL2RB | -6099 |
STAT5A | -5072 |
IL2RA | -4778 |
LCK | -2271 |
IL2RG | 792 |
JAK1 | 937 |
STAT5B | 4737 |
GeneID | Gene Rank |
---|---|
JAK3 | -8638 |
SHC1 | -8297 |
PTK2B | -7580 |
SYK | -7142 |
IL2RB | -6099 |
STAT5A | -5072 |
IL2RA | -4778 |
LCK | -2271 |
IL2RG | 792 |
JAK1 | 937 |
STAT5B | 4737 |
The role of Nef in HIV-1 replication and disease pathogenesis
1346 | |
---|---|
set | The role of Nef in HIV-1 replication and disease pathogenesis |
setSize | 26 |
pANOVA | 6.19e-05 |
s.dist | -0.454 |
p.adjustANOVA | 0.00143 |
Top enriched genes
GeneID | Gene Rank |
---|---|
AP2M1 | -8265 |
DOCK2 | -7984 |
AP2A1 | -7882 |
HCK | -7733 |
AP1S1 | -7103 |
AP2A2 | -6946 |
AP1B1 | -6862 |
CD247 | -6839 |
PACS1 | -6774 |
CD4 | -6660 |
AP2S1 | -6520 |
CD28 | -6042 |
AP1G1 | -5699 |
B2M | -5258 |
AP2B1 | -4237 |
ATP6V1H | -4078 |
AP1S2 | -3988 |
LCK | -2271 |
FYN | -1654 |
ARF1 | -1242 |
GeneID | Gene Rank |
---|---|
AP2M1 | -8265 |
DOCK2 | -7984 |
AP2A1 | -7882 |
HCK | -7733 |
AP1S1 | -7103 |
AP2A2 | -6946 |
AP1B1 | -6862 |
CD247 | -6839 |
PACS1 | -6774 |
CD4 | -6660 |
AP2S1 | -6520 |
CD28 | -6042 |
AP1G1 | -5699 |
B2M | -5258 |
AP2B1 | -4237 |
ATP6V1H | -4078 |
AP1S2 | -3988 |
LCK | -2271 |
FYN | -1654 |
ARF1 | -1242 |
CD8B | -304 |
AP1M1 | -53 |
PAK2 | 1068 |
RAC1 | 1112 |
ELMO1 | 2246 |
AP1S3 | 8087 |
Influenza Viral RNA Transcription and Replication
564 | |
---|---|
set | Influenza Viral RNA Transcription and Replication |
setSize | 134 |
pANOVA | 1.51e-19 |
s.dist | 0.452 |
p.adjustANOVA | 1.12e-17 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IPO5 | 8428 |
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
POLR2F | 7572 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
GeneID | Gene Rank |
---|---|
IPO5 | 8428 |
RPS14 | 8115 |
RPL18A | 7960 |
RPL34 | 7903 |
FAU | 7867 |
RPS7 | 7855 |
RPL15 | 7851 |
RPS11 | 7841 |
RPS3A | 7827 |
RPL5 | 7702 |
RPL4 | 7696 |
RPS15A | 7639 |
RPS27A | 7636 |
RPL7 | 7623 |
RPS5 | 7614 |
POLR2F | 7572 |
RPL39 | 7526 |
RPL17 | 7520 |
RPS6 | 7516 |
RPL30 | 7495 |
RPS10 | 7438 |
RPL29 | 7371 |
RPS13 | 7341 |
RPSA | 7336 |
RPL31 | 7281 |
RPL35A | 7280 |
RPS23 | 7279 |
RPS20 | 7274 |
RPL22 | 7262 |
RPL26 | 7242 |
RPS8 | 7231 |
RPL7A | 7219 |
RPL41 | 7187 |
RPL32 | 7125 |
RPL21 | 7065 |
RPL6 | 7045 |
RPL14 | 7019 |
RPL10 | 7017 |
RPS17 | 6977 |
RPL8 | 6975 |
RPL19 | 6903 |
RPL37 | 6857 |
RPS3 | 6842 |
RPL23 | 6817 |
RPS15 | 6811 |
RPS24 | 6802 |
RPL18 | 6774 |
RPL13A | 6760 |
RPL37A | 6664 |
RPS19 | 6640 |
RPS27L | 6553 |
RPS27 | 6484 |
RPS25 | 6393 |
RPL36 | 6383 |
RPL11 | 6366 |
RPL23A | 6332 |
RPLP2 | 6284 |
RPS29 | 6283 |
RPS28 | 6238 |
RPL24 | 6202 |
HSP90AA1 | 6198 |
RPL3 | 6179 |
RPLP1 | 6158 |
RPL27 | 6127 |
RPS16 | 6124 |
RPS12 | 6075 |
RPL12 | 6004 |
RPL13 | 5974 |
RAE1 | 5844 |
RPL35 | 5831 |
RPS9 | 5735 |
RPL10A | 5726 |
UBA52 | 5692 |
RPS21 | 5653 |
RPL38 | 5646 |
POLR2D | 5643 |
POLR2K | 5572 |
RPS18 | 5530 |
RPL27A | 5467 |
RPL36AL | 5427 |
RPL36A | 5413 |
RPS4X | 5267 |
POLR2I | 5188 |
RPS2 | 4768 |
NUP37 | 4757 |
RPLP0 | 4642 |
NUP107 | 4605 |
NUP155 | 4538 |
GTF2F1 | 4380 |
POLR2C | 3913 |
NUP54 | 3884 |
NUP205 | 3742 |
NUP160 | 3727 |
RPL39L | 3498 |
RPL26L1 | 3493 |
NUP58 | 3403 |
NDC1 | 3347 |
RANBP2 | 3263 |
NUP35 | 3222 |
GRSF1 | 3175 |
RPL28 | 2504 |
RPL9 | 2110 |
RPS4Y1 | 1782 |
NUP153 | 939 |
PARP1 | 567 |
POLR2L | 466 |
NUP42 | -101 |
GTF2F2 | -112 |
SEH1L | -465 |
POLR2J | -1158 |
POLR2E | -1583 |
RPS26 | -1698 |
RPL22L1 | -2079 |
POLR2G | -2169 |
NUP214 | -2301 |
NUP133 | -2747 |
POLR2B | -3059 |
NUP85 | -3196 |
NUP50 | -3212 |
NUP98 | -3712 |
NUP88 | -3834 |
DNAJC3 | -4428 |
SEC13 | -4999 |
NUP210 | -5318 |
POLR2H | -5669 |
NUP188 | -5957 |
NUP93 | -6292 |
NUP43 | -6920 |
POLR2A | -7176 |
TPR | -7346 |
NUP62 | -7910 |
AAAS | -7942 |
POM121 | -8149 |
POM121C | -8222 |
TRAF3-dependent IRF activation pathway
1324 | |
---|---|
set | TRAF3-dependent IRF activation pathway |
setSize | 13 |
pANOVA | 0.0054 |
s.dist | -0.446 |
p.adjustANOVA | 0.0548 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MAVS | -8022 |
IRF3 | -7699 |
IKBKE | -7453 |
IRF7 | -6569 |
TRAF3 | -6357 |
EP300 | -5086 |
SIKE1 | -4505 |
RNF135 | -4377 |
TRIM25 | -3269 |
IFIH1 | -3003 |
CREBBP | -213 |
TBK1 | 2936 |
TRIM4 | 3552 |
GeneID | Gene Rank |
---|---|
MAVS | -8022 |
IRF3 | -7699 |
IKBKE | -7453 |
IRF7 | -6569 |
TRAF3 | -6357 |
EP300 | -5086 |
SIKE1 | -4505 |
RNF135 | -4377 |
TRIM25 | -3269 |
IFIH1 | -3003 |
CREBBP | -213 |
TBK1 | 2936 |
TRIM4 | 3552 |
Packaging Of Telomere Ends
851 | |
---|---|
set | Packaging Of Telomere Ends |
setSize | 13 |
pANOVA | 0.00656 |
s.dist | 0.435 |
p.adjustANOVA | 0.064 |
Top enriched genes
GeneID | Gene Rank |
---|---|
H2AJ | 6939 |
H2BC12 | 6804 |
H2BC21 | 6751 |
TERF2IP | 5689 |
H2BC5 | 5011 |
TERF1 | 4676 |
H2AZ2 | 3625 |
H2AC18 | 3523 |
POT1 | 2505 |
H2AC6 | 2326 |
ACD | 695 |
TERF2 | 691 |
TINF2 | -334 |
GeneID | Gene Rank |
---|---|
H2AJ | 6939 |
H2BC12 | 6804 |
H2BC21 | 6751 |
TERF2IP | 5689 |
H2BC5 | 5011 |
TERF1 | 4676 |
H2AZ2 | 3625 |
H2AC18 | 3523 |
POT1 | 2505 |
H2AC6 | 2326 |
ACD | 695 |
TERF2 | 691 |
TINF2 | -334 |
Retrograde neurotrophin signalling
1096 | |
---|---|
set | Retrograde neurotrophin signalling |
setSize | 14 |
pANOVA | 0.00561 |
s.dist | -0.427 |
p.adjustANOVA | 0.0563 |
Top enriched genes
GeneID | Gene Rank |
---|---|
AP2M1 | -8265 |
AP2A1 | -7882 |
DNM2 | -7713 |
AP2A2 | -6946 |
DNM1 | -6559 |
AP2S1 | -6520 |
SH3GL2 | -5051 |
CLTC | -4933 |
AP2B1 | -4237 |
NGF | -1880 |
NTRK1 | -1821 |
DNAL4 | 393 |
CLTA | 1755 |
DNM3 | 7942 |
GeneID | Gene Rank |
---|---|
AP2M1 | -8265 |
AP2A1 | -7882 |
DNM2 | -7713 |
AP2A2 | -6946 |
DNM1 | -6559 |
AP2S1 | -6520 |
SH3GL2 | -5051 |
CLTC | -4933 |
AP2B1 | -4237 |
NGF | -1880 |
NTRK1 | -1821 |
DNAL4 | 393 |
CLTA | 1755 |
DNM3 | 7942 |
Binding and Uptake of Ligands by Scavenger Receptors
115 | |
---|---|
set | Binding and Uptake of Ligands by Scavenger Receptors |
setSize | 39 |
pANOVA | 4.39e-06 |
s.dist | -0.425 |
p.adjustANOVA | 0.00013 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IGLC1 | -8528 |
IGLC3 | -8412 |
IGLC2 | -7870 |
APOL1 | -7818 |
SCARA5 | -7167 |
JCHAIN | -7064 |
MARCO | -6924 |
HP | -6427 |
STAB1 | -6285 |
FTL | -6137 |
SSC5D | -6127 |
COL1A1 | -5999 |
MSR1 | -5706 |
LRP1 | -5611 |
HYOU1 | -5569 |
CD163 | -5242 |
APOE | -5210 |
COL1A2 | -4914 |
COLEC12 | -4864 |
IGHA2 | -4762 |
GeneID | Gene Rank |
---|---|
IGLC1 | -8528 |
IGLC3 | -8412 |
IGLC2 | -7870 |
APOL1 | -7818 |
SCARA5 | -7167 |
JCHAIN | -7064 |
MARCO | -6924 |
HP | -6427 |
STAB1 | -6285 |
FTL | -6137 |
SSC5D | -6127 |
COL1A1 | -5999 |
MSR1 | -5706 |
LRP1 | -5611 |
HYOU1 | -5569 |
CD163 | -5242 |
APOE | -5210 |
COL1A2 | -4914 |
COLEC12 | -4864 |
IGHA2 | -4762 |
HSP90B1 | -3626 |
SCARF1 | -3471 |
APOB | -3167 |
SCARB1 | -3087 |
MASP1 | -2834 |
FTH1 | -2755 |
COL4A2 | -2649 |
CALR | -2533 |
SPARC | -2263 |
HPX | -1382 |
IGHA1 | -1345 |
IGKC | -1151 |
COL3A1 | -1131 |
CD36 | -683 |
COL4A1 | -331 |
HBB | 39 |
HBA1 | 1971 |
HSP90AA1 | 6198 |
HSPH1 | 7843 |
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
32 | |
---|---|
set | Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 |
setSize | 12 |
pANOVA | 0.0109 |
s.dist | 0.425 |
p.adjustANOVA | 0.0917 |
Top enriched genes
GeneID | Gene Rank |
---|---|
AR | 7372 |
H2AJ | 6939 |
H2BC12 | 6804 |
H2BC21 | 6751 |
H2BC5 | 5011 |
H2AZ2 | 3625 |
H2AC18 | 3523 |
H2AC6 | 2326 |
KDM1A | 1611 |
KDM4C | 1516 |
PKN1 | -145 |
NCOA2 | -1311 |
GeneID | Gene Rank |
---|---|
AR | 7372 |
H2AJ | 6939 |
H2BC12 | 6804 |
H2BC21 | 6751 |
H2BC5 | 5011 |
H2AZ2 | 3625 |
H2AC18 | 3523 |
H2AC6 | 2326 |
KDM1A | 1611 |
KDM4C | 1516 |
PKN1 | -145 |
NCOA2 | -1311 |
Synthesis of PIPs at the Golgi membrane
1282 | |
---|---|
set | Synthesis of PIPs at the Golgi membrane |
setSize | 15 |
pANOVA | 0.00548 |
s.dist | -0.414 |
p.adjustANOVA | 0.0552 |
Top enriched genes
GeneID | Gene Rank |
---|---|
VAC14 | -7867 |
PI4K2A | -7813 |
ARF3 | -6721 |
PI4KA | -6679 |
PI4KB | -6426 |
OCRL | -4561 |
FIG4 | -4515 |
PI4K2B | -4209 |
INPP5E | -4082 |
PIK3R4 | -3943 |
PIKFYVE | -3536 |
SACM1L | -2456 |
ARF1 | -1242 |
PIK3C2A | 4227 |
PIK3C3 | 6135 |
GeneID | Gene Rank |
---|---|
VAC14 | -7867 |
PI4K2A | -7813 |
ARF3 | -6721 |
PI4KA | -6679 |
PI4KB | -6426 |
OCRL | -4561 |
FIG4 | -4515 |
PI4K2B | -4209 |
INPP5E | -4082 |
PIK3R4 | -3943 |
PIKFYVE | -3536 |
SACM1L | -2456 |
ARF1 | -1242 |
PIK3C2A | 4227 |
PIK3C3 | 6135 |
Other semaphorin interactions
820 | |
---|---|
set | Other semaphorin interactions |
setSize | 19 |
pANOVA | 0.00187 |
s.dist | -0.412 |
p.adjustANOVA | 0.0229 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SEMA5A | -8623 |
CD72 | -8617 |
SEMA6D | -8294 |
PLXNA1 | -8165 |
SEMA4D | -7686 |
PLXNC1 | -7303 |
PTPRC | -7022 |
SEMA7A | -6174 |
SEMA4A | -5766 |
TYROBP | -5596 |
PLXND1 | -4500 |
PLXNB3 | -4411 |
TREM2 | -2912 |
ITGB1 | -705 |
PLXNA4 | 656 |
SEMA3E | 1388 |
PLXNA2 | 1738 |
SEMA6A | 6191 |
ITGA1 | 8158 |
GeneID | Gene Rank |
---|---|
SEMA5A | -8623 |
CD72 | -8617 |
SEMA6D | -8294 |
PLXNA1 | -8165 |
SEMA4D | -7686 |
PLXNC1 | -7303 |
PTPRC | -7022 |
SEMA7A | -6174 |
SEMA4A | -5766 |
TYROBP | -5596 |
PLXND1 | -4500 |
PLXNB3 | -4411 |
TREM2 | -2912 |
ITGB1 | -705 |
PLXNA4 | 656 |
SEMA3E | 1388 |
PLXNA2 | 1738 |
SEMA6A | 6191 |
ITGA1 | 8158 |
Role of phospholipids in phagocytosis
1102 | |
---|---|
set | Role of phospholipids in phagocytosis |
setSize | 32 |
pANOVA | 6.82e-05 |
s.dist | -0.407 |
p.adjustANOVA | 0.00153 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IGHG4 | -8636 |
IGLC1 | -8528 |
IGLC3 | -8412 |
FCGR2A | -8279 |
FCGR1A | -8113 |
FCGR3A | -7985 |
IGLC2 | -7870 |
PLPP5 | -7209 |
PRKCD | -7187 |
PIK3R2 | -7148 |
SYK | -7142 |
IGHG2 | -6973 |
IGHG1 | -6890 |
CD247 | -6839 |
AHCYL1 | -5817 |
PLD3 | -5155 |
IGHG3 | -4982 |
PLD1 | -3828 |
PLD2 | -2904 |
ITPR3 | -2786 |
GeneID | Gene Rank |
---|---|
IGHG4 | -8636 |
IGLC1 | -8528 |
IGLC3 | -8412 |
FCGR2A | -8279 |
FCGR1A | -8113 |
FCGR3A | -7985 |
IGLC2 | -7870 |
PLPP5 | -7209 |
PRKCD | -7187 |
PIK3R2 | -7148 |
SYK | -7142 |
IGHG2 | -6973 |
IGHG1 | -6890 |
CD247 | -6839 |
AHCYL1 | -5817 |
PLD3 | -5155 |
IGHG3 | -4982 |
PLD1 | -3828 |
PLD2 | -2904 |
ITPR3 | -2786 |
ITPR2 | -1777 |
PIK3CB | -1354 |
IGKC | -1151 |
PLD4 | -321 |
PLA2G6 | 572 |
PLCG1 | 702 |
PIK3CA | 1041 |
PRKCE | 2755 |
ITPR1 | 3726 |
PIK3R1 | 3780 |
PLCG2 | 6019 |
CD3G | 6329 |
Here is the session info with all the versions of packages used.
sessionInfo()
## R version 4.3.2 (2023-10-31)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 22.04.4 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.10.0
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.10.0
##
## locale:
## [1] LC_CTYPE=en_AU.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_AU.UTF-8 LC_COLLATE=en_AU.UTF-8
## [5] LC_MONETARY=en_AU.UTF-8 LC_MESSAGES=en_AU.UTF-8
## [7] LC_PAPER=en_AU.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_AU.UTF-8 LC_IDENTIFICATION=C
##
## time zone: Australia/Melbourne
## tzcode source: system (glibc)
##
## attached base packages:
## [1] stats4 stats graphics grDevices utils datasets methods
## [8] base
##
## other attached packages:
## [1] pkgload_1.3.3 GGally_2.2.0
## [3] beeswarm_0.4.0 gtools_3.9.5
## [5] echarts4r_0.4.5 kableExtra_1.3.4
## [7] topconfects_1.18.0 limma_3.58.1
## [9] eulerr_7.0.0 mitch_1.14.0
## [11] MASS_7.3-60 fgsea_1.28.0
## [13] gplots_3.1.3 DESeq2_1.42.0
## [15] SummarizedExperiment_1.32.0 Biobase_2.62.0
## [17] MatrixGenerics_1.14.0 matrixStats_1.2.0
## [19] GenomicRanges_1.54.1 GenomeInfoDb_1.38.5
## [21] IRanges_2.36.0 S4Vectors_0.40.2
## [23] BiocGenerics_0.48.1 reshape2_1.4.4
## [25] lubridate_1.9.3 forcats_1.0.0
## [27] stringr_1.5.1 dplyr_1.1.4
## [29] purrr_1.0.2 readr_2.1.4
## [31] tidyr_1.3.0 tibble_3.2.1
## [33] ggplot2_3.4.4 tidyverse_2.0.0
## [35] zoo_1.8-12 R.utils_2.12.3
## [37] R.oo_1.25.0 R.methodsS3_1.8.2
##
## loaded via a namespace (and not attached):
## [1] bitops_1.0-7 gridExtra_2.3 rlang_1.1.2
## [4] magrittr_2.0.3 compiler_4.3.2 systemfonts_1.0.5
## [7] vctrs_0.6.5 rvest_1.0.3 pkgconfig_2.0.3
## [10] crayon_1.5.2 fastmap_1.1.1 XVector_0.42.0
## [13] ellipsis_0.3.2 caTools_1.18.2 utf8_1.2.4
## [16] promises_1.2.1 rmarkdown_2.25 tzdb_0.4.0
## [19] xfun_0.41 zlibbioc_1.48.0 cachem_1.0.8
## [22] jsonlite_1.8.8 highr_0.10 later_1.3.2
## [25] DelayedArray_0.28.0 BiocParallel_1.36.0 parallel_4.3.2
## [28] R6_2.5.1 bslib_0.6.1 stringi_1.8.3
## [31] RColorBrewer_1.1-3 jquerylib_0.1.4 assertthat_0.2.1
## [34] Rcpp_1.0.11 knitr_1.45 httpuv_1.6.13
## [37] Matrix_1.6-4 timechange_0.2.0 tidyselect_1.2.0
## [40] rstudioapi_0.15.0 abind_1.4-5 yaml_2.3.8
## [43] codetools_0.2-19 lattice_0.22-5 plyr_1.8.9
## [46] shiny_1.8.0 withr_2.5.2 evaluate_0.23
## [49] ggstats_0.5.1 xml2_1.3.6 pillar_1.9.0
## [52] KernSmooth_2.23-22 generics_0.1.3 RCurl_1.98-1.13
## [55] hms_1.1.3 munsell_0.5.0 scales_1.3.0
## [58] xtable_1.8-4 glue_1.6.2 tools_4.3.2
## [61] data.table_1.14.10 webshot_0.5.5 locfit_1.5-9.8
## [64] fastmatch_1.1-4 cowplot_1.1.2 grid_4.3.2
## [67] colorspace_2.1-0 GenomeInfoDbData_1.2.11 cli_3.6.2
## [70] fansi_1.0.6 viridisLite_0.4.2 S4Arrays_1.2.0
## [73] svglite_2.1.3 gtable_0.3.4 sass_0.4.8
## [76] digest_0.6.33 SparseArray_1.2.3 htmlwidgets_1.6.4
## [79] htmltools_0.5.7 lifecycle_1.0.4 httr_1.4.7
## [82] statmod_1.5.0 mime_0.12
END of report